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Summary
Breast cancer is the second leading cause of cancer death in women in 
the UK and so there is a need to develop new treatments for this. The 
aims of these studies were to investigate the effects of adenosine 
receptor agonists and antagonists, the endogenous compounds 
adenosine and 2 ’-deoxyadenosine and the clinically used purine 
nucleoside analogues on the viability of breast cancer cells in vitro.
Initial studies identified the expression of all four adenosine receptors in 
the MCF-7 (ER-positive) and MDAMB231 (ER-negative) breast cancer 
cell lines but these receptors were not involved per se in maintaining 
cell viability. Adenosine and 2’-deoxyadenosine were able to reduce cell 
viability by mechanisms involving adenosine receptor activation in the 
MCF-7 cells, a reduction in extracellular regulated kinase 1/2 (ERK 1/2) 
phosphorylation in the MDAMB231 cells and intracellular 
phosphorylation by adenosine kinase in both cell lines.
Further studies identified that the clinically used 2’-deoxyadenosine 
analogue, clofarabine, had equal potency in the ER-negative cell lines 
compared to a leukaemia cell line in vitro. The ER-positive cells were 8 - 
fold more resistant to clofarabine, however. Inhibition of ribonucleotide 
reductase appeared to be the primary mechanism of action of 
clofarabine and cladribine, but not fludarabine in the MCF-7 and 
MDAMB231 cell lines. ERK 1/2 signalling was also partly required for 
the action of clofarabine in the MDAMB231, but not the MCF-7 cells.
Studies on the resistance of clofarabine in ER-positive cells identified 
that increased basal expression of the metabolising enzyme, cytostolic 
5’-nucleotidase II and the ribonucleotide reductase subunit, p53R2, 
were correlated with decreased sensitivity to clofarabine. Drug-induced 
p53R2 expression in p53 wild-type MCF-7 cells also contributed to 
resistance.
The present study highlights the potential for clofarabine as a treatment 
for breast cancers, particularly ER-negative cancers where patients 
have a very poor prognosis.
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Chapter 1: General Introduction
1.1 Adenosine and 2’-Deoxyadenosine
1.1.1 Structure and Physiological Roles
Adenosine (9-p-D-ribofuranosyladenine) is a purine nucleoside with a 
structure consisting of a 6 -aminopurine (adenine) joined to a ribose 
(ribofuranose) moiety by a p-glycosidic bond. Adenosine is found both 
intra- and extracellularly and also exists as 2 ’-deoxyadenosine with the 
deletion of the hydroxyl at the C2 position on the ribose (Figure 1 .1 ).
B
HO
OHOH
HO
OH H
Figure 1.1 Structure of Adenosine (A) and 2 ’-Deoxyadenosine (B)
Adenosine serves a variety of physiological roles, particularly as an 
autocrine and paracrine signalling and regulatory molecule (Borowiec et 
al. 2006). The regulatory functions of adenosine include action as an 
anti-inflammatory agent (Cronstein 1994), regulator of blood flow and 
modulator of neuronal excitability in the central nervous system (CNS; 
Davis et al. 2003) with functions to inhibit the release of neuronal 
transmitters (Yoon and Rothman 1991). During ischaemia or 
inflammation, extracellular adenosine accumulates past normal 
physiological levels to aid in tissue protection and regeneration through 
ischaemic post-conditioning, triggering anti-inflammatory responses and 
stimulation of angiogenesis (Linden 2005). 2’-Deoxyadenosine and 
other deoxypurines and pyrimidines form the nucleobases of DNA.
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1.1.2 Synthesis
Adenosine is continually produced and metabolised and can be 
synthesised both intra- and extracellularly via two distinct pathways 
(Figure 1.2) (Fredholm et al. 2001). The primary pathway involves 
dephosphorylation of adenine nucleotides by intracellular and 
extracellular 5’-nucleotidases (Madrid-Marina and Fox 1986; Loffler et 
al. 2007). The second pathway involves demethylation of S- 
adenosylmethionine (SAM) to S-adenosylhomocysteine (SAH) and 
subsequent hydrolysis of SAH by SAH hydrolase to adenosine and 
homocysteine (Luippold et al. 1999), although this process only occurs 
intracellularly Synthesis of 2’-deoxyadenosine occurs via reduction of 
adenosine diphosphate (ADP) to deoxyadenosine diphosphate (dADP) 
and then subsequent dephosphorylation by nucleotidase enzymes.
OOOOOOCOOOCX
SAH Cytoplasmic 
5 -nucleotidase
SAH
Hydrolase
Komoc
Adenosine
Adenosine
Figure 1.2 Synthesis of Adenosine
Adenosine is synthesised intra- and extracellularly by dephosphorylation of 
AMP and by hydrolysis of SAH to homocysteine and adenosine.
1.1.3 Metabolism
When levels of adenosine or 2’-deoxyadenosine exceed normal 
physiological conditions, they are rapidly deaminated by adenosine 
deaminase (ADA) to inosine or phosphorylated to AMP by adenosine 
kinase (Figure 1.3) (Lloyd and Fredholm 1995; Deussen et al. 1999). 
Whilst ADA works mainly intracellularly, it also functions extracellularly 
by being bound to the cell membrane, anchored by membrane proteins 
CD26 and Ai and A 2b adenosine receptors (Romanowska et al. 2007).
Figure 1.3 Metabolism of Adenosine
Adenosine is deaminated by ADA both intra- and extracellularly to inosine and 
is also phosphorylated by adenosine kinase to AMP.
1.1.4 Nucleoside Transporters
Nucleoside transporters (NTs) play important roles in physiological 
functioning as nucleosides are highly hydrophilic and require active 
transport to cross cellular membranes (Loffler et al. 2007). NTs also 
play an important role in anti-cancer and anti-viral chemotherapy where 
they are involved in transportation of nucleoside analogues (NAs) 
across the plasma membrane (Fang et al. 1996).
InosmeAdenosine
Membrane ADA 
(CD26 protein)
Cytoplasmic ADA
InosineAdenosine
Adenosine
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There are two classes of NTs expressed on mammalian cells. The first 
are the equilibrative nucleoside transporters (ENT), which are passive 
transporters working on the concentration gradient of nucleosides. 
ENTs are more widely distributed than concentrative nucleoside 
transporters (CNTs) (Baldwin et al. 1999) and thus play a greater role in 
adenosine homeostasis. There are four subclasses of ENTs, 1-4, with 1 
and 2  being the most well studied isoforms, and both selectively 
transport adenosine and other nucleosides (Damaraju et al. 2003). ENT 
1 and 2 are distinguished based on their sensitivity to the NT inhibitor, 
nitrobenzylmercaptopurine riboside (NBMPR), with ENT1 being 
NBMPR-sensitive and ENT2 being NBMPR-insensitive (Damaraju et al. 
2003; Ldffler et al. 2007; Zhang et al. 2007).
The second class is the CNTs which are sodium-dependent active 
transporters that transport against the concentration gradient (Fang et 
al. 1996; Ldffler et al. 2007). There are 3 subsets of CNTs classified on 
their substrate selectivity, CNT1 which predominantly transports 
pyrimidine nucleosides; CNT2 that favours purine substrates and CNT3 
that has broad substrate specificity and transports purines and 
pyrimidines (Baldwin et al. 1999; Archer et al. 2004).
1.2 Adenosine Receptors
1.2.1 Structure, Classification and Distribution
Purinergic surface receptors were first identified in 1976 and were later 
sub-divided into those with affinity for adenosine, and those with affinity 
for adenine nucleotides deemed Pi and P2 , respectively (Bumstock 
2006). The physiological actions of adenosine are mediated by Pi 
specific adenosine receptors termed Ai, A2A, A2B and A3 and each 
receptor has a distinct pharmacological profile (Klinger et al. 2002). The 
wide distribution of adenosine receptors in different cells and tissues 
means that adenosine can influence nearly every tissue (Klinger et al.
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2002; Chang et al. 2004) with cells almost always expressing multiple 
adenosine receptor subtypes (Fredholm et al. 2001).
Adenosine receptors are G protein-coupled receptors (GPCRs) 
(Fredholm et al. 2001; Klinger et al. 2002; Jacobson and Gao 2006). In 
humans the A2A and A2B receptors have the most homology at 5 9 %, 
while the human A1 and A3 receptors share 49% homology (Jacobson 
and Gao 2006) These receptors show the typical topological structure 
common to all GPCRs, with seven a-helical membrane-spanning 
domains with an extracellular amino terminus and an intracellular 
carboxyl terminus (Olah and Stiles 2000). Previous work on GPCRs 
suggested that it is the binding of a receptor agonist to the extracellular 
domain that affects orientation of the transmembrane domains of the 
receptor, which in turn causes conformational changes in the 
intracellular aspect of the receptor that can elicit G protein activation 
and thus physiological responses (Olah and Stiles 2000).
1.2.2 Adenosine Receptor Signalling
Adenosine receptors initiate their intracellular signals through G protein 
coupling. Classically, it was thought that the intracellular signalling 
pathways associated with adenosine receptors involved either 
activation or inhibition of adenylate cyclase regulating cyclic adenosine 
monophosphate (cAMP) levels. However, receptors have also been 
associated with phospholipase C, Ca2' and mitogen-activated protein 
kinase (MAPK) pathways (Jacobson and Gao 2006). As a basic 
overview, both A1 and A3 receptors act as inhibitory receptors, 
mediating decreases in cAMP by Gj and G0 proteins. A2A and A2b 
receptors, however, act as stimulatory receptors, increasing cAMP 
levels by G« proteins (Klinger et al. 2002; Lynge et al. 2003; Schulte and 
Fredholm 2003).
The cAMP-dependent pathway involves activation of protein kinase A, 
which can phosphorylate a multitude of other proteins and transcription
5
factors, such as cAMP response element binding protein (CREB) 
(Daniel et al. 1998). CREB is well known for its role in cell proliferation 
and switches on several genes associated with oncogenesis such as c- 
fos and inactivating tumour suppressor genes (Siu and Jin 2007). 
Nishihara et al. (2004) found that activation of the cAMP pathway 
inhibited apoptosis in colon cancer cells by phosphorylation of CREB 
and induced activation of inhibitor of apoptosis protein 2 (IAP-2), via the 
extracellular regulated kinases 1 and 2 (ERK 1/2) and p38 MAPK 
pathways.
Adenosine receptors are also linked to activation of the phospholipase 
C/inositol triphosphate/diacylgyclerol/protein kinase C pathway, where it 
acts on cell growth, differentiation, apoptosis and intracellular signalling 
mechanisms (Brandt et al. 2002). Activation of the phosphatidylinositol- 
3’-kinase (PI3K)-dependent protein kinase B (Akt) pathway by 
adenosine receptors is known to inhibit apoptosis via regulation of 
transcription factors such as Bcl-2, apoptotic inducers and cell cycle 
regulators (Vanhaesenbroeck and Alessi 2000; Downward 2004; 
Hanada et al. 2004).
Adenosine has also been shown to influence ion channel activation via 
adenosine receptor stimulation including K a t p  channels and release of 
intracellular Ca2* that help in cell protection from ischaemia (Mogul et 
al. 1993; Tracey et al. 1998; Haas and Selbach 2000; Andoh et al.
2006).
MAPKs are a well-conserved group of proline-directed serine/threonine 
kinases that transduce extracellular signals with control over a variety of 
cellular responses that include cell growth, division, differentiation and 
apoptosis (Chen et al. 2001; Luttrell 2003; Shulte and Fredholm 2003). 
Over 20 MAPKs have been discovered in mammals (Chen et al. 2001), 
with three primary subfamilies: p42/p44 ERK 1/2, c-Jun N-terminal 
kinases (JNK) and the p38 MAPK (Robinson and Dickenson 2001).
6
The ERK/MAPK pathway is one of the most well studied signal 
transduction pathways. This pathway is amongst the most important for 
control of cell cycle proliferation and is known to activate various proto­
oncogenes (Fang and Richardson 2005). The ERK 1/2 pathway is 
known to be activated in both naive and transfected cell lines by Ai 
(Dickenson et al. 1998; Germack and Dickenson 2000; Robinson and 
Dickenson 2001; Brust et al. 2006; Lee et al. 2007), A2A (Sexl et al. 
1997; Seidel et al. 1999; Merighi et al. 2002; Rivo et al. 2007), A2b 
(Feokistov et al. 1999; Gao et al. 1999; Schulte and Fredholm 2000, 
2002 and 2003; Grant et al. 2001) and A3 receptors (Neary et al. 1998; 
Graham etal. 2001; Schulte and Fredholm 2000, 2002; Trincavelli et al. 
2002; Hammarberg etal. 2003).
1.3 Adenosine and Cancer
1.3.1 Adenosine Receptor Expression in Tumours
The expression of adenosine receptors in tumours has been relatively 
well studied. However, varying results have been found in breast cancer 
cell lines. Lu et al. (2003) and Cheung et al. (2006) found that MCF-7 
cells do not express mRNA for the A3 adenosine receptor, however, 
Panjehpour and Karami-Tehrani (2004) found that MCF-7 cells did 
express A3 adenosine receptor mRNA, but at very low levels. Cheung 
et al. (2006) then found that MCF-7 cells expressed the mRNAs for the 
A2A and A2B receptors only, yet Panjehpour et al. (2005) noted that 
MCF-7 cells were devoid of adenosine receptor expression. This group 
then identified MCF-7 and MDA-MB468 cells that express mRNA for all 
adenosine receptors (Panjehpour and Karami-Tehrani 2007). These 
data highlight clear inconsistencies in the expression of adenosine 
receptors that may be due to experimental methods or variation 
amongst the cell lines. Recent works have also identified that A1 
receptor expression is regulated by the oestrogen receptor alpha (ERa) 
in ER-positive MCF-7 cells (Lin et al. 2010).
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The expression of Ai receptors have been reported in colorectal (Khoo 
et al. 1996; Gessi et al. 2007), melanoma (Merighi et al. 2003) and 
leukaemia cells (Gessi et al. 2001). A2A receptors are expressed on 
epidermoid (Tey et al. 1992), leukaemia (Gessi et al. 2001; Munro et al. 
1998), lymphoma (Munro et al. 1998), colorectal (Gessi et al. 2007) and 
melanoma (Merighi et al. 2003) cell lines. A 2b receptors have also been 
found on colorectal (Gessi et al. 2007), leukaemia (Gessi et al. 2001) 
and melanoma cell lines (Merighi et al. 2003). The A3 receptor has been 
identified on melanoma (Merighi ef al. 2003; Fishman et al. 2002), 
colorectal (Gessi et al. 2007) and leukaemia cells (Kohno et al. 1996; 
Gessi etal. 2001).
1.3.2 Stimulatory Effects of Adenosine on Tumours
Adenosine and 2'-deoxyadenosine are normal physiological metabolites 
with a diverse range of functions. During hypoxia adenosine levels rise 
in the extracellular matrix to 5-40 pM, depending upon tissue type and 
the basal concentration of adenosine, which is usually between 50 and 
500 nM (Schubert et al. 1994; Blay et al. 1997; Harrison et al. 1998). 
This suggests that adenosine has a role in cellular protection during 
ischemia. Indeed, it has been demonstrated that adenosine and 
selective agonists can activate A2A receptors and A 2b receptors to 
induce the expression of vascular endothelial growth factor (VEGF) and 
downregulate the anti-angiogenic matrix protein, thrombospondin I, 
which stimulates angiogenesis (Grant et al. 2001; Feoktistov et al. 
2002; Leibovich et al. 2002; Gardener and Olah 2003; Montesinos et al. 
2004; Desai et al. 2005). As solid tumours are frequently exposed to 
hypoxia until they can develop a blood supply, this strongly suggests 
that adenosine is tumour promoting in vivo and has been suggested as 
the mechanism by which tumours acquire the necessary vasculature 
(Ferrara 2002).
Adenosine is also known to promote tumour growth by other 
mechanisms. Adenosine is known to modulate immune function, and
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levels have been demonstrated to rise in the extracellular fluid to 
concentrations that are immunosuppressive (Blay et al. 1997). 
Adenosine has also been shown to inhibit T-killer cell activation and 
adhesion to carcinoma cells (Hoskin et al. 1994; MacKenzie et al. 1994) 
and suppress production of interleukin- 1 2  and tumour necrosis factor 
alpha (TNFa) (Hask6  et al. 2000). Similarly, Ohta et al. (2006) found 
that adenosine-stimulated A2A receptor activation on T cells inhibited 
their action against mouse solid tumours.
Adenosine has also been shown to activate adenosine receptors on 
cancer cells directly to promote tumour cell survival. Activation of the Ai 
receptor by adenosine was able to induce chemotaxis in A2058 human 
melanoma cells (Woodhouse et al. 1998). Several studies have also 
shown that activation of Ai and A3 receptors can protect against 
chemotherapy-induced apoptosis (Fishman et al. 2000; Gao et al. 2001; 
Shneyvays et al. 2001) and ischaemic injury (Safran et al. 2000). Gessi 
et al. (2007) found that adenosine-stimulated A3 receptor activation 
increased the proliferation of colon cancer cell lines and addition of ADA 
inhibited their proliferation. Mujoomdar et al. (2004) also showed that 
adenosine had mitogenic effects on the breast cancer cell lines MCF-7 
and T47D and colon cancer cell lines between 10-100 pM.
1.3.3 Inhibitory Effects of Adenosine on Tumours
Despite evidence that adenosine can promote tumour survival, there 
are data that show that adenosine and 2 ’-deoxyadenosine can inhibit 
the proliferation of tumours. These effects have been attributed to both 
intracellular and adenosine receptor-mediated mechanisms.
1.3.3.1 Adenosine Acts by an Intracellular Mechanism
Adenosine and 2’-deoxyadneosine have been shown to inhibit 
proliferation or induce apoptosis in breast (Barry and Lind 2000; 
Hashemi et al. 2005), gastric (Saitoh et al. 2004), colon (Barry and Lind 
2000) hepatoma (WU et al. 2006; Yang et al. 2007), ovarian (Barry and
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Lind 2000) and leukaemia (Tanaka et al. 1994; Schneider et al. 2001) 
cell lines. These studies suggested that adenosine and 2’- 
deoxyadenosine were phosphorylated by adenosine kinase to the 
monophosphates and subsequently to the triphosphates that disrupted 
deoxynucleotide triphosphate (dNTP) balance and caused DNA strand 
breakage.
This idea that intracellular phosphorylation is required for the activity of 
adenosine is further compounded by the clinically used 2 ’- 
deoxyadenosine analogues, cladribine, clofarabine and fludarabine, all 
having similar mechanisms of action that require intracellular 
phosphorylation to the mono- and subsequently triphosphates to 
become active (M&nsson et al. 1999). Similarly, deoxycoformycin 
(pentostatin) is a potent and irreversible inhibitor of ADA, which causes 
accumulation of adenosine triphosphate (ATP) and deoxyadenosine 
triphosphate (dATP). These inhibit ribonucleotide reductase and cause 
imbalance of the dNTP pool, which in turn inhibits DNA synthesis and 
results in cell death (Weiss et al. 2003).
1.3.3.2 Extracellular Actions of Adenosine via Adenosine 
Receptors
Evidence suggests that modulation of adenosine receptors are able to 
inhibit the growth of a variety of cancer cell lines. Activation of the Ai 
adenosine receptor has been shown to inhibit the growth of breast 
(Colquhoun and Newsholme 1997), epidermoid (Tey et al. 1992) and 
astrocytoma (Sai et al. 2006) cancer cells. Interestingly, this study by 
Sai et al. (2006) found that along with Ai-mediated mechanisms, 
adenosine could also cause apoptosis by intracellular mechanisms 
involving phosphorylation by adenosine kinase and activation of AMP- 
activated protein kinase (AMPK).
To date there is limited evidence to suggest the involvement of either 
A2A or A2B receptors in mediating growth inhibitory effects. A study by
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Merighi et al. (2002) demonstrated that activation of the A2A receptor 
had anti-proliferative effects in melanoma cells but higher 
concentrations of adenosine activated the A3 receptor and increased 
cell proliferation.
The A3 receptor is by far the most widely studied receptor in terms of 
having anti-cancer potential. Activation of the A3 receptor by either the 
endogenous ligand, adenosine, or selective agonists has been shown 
to inhibit the growth of lymphoma (Fishman et al. 2000), leukaemia 
(Kohno et al. 1996; Yao et al. 1997; Kim et al. 2002; Lee et al. 2005), 
breast (Panjehpour and Karami-Tehrani 2004; 2007), lung (Kim et al. 
2008), colon (Ohana et al. 2001) and hepatocellular (Bar-Yehuda et al. 
2008) cancer cell lines.
1.3.3.3 Anti-Proliferative Effects by Other Mechanisms
Cheung et al. (2006) demonstrated that the A3 selective agonist, LJ- 
529, inhibited the growth of breast cancer cell lines via a mechanism 
independent of adenosine receptors and intracellular phosphorylation. 
Apoptosis was induced by activation of caspase 3 and c- 
poly(ADP)ribose polymerase (PARP) and down-regulation of the Wnt 
signalling pathway and Her2 expression. Similarly to this, Lu et al. 
(2003) found that the A3 receptor agonist, IB-MECA, inhibited the 
growth of ER-positive breast cancer cells by down-regulation of ERa.
Furthermore El-Darahali et al. (2005) suggested that adenosine was 
able to induce cell death in the mouse thyroma (EL-4) cell line via 
extracellular adenosine that was not linked to adenosine receptors, but 
suggested the presence of a non-classical adenosine receptor. This is 
supported by Apasov et al. (2000) who also suggested the expression 
of a non-classical adenosine receptor ‘X’ in mouse thymocytes.
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1.4 Nucleoside Analogues
The purine or pyrimidine NAs are amongst the most common class of 
anti-cancer drugs that are used clinically. These drugs have 
modifications on the ribose moiety, the purine or pyrimidine base, or 
both that aid in their uptake, increase substrate binding and improve 
their ability to pass the natural degradation pathways of nucleosides. 
They mimic the endogenous purines and pyrimidines and act as false 
substrates.
1.4.1 Synthesis of Deoxyribonucleotides
Purine and pyrimidine deoxyribonucleotides are essential in the 
synthesis and repair of DNA. Their synthesis occurs via two distinct 
mechanisms, the de novo and salvage pathways (Figure 1.4). The de 
novo pathway is the primary pathway for synthesis of 
deoxyribonucleotides in normal, differentiated cells but in rapidly 
proliferating cells such as cancer cells, the salvage pathway becomes 
the predominant pathway (Hatse et al. 1999). The purine de novo 
pathway begins with the synthesis of inosine monophosphate (IMP) 
from the purine precursor, 5-phosphoribosyl-1 -pyrophosphate (PRPP). 
IMP is then converted to succinyl-AMP by adenylosuccinate synthetase 
and then to AMP by AMP lyase (Hatse et al. 1999). AMP is 
phosphorylated to ADP and can then undergo reduction to dADP by 
ribonucleotide reductase via reduction of the hydroxyl on the ribose 
(Cerqueira et al. 2005). In the salvage pathway, dATP is formed by 
successive phosphorylation of 2 ’-deoxyadenosine, deoxyadenosine 
monophosphate (dAMP) and deoxyadenosine diphosphate (dADP) by 
nucleoside kinases.
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Figure 1.4 Synthesis of Purine Deoxynucleotides
In the de novo pathway, PRPP is converted to IMP, and then successively to 
AMP, ADP and ATP. ATP then goes on for use as an energy source or 
synthesis into the second messenger, cAMP. ADP can be reduced by 
ribonucleotide reductase to dADP, which is then phosphorylated to dATP for 
use in DNA synthesis and repair processes. In the salvage pathway, 2- 
deoxyadenosine from nutrients and degraded DNA is successively 
phosphorylated by adenosine kinase (AK) to dAMP and then on to dADP and 
dATP by nucleoside mono(NMPK) and diphosphate kinases (NDPK), 
respectively.
To date, there are four clinically used adenosine analogues used in 
anti-cancer treatment, although there is current research being 
undertaken for their use in other conditions such as multiple sclerosis 
based on their immunosuppressive activity (Beutler et al. 1995; Leist 
and Vermarsch 2007). These drugs come under two categories; 
deoxycoformycin is the only inhibitor of ADA, whereas cladribine, 
fludarabine and clofarabine are halogenated nucleosides. Their 
structures are shown in Figure 1.5.
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Figure 1.5 Clinically Used Nucleoside Analogue Structures. Structures of 
deoxycoformydn (A), cladribine (B), fludarabine phosphate (C) and 
clofarabine (D). The different halogenations of cladribine, fludarabine 
phosphate and clofarabine are cirded in red.
1.4.2 Deoxycoformydn
Deoxycoformydn is the only ADA inhibitor used clinically and is also 
unique in that it is the only naturally occurring agent from this class, 
originally isolated from Streptomyces antibioticus (Woo et al. 1974). 
Originally, it was thought to be more active in T-cell based 
malignancies, due to the high levels of ADA in cells of T-cell origin, 
although this eventually proved to be incorrect, with cells of both B and 
T-cell origin proving to be susceptible to deoxycoformydn (Ho and 
Hensel 2006). Clinically it is used to treat hairy cell leukaemia, B-cell 
chronic lymphocytic leukaemia and indolent Non-Hodgkin’s lymphomas 
including Waldenstrbm’s macroglobulinemia (Ho and Hensel 2006).
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Molecularly, it mimics the transition state of adenosine to inosine via 
deamination by ADA. It has a hydroxyl group at the 4 position of the 
purine ring in place of an amino group (Figure 1.4 A). Although its exact 
mechanism(s) of action are still not fully understood, it is thought that 
inhibition of ADA results in an accumulation of 2’-deoxyadenosine that 
is converted to dATP by purine kinases, and this inhibits ribonucleotide 
reductase and SAH hydrolase resulting in decreased DNA synthesis 
and repair and eventual cell death (Fidias et al. 1996, Dillman 2004).
1.4.3 Fludarabine
Fludarabine is the most widely used purine nucleoside analogue (PNA) 
and is the gold standard for treatment of chronic lymphocytic leukaemia 
and Waldenstrbm’s macroglobulinaemia and is also used in conjunction 
with cytarabine to treat acute myeloid leukaemia (Fidias et al. 1996; 
Lenz et al. 2004; Robak and Robak 2007). Fludarabine was originally 
synthesised as the ADA resistant form of the anti-viral drug, vidarabine. 
Fludarabine is a halogenated adenosine analogue, but unlike cladribine 
or clofarabine, is given as the monophosphate form due to its relative 
insolubility as a nucleoside (Figure 1.4 B) (Fidias et al. 1996). 
Fludarabine is dephosphorylated before it enters the cell by membrane- 
bound 5 ’-nucleotidase, where it is then transported intracellularly via 
NTs and phosphorylated by deoxycytidine kinase (dCK) (Mackey et al. 
1998; Galmarini et al. 2001). Fludarabine has similar mechanisms of 
action to other PNAs, whereby the triphosphate derivative has the most 
activity. Fludarabine triphosphate is an inhibitor of ribonucleotide 
reductase, which causes a reduction in dNTP pools, and subsequent 
DNA chain termination. The depletion of dATP and dCTP acts to self- 
potentiate fludarabine and other NAs. Depletion of dCTP increases 
cellular levels of dCK, thus increasing the phosphorylation of NAs. The 
reduced dATP levels mean that more of the NA drugs are then 
incorporated into the DNA (Galmarini et al. 2001). Fludarabine 
triphosphate is also an inhibitor of DNA polymerase-a, whereby it
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competes with dATP for incorporation into the ATP sites of extending 
DNA chains and thus inhibits the polymerase. Also, once incorporated 
into the DNA chain, the ssDNA strand cannot be extended further at the 
3’-end, causing DNA chain termination (Huang et al. 1990). Fludarabine 
has also been demonstrated to be an inhibitor of DNA ligase I which 
inhibits the ligation of AMP on Okazaki fragments during DNA synthesis 
or repair (Yang et al. 1992). Catapano et al. (1991) also found that 
fludarabine triphosphate was able to inhibit DNA primase and thus 
reduce the numbers of RNA primers available for continued DNA 
synthesis, and that this subsequently corresponded to impaired DNA 
synthesis or repair. Another mechanism of action for fludarabine is due 
to its incorporation into RNA and inhibition of RNA polymerase that 
results in inhibition of RNA transcription and ultimately leading to a 
decrease in the ability to produce proteins. (Huang and Plunkett 1991).
Similar to cladribine and deoxycoformydn, fludarabine has shown good 
activity against non-dividing cells most likely involving a mechanism of 
inhibition of the DNA repair process and activation of PARP (Pettitt et 
al. 2 0 0 0 ).
1.4.4 Cladribine
Cladribine (2’-chloro-2’-deoxyadenosine) is a halogenated analogue of 
2 ’-deoxyadenosine and was developed from findings that children with 
severe combined immunodeficiency disorder (SCID) had low or non­
existent levels of ADA and subsequently elevated levels of dNTPs that 
caused lymphotoxicity (Saven and Piro 1994). Carson et al. (1980) 
evaluated a series of ADA-resistant deoxynucleotides, and found 
cladribine to be the most active and potent. Cladribine was first 
synthesised in 1972 by Christensen et al. (1972) but was only then 
looked at for its anti-lympho proliferative actions by Carson in 1980. 
Clinically, cladribine is currently used in the treatment of hairy cell 
leukaemia where it is most effective, but it is also used in other 
malignancies including chronic lymphocytic leukaemia, acute
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myelogenous leukaemia, non-Hodgkin’s lymphoma and Waldenstrom’s 
macroglobulinaemia (Bryson et al. 1993). There has also been recent 
interest in using cladribine to treat multiple sclerosis based upon its 
immunotoxicity and it is currently undergoing clinical trials for this 
indication, with promising results so far (Beutler et al. 1995; Leist and 
Vermarsch 2007).
Structurally, cladribine is a 2’-deoxyadenosine analogue, which is 
halogenated at the 2 ’ position on the purine ring with a chlorine atom 
(Figure 1.4 C). This halogenation confers resistance to deamination by 
ADA. Cladribine has well described mechanisms of action, similar to 
fludarabine and clofarabine. This class of drugs are known as prodrugs, 
as they require some degree of modification or chemical rearrangement 
once inside the cell or body, and are clinically inactive in their 
administered form.
The cytotoxic effects of cladribine require it to be transported 
intracellularly whereby it undergoes primary phosphorylation by 
nucleoside kinases such as dCK or deoxyguanosine kinase to the 
monophosphate, and is then successively phosphorylated to the di- and 
triphosphates. Intracellular cytostolic 5’-nucleotidase II (cN-ll) is 
primarily responsible for the dephosphorylation of these 2 ’-chloro- 
nucleotides (M&nsson et al. 1999), but cN-l can also dephosphorylate 
these nucleotides, albeit to a significantly lesser extent (Fyrberg et al.
2007). Cladribine triphosphate is the primary cytotoxic metabolite of 
cladribine, and inhibits various enzymes responsible for DNA replication 
and repair including ribonucleotide reductase and DNA polymerase 
(Griffig et al. 1989; Bontemps et al. 2000). As the triphosphate it is 
incorporated into the DNA template, which results in inhibition of DNA 
polymerase as it cannot elongate the DNA past this analogue, with the 
end result being DNA strand breakage and activation of the apoptotic 
cascade (Plunkett and Saunders 1991).
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Cladribine has also been shown to induce alterations to mitochondrial 
function and integrity, factors that may be another cause of cladribine’s 
cytotoxicity (P6 rez-Gal£n 2002). Cladribine has been shown to be 
incorporated into mitochondrial DNA by mitochondrial DNA polymerase, 
and this can lead to inhibition of synthesis of mitochondrial proteins, that 
can disrupt the electron transport chain and oxidative phosphorylation 
(Galmarini et al. 2001). Similarly Marzo et al. (2001) demonstrated that 
caspase activation and cell death was preceded by a loss in 
mitochondrial transmembrane potential after exposure to cladribine.
1.4.5 Clofarabine
Clofarabine (2-chloro-2’-deoxy-2’-fluoro-p-D-adenosine) is the latest 
generation of PNAs and is again similar to fludarabine and cladribine in 
terms of structure and mechanisms of action. Clofarabine was 
discovered in a program set up in the 1980’s and 90’s to identify more 
novel NAs as anti-cancer agents. Both cladribine and fludarabine were 
in clinical trials but it was noted that both were susceptible to (3- 
glycosidic bond cleavage between the ribose and the purine ring, either 
enzymatic and hydrolytic with cladribine (Lindemalm et al. 2004) or by 
phosphorylases with fludarabine (Bonate et al. 2006). Substitutions at 
the C2’ position either with a hydroxyl group or other substitutes 
resulted in stability of the glycosidic bond, and it was eventually 
identified that a fluorine substitution conferred most stability. A chlorine 
substitution at the C2’ position on the purine ring conferred resistance to 
ADA and this confirmation had the most anti-cancer activity (Figure 1.4 
D) (Montgomery and Secrist 1997). Unlike fludarabine and cladribine, 
clofarabine is a poor substrate for purine nucleoside phosphorylase, the 
enzyme responsible for the glycosidic bond cleavage of adenine and 
ribose moieties. This combined with the 2’-fluoro substitution which 
resulted in increased acid stability, makes clofarabine more stable and 
increases its oral bioavailability (Faderl et al. 2005).
18
Clinically, clofarabine is used as a second line treatment to treat 
relapsed acute lymphoblastic leukaemia in children, who have received 
at least two other forms of treatment. However, it is being put through 
various clinical trials to treat adult lymphoblastic haematological 
malignancies and myelodysplastic syndromes (Faderl et al. 2005).
Like other drugs of this class, clofarabine requires transport across the 
membrane via ENTs and CNTs, but, over long periods of time, it can 
diffuse across the plasma membrane (King et al. 2006). Intracellular 
phosphorylation is again required by purine kinases, particularly dCK to 
the mono-, di- and triphosphate forms of the drug, with the latter being 
the most important anti-cancer form of the drug. Lotfi et al. (1999) 
demonstrated that the efficiency in terms of Vma)/K mt of clofarabine 
phosphorylation by dCK was 2- and 8 -fold higher compared to 
cladribine and its natural substrate, 2 ’-deoxycytidine, respectively. 
Similarly, Parker et al. (1999) demonstrated increased efficiency of 
clofarabine phosphorylation by dCK compared to cladribine, fludarabine 
and 2’-deoxycytidine. Clofarabine can self-potentiate itself by inhibition 
of ribonucleotide reductase causing a decrease in intracellular 2 ’- 
deoxycytidine levels, which is a feedback inhibitor of dCK.
Clofarabine has mechanisms of action similar to cladribine and
fludarabine and is shown in Figure 1.6 . Firstly inhibition of
ribonucleotide reductase causes dNTP pool depletion. This then 
increases inhibition of DNA polymerase a and £ and encourages 
clofarabine triphosphate insertion into terminal DNA strands resulting in 
impairment of DNA elongation and repair and DNA strand breakage. 
These mechanisms induce apoptosis, but clofarabine can also act 
directly on the mitochondria resulting in altered transmembrane
potential and release of several apoptotic molecules into the cytoplasm
including cytochrome C, apoptotic-inducing factor (AIF), caspase 9 and 
apoptosis protease-activating factor 1 (APAF1) (Xie and Plunkett 1996; 
Genini et al. 2000a; Bonate et al. 2006).
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Figure 1.6 Mechanisms of Action of Clofarabine.
Clofarabine is transported intracellularly by NTs or passive diffusion and is 
then successively phosphorylated by dCK and then nucleoside mono- and 
diphosphate kinases (NMPK and NDPK, respectively) to clofarabine 
triphosphate (ClofTP). ClofTP inhibits ribonucleotide reductase, decreasing 
cellular dNTP pools and causing ClofTP to outcompete dATP. ClofTP inhibits 
DNA polymerase and is incorporated into DNA strands inhibiting DNA 
synthesis and repair and causing DNA damage. This leads to activation of 
PARP which leads to depletion of NAD* causing necrosis and also leads to 
initiation of apoptosis. ClofTP can also act directly on the mitochondria 
causing release of cytochrome c, apoptosis inducing factor (AIF) and apoptotic 
protease activating factor 1 (APAF 1) leading to apoptosis.
1.4.6 Specific Mechanisms of Action
1.4.6.1 Inhibition of Ribonucleotide Reductase
Ribonucleotide reductase is an essential enzyme that produces 
deoxyribonucleotides diphosphates directly via reduction of the hydroxyl 
on the ribose moiety of ribonucleotide diphosphates (Cerqueira et al. 
2005), and is a rate-limiting enzyme in DNA synthesis. Ribonucleotide
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reductase is an essential enzyme for cell viability as it was found that 
cells were unable to produce deoxyribonucleotides directly from cell 
metabolism, but have to be synthesised from ribonucleotides directly via 
reduction by ribonucleotide reductase (Cerqueira et al. 2005). Inhibition 
of ribonucleotide reductase is one of the principle mechanisms of action 
of NAs.
There are two subunits of ribonucleotide reductase, termed RRM1 and 
RRM2 (Cerqueira et al. 2005). The RRM1 subunit is an 85 kDa protein 
that contains the active site for substrate binding, as well as the 
allosteric regulatory site. The RRM2 subunit is 45 kDa and houses the 
diferric iron centre and tyrosyl free radical that are involved in substrate 
reduction reactions (Uhlin et al. 1994; Jordan and Reichard 1998). The 
RRM1 unit is usually termed the regulatory subunit, whereas RRM2 is 
considered the catalytic subunit. Transcriptional regulation of 
ribonucleotide reductase is controlled through cell cycle-specific 
induction. The RRM1 subunit is constitutionally expressed and has a 
half-life of approximately 18-24 hours. RRM2 transcription, however, is 
S-phase specific and has a maximal half-life of 4 hours and is degraded 
rapidly during mitosis (Bjorklund et al. 1990; Cerqueira et al. 2005). 
Enzyme activity is controlled through allosteric regulation. Binding of 
ATP at the active site stimulates enzyme activity, whereas dATP 
binding is inhibitory to function. Binding of allosteric effecters including 
ATP, dATP, thymidine triphosphate and deoxyguanosine triphosphate 
control the overall function of the enzyme stimulating reduction of 
cytidine, uracil, guanosine and adenosine diphosphate, respectively 
(Jordan and Reichard 1998). Inhibition of ribonucleotide reductase 
therefore causes depletion of the cellular dNTP pools, which inhibits 
DNA replication and repair, and encourages incorporation of NAs into 
DNA strands.
Tanaka et al. (2000) first described a p53-dependent protein that was 
expressed in p53-wild type but not in p53-mutant colorectal
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adenocarcinoma (SW480) cell lines. This protein shared 80% sequence 
homology with RRM2 throughout its structure, except for the N-terminal 
region containing the KEN box that enables RRM2 to be recognised 
and induced by Cdh-1 -anaphase promoting complex and as a result, 
p53R2 can be induced throughout the cell cycle (Chabes et al. 2004). 
p53R2 expression is induced by p53 activation in response to DNA 
damage such as chemotherapeutic agents or UV radiation and 
functions to help repair DNA by the supply of dNTPs (Tanaka et al. 
2000). Upon activation, p53R2 forms a complex with the RRM1 subunit 
by binding to the same site and functioning in place of RRM2, although 
with less affinity and resulting in lowered overall enzymatic activity 
(Guittet et al. 2001; Shao et al. 2004). After activation, the p53-p53R2 
complex disassociates and p53R2 translocates to the nucleus where it 
binds with the RRM1 subunit to provide dNTPs (Yamaguchi et al. 2001; 
Xue et al. 2003). p53R2 also functions to protect cells against oxidative 
stress, as it has been found to have catalase activity (Xue et al. 2006).
1.4.6.2 Inhibition of DNA Polymerase and DNA Strand Breakage
DNA polymerase is a key enzyme in DNA synthesis and repair. It is 
responsible for the polymerization of deoxyribonucleotides during DNA 
strand synthesis. NAs including cladribine, fludarabine and clofarabine 
compete with dATP for the binding site in DNA polymerase. Clofarabine 
is an inhibitor of a and e subtypes but not P or y (Bonate et al. 2006), 
which then incorporates these drugs as the monophosphate into the 
DNA strand. DNA elongation and repair is then inhibited when it comes 
to a site of a NA rather than a normal nucleotide, which cause chain 
termination and DNA strand breakage.
1.4.6.3 Inhibition of SAH Hydrolase
Inhibition of ADA by deoxycoformydn causes an accumulation of 2’- 
deoxyadenosine which in turn inhibits the enzyme SAH hydrolase. This 
leads to an increase in intracellular SAH concentration (Fidias et al.
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1996). Accumulation of SAH inhibits methyltransferases, which results 
in an inhibition of essential methylation reactions involved in the 
epigenetic regulation of DNA, RNA and proteins (Hermes et al. 2008) 
leading to p53-dependant apoptosis (Jackson-Grusby et al. 2001; Karpf 
et al. 2001). Interestingly, a study by Wyczechowska and Fabianowska- 
Majewska (2003) found that fludarabine and cladribine were also able 
to inhibit SAH hydrolase resulting in hypomethylation and a reduction in 
DNA synthesis in a human myelogenous leukaemia cell line (K562). 
Similarly, Hermes et al. (2004) identified that adenosine-mediated 
inhibition of SAH hydrolase caused upregulation of various p53-target 
and apoptosis-inducing genes.
1.4.6.4 Activation of PARP
PARP are a family of enzymes involved in DNA repair and apoptosis. 
PARP enzymes function to signal DNA damage to the cell by binding to 
the ssDNA or dsDNA breakage via zinc fingers. Then, using 
nicotinamide adenine dinucleotide (NAD*) as a substrate, PARP 
attaches multiple ADP-riboses to DNA repair proteins, DNA and 
histones, ultimately leading to unwinding of the damaged DNA and its 
repair via the base excision repair pathway (Ratnam and Low 2007). 
Indeed, over activation of PARP leads to cellular necrosis via depletion 
of NAD* and thus energy stores of the cell, but it has also been 
demonstrated to induce cell death by apoptosis via the release of AIF 
from the mitochondria (Yu et al. 2002). Both fludarabine and cladribine 
have been shown to induce PARP activation due to their mechanisms 
of action on initiation of DNA damage that ultimately leads to this NAD* 
depletion and cell death and is thus suggested as a cytotoxic 
mechanism in non-dividing cells. However, Pettitt et al. (2000) found in 
patients with leukaemia that whilst the activation of PARP was able to 
induce cell death in occasional cases, activation of PARP instead 
contributed to the acceleration of cell membrane disruption in the later 
stages of apoptosis in response to fludarabine. They also noted that
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PARP-associated cell death was second only to dysfunctional p53- 
dependent cell death as this was the most rapidly observed cell death 
pathway.
1.4.6.5 p53-Dependent and Independent Induced Apoptosis
The tumour suppressor, p53, is the quintessential tumour suppressor 
and is one of the most widely studied molecules involved in cancer, cell 
cycle, apoptosis and ageing. Coded for by the TP53 gene, the protein is 
often termed the 'guardian of the genome’ and is known for its ability to 
suppress cancer cell genesis. DNA damage is able to induce activation 
of p53, which can either permanently halt cell cycle progression (cellular 
senescence) or induce apoptosis of the damaged cell before it turns 
cancerous. The importance of p53 in halting the neoplastic 
transformation of damaged cells is demonstrated by the fact that 50% of 
all human cancers have a loss of or mutated forms of p53 that render it 
inactive (Efeyan and Serrano 2007). Literature suggests that loss of 
p53 function either by mutation or total loss of the protein is associated 
with poorer prognosis, due to these cells displaying increased 
resistance to DNA damaging agents (Sturm et al. 2003).
Pettitt et al. (1999) using a p53 knockout splenic cell model, found 
cladribine and fludarabine were able to induce apoptosis in both a p53- 
dependent and -independent fashion, albeit, p53 knockout cells were 
more resistant to the nucleosides. Galmarini et al. (2003a) showed that 
in colorectal carcinoma cells (HCT116) that express wild type p53 
protein, cladribine was able to induce apoptosis by p53 activation, cell 
cycle arrest and PARP and Bax overexpression. Similarly, they found 
that p53 negative cells were more resistant to cladribine’s toxicity.
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1.5 Breast Cancer
1.5.1 Breast Anatomy
The human breast describes the mammary glands that function 
physiologically and developmentally as a source of nutrition for the 
young, being only functional in females. Each breast itself is positioned 
anterior to the chest wall and lies within the superficial fascia of the 
pectoral muscles and subcutaneous fat of the skin. A central areola and 
nipple forms the site of lactation. Histologically, the breast is made up 
predominately of connective, glandular epithelial, and adipose tissues 
which make up the four essential structures; lobules, ducts, fatty tissue 
and supportive/connective tissue (Mostafa et al. 2006). Each breast 
consists of between 15-25 lobes that are arranged in a radial fashion 
around the central nipple region, with each lobe separated by fatty and 
connective tissue and suspensory ligaments. Within each lobe, 
numerous lobules containing glandular alveoli produce milk during 
lactation. The milk is secreted into the lactiferous ducts that protrude 
through the lobes, whereby they pass through the lactiferous sinus that 
open to the nipple (Marieb et al. 2004).
1.5.2 Breast Cancer Epidemiology
In the UK there are over 44,000 new cases of breast cancer diagnosed 
annually. Worldwide, this number rises to over 1 million new cases and 
the majority of these are in more affluent countries. Despite the steady 
decline in breast cancer mortality rates over the last 1 0  years, some 
12,000 breast cancer deaths occur annually in the UK and 1,400 of 
these deaths occur in women under 50. This earlier onset breast cancer 
tends to be associated with an ER-negative and significantly more 
aggressive phenotype with a poorer prognosis and is a major clinical 
problem where new treatment options are needed.
25
1.5.3 Breast Cancer Sub-Types, Classifications and Staging
Breast cancer refers to a number of different neoplasms of the breast 
tissue and there are now numerous ways to identify and type breast 
cancers, based upon histology, molecular biology or genetic markers. 
Nearly all cancers of the breast are carcinomas or adenocarcinomas, 
i.e. they arise from the epithelial or glandular epithelial tissue, 
respectively. Connective tissue cancers (mostly angiosarcomas) are 
extremely rare in the breast, and most cases occur in patients who have 
previously had a carcinoma of the breast, and/or radiation therapy 
(Cozen et al. 1999).
Classifying breast cancers, and providing information on their histology 
and molecular status provides important prognostic information and is 
used to determine the treatment options. There are varying ways to 
classify and group breast cancers, usually relying on morphological and 
histopathological assessment, hormone and molecular marker status 
(Elston et al. 1999). A relatively recent method looks at the molecular 
sub-type of breast cancer by identifying patterns of genes and 
associating them with being basal or luminal and various classes in 
between.
1.5.3.1 Pathological Classification
Pathological classification of breast cancers uses traditional 
morphological aspects of pathology including tumour size, 
differentiation (including histological type and grade), lymph node 
involvement and vascular invasion. There are different systems for this, 
usually employing the TNM system from the American Joint Cancer 
Committee on Cancer (tumour size; T, number of nodes involved and 
location; N, and presence or absence of metastasis beyond the regional 
lymph nodes; M) or the Nottingham Prognostic Index (NPI) which looks 
at tumour size, histological status and lymph node involvement and is 
widely used in the UK and Europe (Yu et al. 2004). Although extremely
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valuable for determining clinical outcomes, there are limitations to these 
systems as grading and analysis of tumours is subject to inherent 
personal bias and variability.
1.5.3.2 Lymph Node Involvement and Vascular Invasion
Pathological classifications are used to determine the extent of the 
tumour within the body. Nodal involvement is much more widely used 
and of more prognostic value than vascular invasion. The NPI simply 
uses the terms ‘unspecified’ or ‘vascular invasion’ to classify the 
presence of tumour emboli in the circulatory system as its value is still 
under debate although it is becoming a more important prognostic 
factor as more is understood (Elston et al. 1999). Lymph node 
involvement with metastatic tumours is associated with prognosis, and 
is used in the TNM and NPI systems. Those patients showing no nodal 
involvement have a 75% chance of surviving past 10 years, compared 
to only a 25-30% chance in those showing metastases (Elston et al. 
1999).
1.5.3.3 Tumour Size
Generally, patients with a smaller tumour size upon presentation are 
suggested to have a better prognosis than those with larger tumours, 
regardless of other factors. Tumours termed minimal invasive 
carcinoma, are tumours that are less than 9 or 10 mm in diameter and 
are associated with an excellent prognosis (Elston etal. 1999).
1.5.3.4 Differentiation
Tumours are now classified based on their differentiation, that is how far 
the tumour cells are differentiated from their normal, non-cancerous 
tissues from which they derived. Tumours are not just broadly split into 
in-situ or invasive but looks at histological type and histological grade. 
Histological type refers to the architectural pattern of the tumour and its 
origins and can be classified into the categories below.
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1.5.3.4.1 Carcinoma In-Situ
The term carcinoma in-situ is a frequently used term meaning a benign 
tumour and is preceded by either ductal or lobular, referring to the origin 
of the cells. The term refers to increased hyperplasia, i.e. an increase in 
cell number, where the cells are within the confines of the duct or lobule 
accordingly, and is an indicator of likely progression to a malignant 
cancer (Hammer et al. 2008).
1.5.3.4.2 Inflammatory Breast Cancer
Inflammatory breast cancer (IBC) is a relatively rare form of breast 
cancer, and accounts for between 1 -6 % of all new breast cancer cases 
annually (Kleer et al. 2000). IBC is amongst the most aggressive type of 
breast cancer and is distinctly different from other breast cancers as the 
clinical symptoms do not mach those of other breast tumours. There is 
usually no palpable lump or tumour mass, instead cancer is spread 
throughout the breast and, in nearly all cases, there is lymph node 
metastasis, with about a third showing distant metastasis (van Golen et 
al. 2000). The appearance of the breast differs from that of classical 
breast carcinoma, exhibiting signs of inflammation including redness, 
swelling, firmness and soreness. These symptoms are rapidly 
progressing, usually within 2 months of initial onset. Primary IBC refers 
to a patient with an underlying carcinoma of the breast, but this usually 
remains undetectable at the time of diagnosis. Secondary IBC is the 
result of reoccurrence of inflammation of a non-inflammatory breast 
carcinoma (Kleer et al. 2000).
1.5.3.4.3 Invasive Ductal or Lobular Carcinoma of the Breast
Most incidences of breast cancer are invasive ductal or lobular 
carcinoma (IDC and ILC, respectively). Invasive mixed ductal-lobular 
carcinoma (IDLC) are tumours that express mixed populations of ductal 
or lobular cells and the origin of the tumour is undecipherable. IDC is 
the most common form of cancer, accounting for between 70-80% of
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breast cancers (Berg and Hutter 1995). ILC, however, accounts for only 
15% of breast cancers. Clinically, ILC is more likely to be hormone- 
receptor positive and is generally associated with better clinical 
outcomes and increased survival rates compared with IDC (Li et al. 
2003).
There are other forms of breast cancer that do not fall into the above 
categories, but these tend to be very rare and account for <1 % of 
breast cancers each. These may include medullary, tubular, cribiform or 
mucinous breast cancers.
1.5.3.5 Histological Grading
Tumour grading is based upon the Scarf-Bloom-Richardson system, 
which takes into account nuclear grade, tubule formation and mitotic 
index and assigns a score based upon these. The Nottingham variation 
of this is now becoming the most widely used system in the UK, Europe 
and America. This method gives a score of 1 -3 for each category with 1 
being the best and 3 being the worst. The scores are tallied and used to 
determine the ‘grade’ or degree of differentiation of the tumour. A high 
grade, poorly differentiated tumour (the cancer cells are very different to 
the normal cells from which they derived; Grade III) is associated with a 
more aggressive tumour and poorer clinical prognosis. Tumours that 
are low grade and are well differentiated (the cancer cells are very 
similar to the normal cells they are derived from; Grade I) have a better 
overall prognosis. Indeed it is suggested that those with grade I 
tumours, have an 85% 10 year survival rate, compared to a 45% 10 
year survival rate for those with grade III tumours (Elston et al. 1999).
1.5.3.6 Hormone Status
The hormone status of breast cancers is widely used to determine 
prognostic information, but also used to dictate treatment regimes. 
Breast cancer, as well as other cancer types such as prostate or 
ovarian cancer, can be responsive to the actions of various hormones,
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and deprivation of these hormones can reduce the growth of these 
tumours. In breast cancer, hormone status usually refers to oestrogen- 
receptor alpha (ERa) status and progesterone-receptor (PR) status, 
being positive or negative for detectable amounts of the protein. ERp 
status is not usually used to classify breast tumours (Rochefort et al.
2003).
Upon presentation, approximately 60-70% of breast tumours are ER- 
positive and the presence or absence of detectable ER is an important 
prognostic indicator (Brinkman and El-Ashry 2009). Those who initially 
present as ER-positive are likely to encounter longer disease-free 
survival and an overall better prognosis than those with an ER-negative 
phenotype (Rochefort et al. 2003). ER status determines treatment 
options, with those being ER-positive, likely to benefit from endocrine 
therapies such as tamoxifen or faslodex. However 25-30% of ER- 
positive tumours do not respond to tamoxifen initially, and most will go 
on to develop resistance in the future (Brinkman and El-Ashry 2009). 
Those with the ER-negative phenotype will generally not respond to 
endocrine therapy and its use is not advocated.
1.5.3.7 Oestrogen and the ER
Oestrogens are steroid hormones primarily found in females that serve 
to regulate the growth and physiological processes of the reproductive 
system. They also have influence over pathological process, particularly 
hormone-dependent cancers such as breast, ovarian, prostate and 
endometrial (Chen et al. 2008). The most predominant of this class of 
hormone is 17p-oestradiol (oestrogen), which is regulated by 17p- 
hydroxysteroid dehydrogenase, an enzyme that converts oestrogen to 
its less active metabolite, oestrone (Bai and Gust 2009).
The physiological activity of oestrogen is modulated by binding to the 
oestrogen receptors a and p (Katzenellenbogen et al. 2000). In breast 
cancer, ERa is suggested to be the predominant receptor in activation
30
of oestrogen-responsive genes (Nicholson and Johnston 2005). The 
ERs belong to the nuclear receptor superfamily, a class of ligand- 
regulated transcriptional factors (Matthews and Gustafsson 2003). Both 
isoforms of ER share significant homology, both consisting of domain 
regions A-F, where region C is associated with DNA binding and 
receptor dimerisation. Upon binding of the ligand to the ER, the receptor 
undergoes significant conformational changes and the disassociation of 
various heat shock proteins including hsp90 and hsp70 (Klinge 2001) to 
allow it to dimerise with other ligand-bound ERs (Yang et al. 2008).
The oestrogen-ER complex can then influence transcription by two 
mechanisms, binding of the oestrogen-ER complex to a specific 
nucleotide sequence found in the promoter regions of oestrogen- 
responsive genes called the oestrogen response element, aided by zinc 
fingers on the oestrogen-ER complex that sit into the major grove of the 
DNA helix (Klinge 2001) or by binding of the oestrogen-ER complex to 
another DNA-bound transcription factor such as AP-1 that will stabilize 
the binding of that transcription factor to the DNA. Both methods result 
in the recruitment of coactivators and activation of the transcriptional 
machinery activating genes associated with cell or tumour growth 
(Klinge etal. 2004).
1.5.3.8 Molecular Markers
Molecular markers including over- or underexpression of various genes 
and their respective proteins offer a new way of classifying breast 
cancers and are able, in combination with pathological and hormonal 
status, to determine prognostic information and suggest treatment 
options (Esteva and Hortobagyi 2004). Some of these markers include 
the epidermal growth factor receptor 2 (EGFR2; Her2), Ki-67, c-myc, 
p53 and E-cadherin (Elston et al. 1999). Of these, Her2 is arguably the 
most important in determining treatment options and prognosis, 
although the others still have value. Ki-67 for example, is a nuclear 
antigen that is expressed during proliferative stages of the cell cycle,
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but not under resting phase (GO). Those patients who exhibit high 
indices of Ki-67 compared to low expressing tumours demonstrated a 
higher disease reoccurrence and shorter survival times (Veronese et al. 
1993\
1.5.3.9 Her2 Status
The most widely used molecular marker in breast cancer classification 
is Her2 status. This and other members of this type 1 superfamily, 
including EGFR, Her3 and Her4, belong to the tyrosine kinase 
receptors. In normal cells, expression of Her2 found on chromosome 17 
encodes a 185-kDa transmembrane protein, with tyrosine kinase 
activity. Via heterodimerisation with other members of the EGFR family, 
Her2 mediates signal transduction pathways involved in cell 
proliferation and differentiation (Guan et al. 2005). Overexpression of 
the Her2 gene causes an increase in the number of receptors on the 
cell, which causes excessive receptor activation and a subsequent 
increase in cell proliferation, division and eventually tumour formation. 
Her2 overexpressing breast cancer tumours are associated with a more 
aggressive phenotype, higher tumour grading and ultimately, shorter 
disease-free and overall survival rates (Hicks and Kulkarni 2008). 
Approximately 25% of breast tumours present with this over-expression 
of Her2 (Hicks and Kulkami 2008). However, those who are Her2 
overexpressing are likely to respond to the monoclonal antibody 
therapy, trastuzumab (herceptin) with good results. Trastuzumab has 
been shown to downregulate expression of Her2, most likely by 
increasing receptor endocytosis and degradation (Molina et al. 2001).
1.5.3.10 Basal and Luminal Classification
With the advent of increasingly better biotechnology, specifically 
microarray technology, a relatively new system of breast cancer 
classification has arisen. This method looks at the expression of a 
cohort of genes and classifies breast cancers into a certain group based
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upon over or underexpression of gene clusters. The pioneers of 
classifying breast cancers in this way were Perou et al. (2000) who 
looked at the expression of 500 genes in normal and breast cancer 
tissues and were able to show clear correlations of gene clusters in 
individual samples. Subsequent work has now identified five sub-types, 
luminal A and B, basal, Her2 overexpressing and normal-like (Adelaide 
etal. 2007).
Luminal A and B are ER-positive and share features with luminal cells 
of the mammary ducts. The normal-like sub-type demonstrates 
increased expression of basal-genes, but reduced expression of 
luminal-associated genes. The basal subtype shares characteristics 
with normal breast basal epithelial cells, but are generally devoid of ER 
and PR and are not Her2 overexpressing and are termed ‘triple- 
negative’. These tumours originate from the basal layer of the 
mammary duct epithelium (Cleator et al. 2007). Basal-like tumours 
express high molecular weight cytokeratins associated with basal cells, 
including CK, CK5/6, CK14 and CK17 (Reis-Filho and Tutt 2008). A 
small number of basal-like subtype cells do express some of these 
receptors, however, suggesting there is not a complete correlation with 
basal and triple negative breast cancers (Cleator et al. 2007). Luminal A 
breast cancer is associated with a good overall prognosis. Luminal B, 
basal and Her2 overexpressing breast cancers, however, are 
associated with a much poorer prognosis, with Her2 overexpressing 
being the only group with a specific targeted therapy in the form of 
trastuzumab (Adelaide et al. 2007).
1.5.3.11 ER-Negative and Triple-Negative Breast Cancer
ER-negative breast cancers, although they are less frequent then their 
ER-positive counterparts, are associated with a more aggressive 
phenotype, although the reasons for this are still largely unknown 
(Rochefort et al. 2003). ER-negative cancers can arise from ER-positive 
premalignant lesions that undergo genetic or epigenetic alterations in
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the ER gene regions, or have an increased degradation of ER proteins. 
ER-negative cancers are suggested to arise directly from a hormone- 
independent pathway (Rochefort et al. 2003). Those patients defined as 
ER-negative (which clinically refers to ERa status) encompasses those 
with a poorer prognosis, and limited treatment options available 
compared to those with ER-positive cancer (Skiiris et al. 2008). 
However, those with ER-negative, but Her2 overexpressing tumours 
have targeted therapies available with trastuzumab (Doane et al. 2006).
Triple-negative breast cancers (TNBCs) account for approximately 15- 
20% of all breast cancers (Cleator et al. 2007). This group is similar to 
the basal subtype described by genetic fingerprinting, but not all basal 
termed tumours are triple negative. Triple negative and basal-like 
tumours share certain clinical characteristics that differentiate them from 
other tumour types including increased incidence in African-American 
women, often affecting younger women less than 50 years old, and 
being considerably more aggressive than other subtypes. Clinically this 
relates to reduced 5 and 10 year survival rates compared to non-basal 
or ER-positive/Her2 overexpressing tumours (Reis-Filho and Tutt 2008). 
Patients with TNBC are also more likely to see disease reoccurrence 
both locally and with distant metastasis than those with ER-positive or 
Her2 overexpressing tumours (Dent et al. 2007). These clinical 
outcomes are expected as most triple-negative and basal-like tumours 
are associated with histological grade 3, known to be correlated with the 
worst clinical outcome (Elston et al. 1999; Reis-Filho and Tutt 2008).
1.6 Current Treatments in Breast Cancer
Treatment options for breast cancer are varied and determination of the 
appropriate treatment for the individual patient is decided by the 
patient’s condition i.e. extent of the disease, age, general health and 
menopausal status; as well as the subtype of breast cancer present, 
particularly steroid hormone receptor status and Her2 status. Treatment 
nearly always begins or involves at some stage a mastectomy or
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surgery to remove the tumour and help define the cancer stage 
(Hammer et al. 2008). This is then followed by chemotherapy and 
endocrine therapy to reduce the chance of metastasis, and radiotherapy 
to reduce the risk of recurrence (Ismaili et al. 2009). Neoadjuvant 
treatment is sometimes given to reduce the size of the tumour prior to 
surgical intervention in order to increase the success of the surgery. 
However, whether or not neoadjuvant therapy leads to improved 
disease-free survival and better prognosis overall is still under debate, 
and neoadjuvant therapy is only given to select patients, particularly 
those with large tumours (Smith 2008).
1.6.1 ER-positive Breast Cancer: Endocrine Therapy
Endocrine therapy is based upon the reasoning that most breast 
cancers rely on the growth-promoting effects of oestrogen to proliferate. 
Endocrine therapy therefore lends itself in two ways; ablative therapy to 
remove the source of the oestrogen and additive therapy to act upon 
the cancer itself to prevent the proliferative action of oestrogen, 
primarily through antagonising the oestrogen receptor. Approximately 
60-70% of breast tumours are ER-positive and its presence strongly 
supports the use of endocrine therapy (Brinkman and El-Ashry 2009).
Ablative therapies can refer to surgery or chemotherapy. In surgery, the 
glands that produce oestrogen are removed and thus the source of 
endogenous oestrogen is removed. In premenopausal women these 
are the ovaries, in postmenopausal women these are the adrenal 
glands. In postmenopausal women, oestrogen can still be produced by 
aromatisation of circulating hormones, particularly testosterone and 
androstendione to oestrogen and oestrone. This reaction is catalysed 
by the enzyme aromatase, which controls the rate-limiting step in 
oestrogen synthesis (Macedo et al. 2009). Further to this, two-thirds of 
breast cancers express the aromatase enzyme and are likely to 
synthesise their own oestrogen (Lipton et al. 1987). The development of 
aromatase inhibitors has progressed rapidly, and the current, third
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generation drugs include anastrozole (Arimidex), letrozole (Femara) 
and exemestane (Aromasin). These drugs exhibit high selectivity and 
potency for aromatase and, such is their success, they have now 
replaced tamoxifen as a first-line therapy against ER-positive breast 
cancer (Macedo et al. 2009; NICE Guidelines 2006).
Additive therapies are largely based upon anti-oestrogens, being well 
described for the treatment of ER-positive, oestrogen-dependent breast 
cancers. These act to stop the proliferative effects of oestrogen at the 
cancer cell itself. The selective oestrogen receptor modulator (SERM), 
tamoxifen, had been the gold standard in treating ER-positive breast 
cancer for over 30 years (Schwartzberg et al. 2009). Indeed, endocrine 
therapy offers the advantages of conventional cytotoxic chemotherapy 
but without many of the unwanted side effects (Nicholson and Johnston
2005). Tamoxifen therapy has its own drawbacks however, including 
endometrial hypertrophy, endometrial cancer and an increased risk of 
venous thrombi, all due to the partial agonist activity of tamoxifen for the 
ER (Patel et al. 2007). Although the benefits of tamoxifen far outweigh 
the risks for most people, the major limitation in its use is the 
development of acquired resistance to the drug (Goss and Strasser 
2 0 0 2 ), which results in relapse of the cancer and ultimately, patient 
death.
The need for oestrogen receptor antagonists without agonist activity 
was evident, however, and led to the development of a novel oestrogen 
analogue, fulvestrant (faslodex). Faslodex is devoid of agonist activity 
and binds to the ER with similar affinity to oestrogen itself (Nicholson 
and Johnston 2005). As well as being able to antagonise the ER and 
thus inhibit oestrogen signalling, faslodex is able to impair receptor 
dimerisation and thus reduce translocation of ER to the nucleus. As the 
faslodex-ER complex is unstable, this hastens the degradation of the 
ER protein, resulting in down-regulation of available ER (Osborne et al.
2004).
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All patients on tamoxifen, whilst responding well initially will go on to 
develop a degree of resistance, characterised by continued growth of 
the tumour in the presence of the drug. Some tumours will, however, 
respond to second or third line endocrine therapy, but not all and as 
such, resistance to endocrine treatments is a major clinical problem 
(Larsen et al. 1997). One of the other major drawbacks in endocrine 
therapy is de novo resistance to endocrine therapy from the start, 
mainly due to the absence of functional ER expression (Nicholson and 
Johnston 2005).
1.6.2 Her2 Overexpressing Breast Cancer: Trastuzumab Therapy
Her2 overexpressing tumours account for approximately 25% of 
reported breast cancers, and although Her2 overexpression suggests a 
more aggressive cancer, specific targeted therapies have been 
developed against this target, namely trastuzumab. Trastuzumab is a 
humanized monoclonal antibody directed against the Her2 protein. 
Trastuzumab was given FDA approval for the treatment of Her2 
overexpressing metastatic breast cancer in 1998, and was active as 
both a single agent and in combination with standard chemotherapy 
(Nahta and Esteva 2006). However, most tumours will go on to acquire 
resistance within a year. Treatment with adjuvant chemotherapy of 
paclitaxel or docetaxel can reduce acquired resistance and lead to 
longer disease-free survival (Nahta and Esteva 2006).
The Her2 status has been suggested to influence response to various 
chemotherapy treatments. Indeed, Her2 overexpressing tumours have 
been demonstrated to show increased sensitivity to doxorubicin and 
anthracycline chemotherapy, as well as other chemotherapeutics 
including cyclophosphamide and 5-fluorouracil (Muss et al. 1994; Paik 
et al. 1998; Thor et al. 1998). However, response to the taxanes 
including paclitaxel does not appear to be correlated with Her2 
overexpression (Van Poznak et al. 2002).
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The interaction between ER and expression of Her2 is still under 
review. However, Her2 and the ER co-activator AIB1 are often elevated 
together, and there are data to show crosstalk between the ER and 
Her2 pathways (Shou et al. 2004). A study by Lipton et al. (2002) 
demonstrated that patients who are ER-positive and Her2 
overexpressors, were less likely to respond to anti-hormone therapy 
than their Her2 normal-expressed counterparts. This also correlates to 
shorter survival times with similar results found by Arpino et al. (2004).
1.6.3 Treatment of ER-negative and TNBC
For those who have either ER-negative or Her2 normal-expressed 
tumours, treatment is generally based upon the other target i.e. in ER- 
negative but Her2 overexpressing, trastuzumab, and 
SERMs/aromatase inhibitors with ER-positive but Her2 normal 
expressed tumours. Depending upon the stage, spread and histological 
grade/classification of the disease, these treatments may be backed up 
with adjuvant cytotoxic chemotherapy also. However, for those who lack 
expression of ER and are Her2 normal, standard cytotoxic 
chemotherapy is the only option after surgery an/or radiation. Current 
chemotherapy treatment of TNBC patients relies on combinations of 
cytotoxic agents, although there is no standard regime for this (Cleator 
et al. 2007).
Triple-negative and basal like tumours are highly sensitive to 
anthracycline and taxane chemotherapy, especially when combined. In 
fact, triple-negative and basal-like tumours often show increased 
sensitivity to cytotoxic chemotherapy compared to luminal A, or 
hormone-responsive tumours. However, despite this increased initial 
sensitivity, disease free and overall survival remain poorer (Anders and 
Carey 2008).
Due to the linkage of TNBC and dysfunctional DNA repair mechanisms, 
the use of DNA damaging agents could be indicated as a treatment
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option. Recent data has suggested the use of platinum-based 
treatments, which are DNA damaging agents, such as cisplatin 
encouragingly show sensitivity of these tumours to platinum-based 
agents. However, to date no optimal regimes have been established for 
their use and they remain in trial stages (Gluz et al. 2009).
For those who are Her2 normal-expressed, treatments consist generally 
of standard regimes of multiple cytotoxic agents including 
cyclophosphamide, 5-fluorouracil, doxorubicin, methotrexate or 
epirubicin (EBCTCG, 2008). These drugs belong to the DNA 
replication/inhibitor class, and are folic acid inhibitors (methotrexate), 
alkylating agents (cyclophosphamide), topoisomerase inhibitors 
(doxorubicin, epirubicin) or pyrimidine thymidylate synthase inhibitors 
(5-fluorouracil). Although these drugs are effective against cancer, the 
biggest limitation is lack of specificity and the side effects of the drugs 
as they also act on other tissues, specifically fast-dividing cells such as 
those found in the mucosa and epithelial linings. Fortunately, ER- 
negative breast cancers are often associated with being Her2 
overexpressed and may benefit from trastuzumab therapy (Doane et al.
2006). Although anthracyclines and taxanes are effective against ER- 
negative and TNBCs, their main drawback is the development of severe 
side effects, in particular heart failure and the development of 
leukaemia (Shapiro and Recht 2001; Nowak et al. 2004).
1.6.4 Why NAs as Treatments for Breast Cancer?
1.6.4.1 Selectivity
Modem cancer research is directed at targeted therapies to specific 
cancer cell traits. A drawback of these methods is that finding a target is 
more challenging i.e. does every type of cancer express a particular 
protein. What makes PNAs different from standard chemotherapeutics 
is their degree of selectivity for malignant cells over normal tissue.
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As NAs are prodrugs and require phosphorylation by dCK, malignant 
cells expressing high dCK levels compared to non-malignant tissues 
are likely to be more susceptible to the action of NAs (Eriksson et al. 
1994; Spasokoukotskaja etal. 1995; van der Wilt etal. 2003).
Similarly, malignant cells of solid tumours have higher expression of 
NTs compared to normal, surrounding tissue (Mackey et al. 1998; 
Zhang et al. 2007) making these cells more susceptible to the action of 
NAs (Pennycooke et al. 2001).
There are contrasting studies on the expression of the metabolising 
enzyme cN-ll between malignant and normal tissue (Rosi et al. 1998a 
and 1998b; Vannoni et al. 2004). It is difficult to interpret whether the 
expression of cN-ll between malignant and non-malignant tissues can 
influence selectivity of NAs (Hunsucker et al. 2005)
1.6.4.2 Drug Tolerance
PNAs have minimal non-haematological associated toxicities that 
makes them excellent agents when considering the effects on a 
patient’s quality of life. The minimal toxicities also make them attractive 
candidates to be considered in multi-drug regimes for patients (Rummel 
et al. 2002).
Guchelaar et al. (1994) suggested that cladribine is a well-tolerated 
drug, and that side effects including nausea, vomiting, alopecia, 
stomatitis and organ toxicity are mild to absent. Robak et al. (2006) 
states that cladribine has distinguishable toxicities compared to other 
cytotoxic agents that commonly include nausea, vomiting, hair loss and 
abnormal liver or kidney function and these are rarely reported. 
Similarly, at standard doses, neurotoxicity is also rare. Studies in 
patients with multiple sclerosis, for which cladribine is being 
investigated, suggests that cladribine at standard chemotherapeutic 
doses is remarkably well tolerated, with even limited myelosuppression 
observed (Selby et al. 1998). These data are shown clinically as
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demonstrated by a case report of a woman with hairy cell leukaemia, in 
which the authors state that cladribine is drug of choice for hairy cell 
leukaemia because of the ease of administration, it is well tolerated and 
has minimal side effects (Seshadri et al. 2000).
Jeha et al. (2004) found that clofarabine was well tolerated in children 
with relapsed acute lymphatic leukaemia, and, importantly for its 
implications in breast cancer, is well tolerated even in the elderly (Pui et 
al. 2005). A study by Cooper et al. (2004) identified that clofarabine was 
again well tolerated and the dose-limiting toxicity was 
myelosuppression. However, the number of patients in this group was 
small (n=13) and the solid tumours were not defined, although they 
were stated to be metastatic.
1.7 Conclusions
Although treatments for breast cancer have come a long way as 
suggested by the reduced incidence and mortality of breast cancer, 
there is still an obvious need to develop further treatments. Whilst 
treatments for those women who are ER-positive, or who overexpress 
Her2 with aromatase inhibitors or trastuzumab, respectively, are well 
established and achieve good response rates, there is a subset of 
women who benefit little from these methods of therapy and instead rely 
on standard cytotoxic chemotherapy (Howell et al. 2005). Those termed 
triple-negative, although making up a small number of breast cancer 
patients, have limited treatment choice and very poor prognosis (Doane 
etal. 2006).
Targeted therapies are the mainstay of research in the modern era, but 
the effectiveness of cytotoxic agents cannot be ignored. Their 
limitations however, including toxicity towards other tissues and side- 
effects, are a major drawback and can drastically reduce quality of life 
for patients on these therapies. The PNAs are a unique sub-set of 
cytotoxic agents in that they can offer some selectivity over standard
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cytotoxics, which also contributes to them being well tolerated and thus 
having reduced side effects. Another major advantage of using PNAs is 
that they are already in the clinic and their usage and safety profiles are 
well documented, with clinicians having wide experience in their use. 
This could potentially lead to the treatments being available to patients 
much sooner, and having the advantage of clinicians knowing the most 
effective regimes for these drugs.
1.8 Thesis Aims
The principle aims of this thesis were to investigate the activity and 
mechanisms of action of adenosine, 2 ’-deoxyadenosine and their 
clinically used analogues in breast cancer cell lines in vitro.
The main objectives for this thesis include:
• To investigate the expression and role of adenosine receptors in 
breast cancer cell proliferation.
• To determine what effects manipulating endogenous and 
exogenous adenosine and 2 ’-deoxyadenosine would have on the 
viability of breast cancer cells
• To investigate the pharmacological activity of clinically used 
purine analogues in breast cancer cell lines.
• To determine the mechanism(s) of action of these analogues and 
to identify any particular relationships between breast cancer 
phenotypes and drug activity.
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Chapter 2: Materials and Methods
This chapter details the materials and methods for the experimental 
work carried out during this thesis. At the start of each experimental 
chapter there is also a brief overview of the methods used.
2.1 Materials
2.1.1 General Reagents
All general laboratory reagents and plastic/glassware were from Sigma 
(Poole, UK) or Fisher Scientific (Loughborough, UK) and were 
analytical or molecular biology grade.
The bicinchoninic acid (BCA) protein assay kit was from Thermo 
Scientific (Hampshire, UK). Bis-acrylamide, sodium dodecyl-sulfate 
(SDS) and ammonium persulphate were from BioRad (Hemel 
Hempstead, UK). Nitrocellulose membrane was from GE Healthcare 
(Buckinghamshire, UK). Western blot cassettes were from Invitrogen 
(Paisley, UK). Blotto was made using full fat Marvel milk powder.
2.1.2 Cell Culture
RPMI 1640 (with and without phenol red), 0.025% trypsin/EDTA, 
phosphate buffered saline (PBS) and L-glutamine came from Invitrogen 
(Paisley, UK). Foetal calf serum was from Hyclone (Thermo Scientific, 
Hampshire, UK).
All plasticware including plates, culture flasks, centrifuge tubes and 
stripettes came from Coming (Fisher Scientific, Loughborough, UK).
The MTS reagent was purchased from Promega (Hampshire, UK). 
Isoton and accuvettes were purchase from Beckman Coulter (High 
Wycombe, UK).
2.1.3 Drugs
All drugs were obtained from Tocris Bioscience (Bristol, UK) apart from 
the following, adenosine, 2 ’-deoxyadenosine, 2 ’-deoxycytidine, inosine, 
hydroxyurea and 5 ’-amino-5 ’-deoxyadenosine were from Sigma (Poole,
43
UK). Adenosine deaminase was from Roche Diagnostics (Lewes, UK). 
Sterile DMSO used as the vehicle was from Sigma (Poole, UK).
2.1.4 Antibodies
The (3-actin antibody was from Sigma (Poole, UK). GAPDH, cN-ll, 
p53R2, total ERK 1/2 (tERK1/2), phosphorylated ERK 1/2 (pERK1/2), 
adenosine Ai and A2B receptor antibodies were all from Abeam 
(Cambridge, UK). The adenosine A2A and A3 receptor antibodies were 
from Alpha Diagnostics International (Autogen Bioclear, Nottingham, 
UK).
2.1.5 Annexin V/PI Flow Cytometry
The annexin V/PI apoptosis assay kit was from Abeam (Cambridge, 
UK). FACS flow, rinse and clean solutions were all from Becton 
Dickenson (Oxford, UK). FACS tubes were from (Fisher Scientific, 
Loughborough, UK).
2.1.6 PCR
TRI® total RNA extraction reagent, 1-bromo-3-chloropropane and 
isopropanol (molecular biology grade) were bought from Sigma (Poole, 
UK). The ImProm-ll Reverse Transcription kit, 100bp DNA ladder and 
6 x sample loading dye were all from Promega (Hampshire, UK). The 
LightCycler DNA Master SYBR Green I kit and LightCycler capillaries 
were obtained from Roche Diagnostics (Lewes, UK). All primers were 
purchased from Invitrogen (Paisley, UK).
2.2 Cell Culture
2.2.1 General Cell Culture and Cell Maintenance
MCF-7 and MDAMB231 human breast adenocarcinoma cells were 
purchased from the European Cell Culture Collection (ECACC, UK). 
The human B-cell promyelocytic leukaemia cell line, HL60, was a gift 
from Dr. Arwyn Jones (Welsh School of Pharmacy, Cardiff, UK). The 
human breast cancer cell lines MDAMB436, SKBR-3, BT 474 and
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T47D were a gift from The Tenovus Centre for Cancer Research 
(Welsh School of Pharmacy, Cardiff, UK).
All cells were routinely grown in RPMI 1640 supplemented with 4 mM 
L-glutamine and 10% foetal bovine serum. All cells were maintained at 
37°C with 5% CO2 in air in a humidified atmosphere and media was 
replenished every 3-4 days. Adherent breast cancer cells were 
routinely passaged when they reached -70% confluency at a ratio of 
between 1:5 and 1:15. HL60 cells were split every 5-6 days between 
1:15 and 1:25 dilutions
To passage adherent cells, except for the MDAMB436 cells, the media 
was removed and replaced with 0.025% trypsin/EDTA. Flasks were 
returned to the incubator and left for approximately 5 minutes until the 
cells detached. A two-fold greater volume of media was added to the 
flasks and cells were resuspended by pipetting up and down, placed 
into centrifuge tubes and spun at 1000 x g for 5 minutes to pellet the 
cells. The supernatant was poured off, and the pellet resuspended in 
an appropriate volume of media which was then diluted appropriately 
into fresh flasks and new media added. The cells were then allowed to 
grow as normal at 37°C.
MDAMB436 cells were passaged by scraping off the cells into new 
media, followed by appropriate dilutions into fresh flasks and new 
media being added. The cells were then allowed to grow as normal at 
37°C.
To passage the HL60 cells, the cells were transferred to a centrifuge 
tube and centrifuged at 1000 x g for 5 minutes to pellet the cells. The 
supernatant was poured away, and the remaining pellet resuspended 
in media by repeated pipetting up and down. Appropriate dilutions were 
then transferred to fresh flasks, new media added and allowed to grow 
as normal.
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Cells were not allowed to go past 15 passages from cell resuscitation 
in order to preserve the integrity of the cell lines and subsequent 
experiments.
2.2.2 Setting up 96 Well Plates
Cells were passaged in log growth phase at -70% confluency. After 
collection of the cells by the appropriate methods described above, 100 
pL of the cell suspension was added to 9.9 mL of Isoton (Beckman 
Coulter) in an accuvette and 500 pL counted in a Beckman Z2 Coulter 
Counter set to read particle sizes between 9 and 30 pm. The cell 
suspension was then diluted accordingly, and cells were seeded into 
96 well plates at 5000 cells per well. No cells were seeded into edge 
wells to exclude possible edge effects during the assay. The cells were 
left to plate down for 24 hours before drug treatments were added.
2.2.3 Setting up 24 Well Plates
Cells were collected and counted as described above, and seeded into 
24 well plates at a density of 10,000 cells per well. The cells were left 
to plate down for 24 hours before the media was changed and cells 
were allowed to grow for the desired time before counting
2.2.4 Setting up 6 Well Plates
As before, cells were collected, counted and seeded into 6 well plates 
at 300,000 cells per well for the MAPK and adenosine agonist assay, 
or 100,000 cells per well for drug treatment and lysis for Western 
blotting. In each case, the cells were then left to plate down for 24 
hours before treatments or media were added.
2.2.5 Cellular Quiescence
For the MAPK/adenosine receptor agonist assay, cells were quiesced 
prior to addition of drug treatments for 24 hours to reduce basal MAPK 
signalling. After the cells had been left to plate down for 24 hours, the 
media was removed and cells were washed with sterile PBS to remove 
any residual media. The media was then replaced with quiescence
46
media (RPMI 1640 without phenol red, 4 mM L-glutamine and 0.1% 
charcoal-stripped foetal bovine serum). This media was then left on for 
24 hours before the assay prior to the addition of adenosine receptor 
agonists and antagonists.
2.3 MTS Cell Viability Assay
To determine the cytotoxic effects and mechanism(s) of action of the 
various drugs, the CellTiter 96® AQueous Assay (Promega, UK) was 
performed following incubation of the cells with these agents. The 
assay uses a tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3- 
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; 
MTS) and the electron-coupling reagent, phenazine methosulfate. In 
metabolically active cells, MTS is reduced by dehydrogenase enzymes 
into a formazan product that is soluble in culture medium. The 
absorbance of the formazan is then measured at 492nm. The assay 
works on the principle that the quantity of the formazan product is 
directly proportional to the number of viable cells.
2.3.1 Setting up Treatments
Cells were set up in 96 well plates as described (2.2.2). Drug 
treatments at the appropriate concentrations were made up in normal 
growth media and warmed to 37°C. The media on the cells was then 
aspirated and replaced with 100 pL of drug treatment. Drug treatments 
and controls were repeated in at least triplicate wells and three empty 
wells on the edge of the plate had 100 pL of normal drug-free media 
added for the background control. Cells were then left for 96 hours 
(unless stated otherwise) at 37°C in a 5% CO2 humidified atmosphere.
2.3.2 MTS Assay
After the required incubation time with the drug treatments the MTS 
assay was performed. To each well, including the three blank media 
control wells with no cells, 20 pL of MTS reagent was added, the plate 
wrapped in foil and placed back into the incubator. This was then left
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for 2 hours before the absorbance was determined using a microtitre 
plate reader (Tecan, Switzerland) at 490 nm.
The % of cell viability was then calculated by the following formula: 
(mean Abs. of treated cells -  mean Abs. of blanks)
—— ---------------------------------------------------------- —  X 100 = % cell viability
(mean Abs. of control cells -  mean Abs. of blanks)
Abs. (Absorbance reading)
2.4 Annexin V/Propidium Iodide Apoptosis Assay
The annexin V/propidium iodide (PI) apoptosis assay was used to 
determine and quantify apoptotic and dead cells after drug treatment. 
The assay works on the principle that one of the earliest stages of 
apoptosis is the translocation of phosphatidylserine residues to the 
outer side of the plasma membrane. Annexin V is an anticoagulant 
protein that preferentially binds to phosphatidylserine and, when 
labelled with a fluorochrome such as fluorescein isothiocyanate (FITC), 
can be detected by flow cytometry (Koopman et al. 1994). PI is then 
used as an indicator of plasma membrane integrity as only cells that 
have lost membrane integrity i.e. late apoptotic/necrotic cells will allow 
entry of PI and thus binding to nucleic acids.
2.4.1 Setting up Flasks
For the assay, 500,000 cells were seeded into 25 cm2 flasks and left to 
plate down overnight at 37°C. Appropriate drug treatments, including 
positive (2 pM staurosporin), vehicle and negative controls were made 
up in normal growth media and warmed to 37°C. The media was then 
removed from the flask, and replaced with 3 ml_ of drug media. Positive 
controls were replaced with normal growth media, and then this was 
replaced with staurosporin-containing media 48 hours before the end of 
the assay. This was because staurosporin induced complete cell death
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after 96 hours and the cells could not be analysed using flow 
cytometry.
2.4.2 Sample Preparation
After 96 hours of drug treatment, the media was removed and 
centrifuged at 1000 x g for 5 minutes to pellet any detached cells. The 
flasks were rinsed gently in PBS, and 1 mL of pre-warmed trypsin was 
added and left until the cells became detached. 2 mL of normal growth 
media was added to this, and the cell suspension was centrifuged at 
1000 x g for 5 minutes. The supernatant was then removed and the cell 
pellet, resuspended in 1 mL of PBS, was added to the media cell pellet 
and resuspended by gentle pipetting up and down. This was then 
centrifuged again as before, and 1 mL PBS added and cells 
resuspended. Again this was centrifuged as before, and the PBS then 
removed. The cell pellet was resuspended in 500 pL annexin V binding 
buffer (Abeam, UK) and then passed through a fine gauge needle 
(21G) to create a single cell suspension. To this, 0.25 pg annexin V- 
FITC conjugate and 1 pg PI was added and pipetted up and down to 
mix. This suspension was then left on ice for 5 minutes in the dark 
before being analysed immediately using FACS.
2.4.3 Flow Cytometry
A BD FACSCalibur system was used with the FL1 and FL2 channels to 
detect FITC and PI, respectively, set to count 10,000 counts. Negative 
control cells (no staining) were used first to calibrate the flow cytometer 
using forward and side scatter to gate out debris and non-specific 
counts by altering the voltage, amp gain and threshold values. The 
region was gated and set to record counts only within this region. The 
voltage on the FL1 and FL2 channels was altered to bring the negative 
control within the first log on each scale. Next, single colour controls 
were used for FITC and PI to correct for colour compensation where 
FITC and PI channels bleed into one another by adjusting the 
compensation between FL1-%FL2 and FL2-%FL1. Once calibrated,
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samples were analysed using a dot plot and quadrants (see 
representative dot plot; Figure 2.1). The data were collected using 
CellQuest software (Becton Dickinson, Oxford, UK) and analysed in 
Cyflogic software (CyFlo Ltd, Turku, Finland).
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Figure 2.1 Representative dot plot obtained from Annexin V/PI stained 
cells and analysed with flow cytometry
Live cells that are negative for both annexin V and PI appear in the lower left 
quadrant. Cells in the lower right quadrant are positive for annexin V but have 
not taken up PI and in the early stages of apoptosis. The upper right quadrant 
contains cells that are in late apoptosis/necrosis and are stained with both 
annexin V and PI.
2.5 Western Blotting
Western blotting was used to determine the expression of proteins in 
cells and, combined with densitometry, was used to semi-quantify this 
expression. Western blotting uses antibodies to bind to and ‘label’ a 
specific protein which is then detected, in this instance using enhanced 
chemiluminescence (ECL).
2.5.1 Normal Cell Lysis
Cells were set up in 6 well plates as described (2.2.4) at the required 
seeding density. After the appropriate treatment time, media was 
removed and wells were gently washed in 1 x PBS twice. Lysis buffer
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was then added (Tris 50 mM, EGTA 5 mM, NaC1150 mM, Triton-X 1%, 
NaV04 0.4 mM, NaF 50 mM, phenylmethanesulfonylfluoride 1 mM, 
phenylarsine oxide 20 mM, sodium molybdate 20 mM, leupeptin 0.1 
mg/mL and aprotinin 0.1 mg/mL) to the cells, and placed upon a rocker 
on ice for 15 minutes. Cells were then scraped off and transferred to 
microcentrifuge tubes on ice. These were then spun at 16,000 x g for 
15 minutes at 4°C. Supernatants were then aliquoted into boiling tubes 
and stored at -20°C.
2.5.2 Cell Lysis for MAPK Assay
The cells were quiesced for 24 hours as described (2.2.5). Drug 
treatments were made up in quiescing media and warmed to 37°C. The 
media was removed and replaced with drug media for the stated 
amount of time (0 minute time point was where the drug was added 
and taken off again immediately). The reaction was then stopped by 
removal of the drug media, and addition of the lysis buffer. Cells were 
then lysed as before (2.5.1).
2.5.3 Protein Assay
The BCA protein assay is a colourmetric method for determining total 
protein concentration in samples. It is based upon the reduction of 
copper ions by proteins in alkaline medium and detection of the 
cuprous cation. The purple-coloured reaction is formed by chelation of 
two molecules of BCA with one cuprous ion that exhibits strong 
absorbance at 592 nm and is linear with increasing protein 
concentrations up to ~2 mg/mL. Unknown concentrations are 
calculated by comparing to a standard curve of serial diluted protein 
concentrations.
Firstly, a serial dilution of bovine serum albumin was prepared in the 
range of 0.01 to 2 mg/mL in H2O. Both H2O and lysis buffer were also 
used and served as background controls. The working reagent was 
prepared according to the manufacturer’s instructions (Pierce, UK) and 
between 1 - 5 pL of each standard or sample was added to a 96 well
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plate in duplicate. To each standard or sample, 200 pL of the working 
reagent was added and the plate mixed on a plate shaker for 30 
seconds. The plate was then incubated for 30 minutes at 37°C before 
being cooled to room temperature for 5 minutes to stop the reaction.
The absorbance was then read on a microplate reader at 540 nm and 
the average of the duplicates for each sample or standard was 
calculated, with the average of the relevant blank subtracted from each 
calculated average. A standard curve was drawn and the 
concentrations of the unknown samples were calculated.
2.5.4 SDS-PAGE
Proteins were resolved routinely on 8-10% bis-acrylamide gels set in 
Novex gel cassettes (Invitrogen, UK). An 8-10% resolving gel was 
prepared (8-10% acrylamide, 375 mM Tris/HCI, 0.1% w/v SDS, 0.05% 
w/v ammonium persulfate and 0.05% TEMED) and poured into the 
cassettes. Water-saturated 2-butanol was overlaid on the gel and it 
was left to set for -30  minutes. Once set, the 2-butanol was decanted 
and the cassette/gel was washed with distilled H2O. A 5% stacking gel 
was prepared (5% acrylamide, 1% w/v SDS/125 mM Tris/HCI, 0.05% 
w/v ammonium persulfate and 0.08% TEMED) and poured over the 
resolving gel immediately prior to inserting a well comb to create lanes. 
The gel was then left to set for 30 minutes at room temperature. Once 
set, the comb was removed and the gel washed with 1 x tank buffer (25 
mM Tris, 192 mM glycine and 0.1% SDS, pH 8.6).
Protein samples were made up in Laemmli sample buffer at a ratio of 
2:1 (6% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% 
bromophenol blue and 125 mM Tris HCL, pH 6.8), vortexed thoroughly 
and then spun down. This was then heated at 95°C for 5 minutes 
before use. Between 5 and 20 pg of protein was loaded per well 
depending on the assay. A protein marker (Precision Plus Protein 
Standard, BioRad, Hertfordshire, UK) was added to each gel to allow
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for sizing of the bands. The gels were run for 30 minutes at 50 V, 
followed by 120 minutes at 150 V.
2.5.5 Immunoblotting
After electrophoresis, gels were removed from the cassettes and 
placed into transfer buffer (42.9 mM Tris, 38.9 mM glycine, 0.038% w/v 
SDS and 20% methanol). Filter papers and 0.2 pm Hybond™ ECL™ 
nitrocellulose membrane (GE Healthcare, Buckinghamshire, UK) were 
cut into 6 x 8 cm pieces, the same size as the gel, and soaked in 
transfer buffer. The proteins were transferred from the gel to the 
nitrocellulose membrane using a semi-dry Multiphor II Electrophoresis 
system (GE Healthcare, Buckinghamshire, UK). The cathode was 
wetted with transfer buffer, and a stack of filter papers placed upon it. 
The nitrocellulose membrane was placed on top of this, followed by the 
gel. Another stack of filter papers were placed upon this, and any 
trapped air was removed by gently rolling the stack with a glass rod. 
Finally the anode was fitted on top of this, and gels blotted for 60 
minutes at 0.8 mA/cm2 gel.
2.5.6 Immunodetection
Once blotted, the nitrocellulose membranes were washed in 1 x TBST 
(50 mM Tris HCL, 150 mM NaCI, pH 7.4 and 0.1% Tween 20) and 
were then blocked in 5% Blotto (1 x TBST and 5% non-fat milk powder, 
filtered through qualitative filter paper to remove aggregates of milk 
powder) for at least 60 minutes at room temperature. If blocked 
overnight, then this was done at 4°C. Primary antibodies were diluted 
in 1 % or 2% Blotto (1 x TBST and 1 or 2% blotto) to a final volume of 1 
or 2 mL and the membranes incubated on a roller overnight at 4°C, or 
for 1 hour at room temperature. The next day, the blots were washed 
rapidly in 1 x TBST twice to remove excess antibody, followed by 2 x 5 
minutes and 1 x 10 minute washes. The horseradish peroxidase- 
conjugated secondary antibody (range between 1:10,000 and 
1:60,000) to the primary was diluted again in 1% Blotto and incubated
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with the blots for 1 hour at room temperature. The blots were then 
washed as before, with two rapid washes followed by 2 x 5 minute and 
1 x 1 0  minute washes.
Proteins were visualised by an ECL detection system. Excess liquid 
was shaken off the blots and they were placed onto Saran™ wrap. A 
1:1 solution of solution A and B from the Supersignal® West Dura 
Extended chemiluminescent substrate kit (Pierce Biotechnology, UK) 
was allowed to incubated with the blots for 5 minutes. Membranes 
were then exposed to ECL Hyperfilm (GE Healthcare, 
Buckinghamshire, UK) in a dark room. Exposures ranged from 1 
second to 120 minutes depending upon signal strength. If no bands 
appeared after this time, then exposures were left overnight to confirm 
no signal was present. The films were developed using Photosol RG X- 
ray developer and fixer (Photon Imaging Systems, UK) and the films 
scanned into the computer.
Densitometry was carried out on scanned images using ImageJ 
software (NIH, USA). Protein bands were sized by calculating an Rf 
value against the protein ladder standards and were expressed as the 
average of at least three separate blots ± S.E M.
2.6 Real Time-PCR
Real time -  polymerase chain reaction (RT-PCR) was used to semi- 
quantitate levels of RNA of particular genes. RT-PCR involves reverse 
transcribing RNA extracted from cells using a reverse-transcriptase 
enzyme to produce a cDNA template. This is then incubated with gene- 
specific primers and DNA polymerase to amplify a particular segment 
of DNA within the gene region by heating and cooling cycles. The end 
result is an exponential increase in DNA copies of this segment that 
can be recorded. The product can be run through an agarose gel and 
compared to a specific base pair sized ladder to determine the product 
size. In the SYBR green assay, however, SYBR green is added to the 
reaction mix, which preferentially binds to double-stranded DNA over
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single stranded DNA, and emits a fluorescence signal. This signal is 
then recorded, and is proportional to the amount of gene product 
made. This process can be made quantitative by producing a standard 
curve of known RNA copy numbers of the particular gene of interest. It 
is semi-quantitative when making relative quantification methods 
against a control cell line or treatment.
2.6.1 Primer Design
Primers were designed for specific use in SYBR green real-time PCR 
with Beacon Designer 7.60 software (Premier Biosoft, California, USA) 
and checked for selectivity using Basic Local Alignment Search Tool 
(NCBI) and are shown in Table 2.1 below.
Gene Primer Sequence Product
Size
Melting Tm of 
Product (°C)
GAPDH Forward GTCGGAGTCAACGGATTT 220 81.6
Reverse CCT GG AAG ATGGT GAT GG
dCK Forward CGCCACAAGACTAAGGAA 139 82.2
Reverse AGGATATT CACAAAT GTT GACTT C
cN-ll Forward GACAGCAGTAGCAATGAG 195 81.2
Reverse GTAATACAGCAGGTT GAT G A
RRM1 Forward ACAT CC ACATT GCT G AGCCTAA 195 78.5
Reverse TGTT CCT CT CCTT CT CTT CTT CCT
RRM2 Forward CT GGCT GGCT GT GACTTA 120 79.8
Reverse ACTGGCTGTGCTGGTTAA
p53R2 Forward CTTT GTTT CCCACCATTT CCCTTT 168 76
Reverse CT CT CC AGCCTT CCAT CTT CAC
Table 2.1 Description of Primers, Their Amplicon Sizes and Melting 
Temperatures.
55
Primers were designed to have an optimal annealing temperature of 
60±2°C, be between 18-25 base pairs in length and be exon spanning 
if possible. Primers were selected according to these criteria and as 
judged by the designer software and also the likelihood of forming 
cross-dimers, self-dimers or hairpins.
2.6.2 RNA Extraction and Quantification
All work for PCR was done using RNase/DNase free sterile pipette tips 
and microcentrifuge tubes. All reagents were of molecular biology grade 
and free of RNase/DNase and contaminating RNA/DNA. All work was 
carried out on ice unless stated otherwise.
The RNA extraction procedure is based upon the widely used methods 
from Chomczynski and Sacchi (1987) using TRI® reagent, a total RNA 
isolation reagent. The reagent contains guanidine thiocyanate and 
phenol which act to dissolve DNA, RNA and proteins. Adherent cells 
were grown in a 25 cm2 flask until -60% confluent. The media was 
aspirated and 2.5 mL of TRI® reagent was added to the cells. HL60 
cells were grown for 3 days after passage to ensure they were in 
logarithmic growth phase, spun down and 2.5 mL of TRI® reagent was 
added to the cell pellet and resuspended by pipetting up and down. 
This suspension was left on the cells for -15 seconds and then 
transferred into microcentrifuge tubes. The cell suspensions were 
centrifuged at 12,000 x g for 10 minutes at 4°C to remove cell debris. 
The supernatant was then transferred into microcentrifuge tubes. In a 
fumehood, 0.5 mL of 1 -bromo-3-chloropropane was added, tubes were 
capped and shaken vigorously for 15 seconds before being left for 15 
minutes at room temperature. This mixture was then aliquoted equally 
into two microcentrifuge tubes and centrifuged at 12,000 x g for 15 
minutes at 4°C. The upper, clear aqueous phase containing the RNA 
was removed into a sterile tube and 1.5 mL 2-propanol was added and 
vortexed. This mixture was allowed to stand at room temperature for 10 
minutes before being centrifuged again at 12,000 x g for 15 minutes at
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4°C. The supernatant was carefully removed, being careful not to 
disturb the RNA pellet at the bottom of the tube, before being allowed to 
air dry at room temperature. The pellet was then washed by adding 2.5 
mL of 75% aqueous ethanol, and pipetted up and down. The sample 
was then vortexed and centrifuged at 7,500 x g for 5 minutes at 4°C. 
The ethanol was then removed and the pellet allowed to nearly dry, 
being careful not to over-dry the pellet. The pellet was then suspended 
in PCR-grade water and stored at -80°C until use.
RNA content and purity was established by determining the optical 
density at 260 nm and 280nm by UV spectroscopy. Absorbance at 260 
nm measures RNA content whereas absorbance at 280 nm measures 
protein content. RNA content compared to protein content is used to 
establish the purity and yield of RNA from the extraction and a ratio of 
£1.7-2.0 RNA to protein is considered suitable. Total RNA yield and 
concentration is calculated from the following formulae:
Total A26onm = optical density x dilution factor
RNA Concentration (pg/mL) = Total A260 nm x 40*
RNA Yield = RNA concentration x Original resuspension volume
* 1 optical density unit of single-strand RNA is = 40 pg/mL
2.6.3 Reverse Transcription
The Im-Prom II Reverse Transcription kit (Promega, USA) was used for 
the reverse transcription and the method was followed as described by 
the manufacturer. To 1 pg RNA, 0.5 pg of Oligo(dT)15 was added and 
made to volume (10 pL) with H2O. The solution was heated at 70°C for 
5 minutes and then rapidly quenched on ice for at least 5 minutes. 
Tubes were spun down to collect any condensate. To this, 5 x reaction 
buffer, MgCfe (3.25 mM final concentration), dNTPs (0.5 mM final 
concentration for each dNTP), RNase inhibitor (20 lU/per reaction) and 
reverse transcriptase (1 lU/per reaction) were added, made up to
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volume (20 pL) with H2O and mixed by pipetting up and down. This 
solution was then incubated at 25°C for 5 minutes followed immediately 
by 42°C for 1 hour. The reverse transcriptase was then inactivated by 
heating for 15 minutes at 70°C. cDNA were then stored at -80°C until 
use.
2.6.4 RT-PCR
The RT-PCR was carried out using the LightCycler® DNA Master 
SYBR Green I kit (Roche Applied Science, Burgess Hill, UK) according 
to the manufacturer’s instructions. A master mix was prepared 
containing H2 0 , MgCh (3 mM final concentration), primers (0.5 pM final 
concentration each) and 1 x SYBR green I mix which contains Taq DNA 
polymerase, dNTP mix, SYBR Green I dye and 10 mM MgCh, which 
was made to a final volume of 19 pL per reaction and scaled up 
accordingly. To each capillary, 19 pL of the master mix was added, and 
1 pL of cDNA or 1 pL of the reverse transcription negative control (RNA 
that was incubated under the same conditions as normal, but the 
reverse transcriptase enzyme was replaced with H2O) or H2O control 
was added. These were capped and pulsed in a microcentrifuge to 
transfer the liquid from the reservoir into the capillary body. The 
capillaries were then transferred to the LightCycler and the PCR was 
run immediately.
The conditions for the PCR runs are detailed in the methods section of 
each chapter accordingly. All PCR runs followed the same protocol:
1. Denaturation -  initial separation of the DNA strands
2. Amplification
a. Denaturation -  DNA strand separation
b. Annealing -  primer annealing
c. Elongation -  elongation of the product
3. Melting Curve Analysis -  increased heating for amplicon 
identification
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4. Cooling -  cools the rotor and samples chamber
The exception to this was when PCR amplicons were to be run under 
gel electrophoresis for size comparison where the melting curve 
analysis step was omitted.
2.6.5 Gel Electrophoresis
For amplicon size analysis, PCR amplicons were run on a 2% agarose 
gel to separate the amplicons based upon size and compared to a base 
pair ladder of known sizes.
After the cooling step, the capillaries were de-capped, and place upside 
down into DNase/RNase free 1.5 mL microcentrifuge tubes and pulsed 
in a microcentrifuge for 5 seconds to transfer the sample into the tube. 
These were then capped and stored at -20°C until use, but were not 
kept for more than 48 hours. A 2% agarose gel was prepared in 1 x Tris 
acetate EDTA (TAE) buffer and contained 0.005% ethidium bromide. 
Samples were mixed with loading dye and 15 pL was loaded into the 
gel. The gel was then run at 100V for approximately 1 hour. The gel 
was then visualised under UV illumination and photographed using an 
Alpha DigiDoc room temperature system (Alpha Innotech, USA).
2.6.6 Relative Quantification
Relative quantification of RNA to a particular gene measures the 
relative difference in RNA levels compared to a control treatment, 
sample or group. It does not determine an absolute copy number, as 
can only be achieved with a standard curve (Pfaffl et al. 2006). Relative 
quantification was used for this thesis due to the lack of availability of 
standards for the different genes investigated and also as this method 
allows for comparisons between multiple PCR runs (Pfaffl et al. 2006).
To determine expression, the threshold cycle (Ct) value is calculated by 
the LightCycler Software v3.5 (Roche, Burgess Hill, UK) using the 
second derivative maximum method. The Ct value is the number of 
cycles required for the fluorescent signal to pass a predetermined
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threshold i.e. the more RNA, the lower the Ct value will be. This method 
calculates the Ct value automatically and therefore reduces user 
subjectivity and increases reproducibility.
Relative quantification of the genes was determined using the HL60 cell 
line as the control group comparator. Each PCR run included a negative 
control as described (2.6.4) and GAPDH as a positive control. All data 
were then normalised to GAPDH data to correct for any differences in 
starting RNA and cDNA levels. The normalised data were uploaded into 
Relative Expression Software Tool (REST, Germany) and the relative 
expression of genes was calculated compared to HL60 cells. The 
software determines significant differences between groups using a 
pair-wise fixed reallocation randomisation test (Pfaffl etal. 2002).
2.7 Cell Growth Assay
Cells were seeded into 24 well plates as described (2.2.3), set up in 
triplicate. After being left to plate down overnight, the media was 
aspirated and replaced with 1 mL fresh media. The cells were then 
returned to the incubator and left for the required time, 24, 48 or 96 
hours. At the appropriate time point, the media was removed from the 
cells, and replaced with 0.1% trypsin/EDTA and returned to the 
incubator until the cells were detached. The cells were taken up into a 
syringe through a 21G needle to create a single cell suspension. 1 mL 
of Isoton was added to the well to obtain any remaining cells, and this 
was also taken up into the syringe. This step was repeated twice more 
until a final volume of 4 mL was in the syringe. This was then 
transferred into an Accuvette containing 6 mL of Isoton and counted on 
the Beckman Coulter Counter 22 set to measure 500 pL reading 
particles between 9 -  30 pm. Readings from each Accuvette were 
taken in duplicate and the mean taken.
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2.8 Data Analysis
All IC50 data were calculated using GraphPad Prism v5.0b for Mac OS 
X. Concentration response curves were fitted using non-linear 
regression with a fixed slope (assumes a Hill slope = -1). This uses the 
following formula to calculate the IC50:
_ „ (Top - Bottom) y -  Bottom + -— — '
1 + 10
Where:
y = response
x = log (drug concentration)
Top = y value at the top of the plateau 
Bottom = y value at the bottom of the plateau
IC50 values are presented as the mean and the 95% confidence 
intervals (C.I.). Comparisons between IC50 of different cell lines were 
determined in GraphPad Prism, using either a Student’s t test for two 
groups, or a one-way analysis of variance (ANOVA) with a Tukey- 
Kramer post hoc test to compare multiple groups. Probability values (p) 
of less than 0.05 were considered statistically significant.
The cell MTS (excluding the dose-response curves explained above), 
annexin V FACS and densitometry data from Western blotting are 
displayed as the mean ± S.E M. unless otherwise stated. Comparisons 
between groups were determined in GraphPad Prism, using either a 
Student’s t test for two groups, or a one-way ANOVA with a Tukey- 
Kramer post hoc test if a significant difference was observed between 
three or more groups. If only selected means were compared than the 
Bonferroni correction test was used. The Kramer correction corrects for 
unequal sample sizes. The Tukey-Kramer assumes normally distributed 
data, although this was not calculated as the n were too small (£3 but 
<5). A two-way ANOVA was used to determine statistical significance
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when two independent variables were being considered, such as time 
and concentration, followed by a Bonferroni posf hoc test. Probability 
values (p) of less than 0.05 were considered statistically significant.
Correlations between IC50 values and gene expression (determined by 
REST software, section 2.6.6) were determined using GraphPad Prism. 
The Pearson correlation coefficient (r) was calculated for each gene 
compared to the IC50 value. Probability values (p) of less than 0.05 
were considered statistically significant.
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Chapter 3: The Effects of Adenosine and 2’- 
Deoxyadenosine on Human Breast Cancer Cells
3.1 Introduction
Adenosine and 2’-deoxyadenosine are essential purine nucleosides that 
have functions in regulating blood flow, inflammation and neuronal 
excitability. They are also precursors for essential molecules such as 
cAMP, ATP and as a nucleobase in DNA/RNA (Yoon and Rothman 
1991; Cronstein 1994; Davis etal. 2003).
Synthesis occurs primarily by dephosphorylation of adenine nucleotides 
or via hydrolysis of S-adenosylhomocysteine (Luippold et al. 1999; 
Ldffler et al. 2007). Their metabolism is regulated primarily by ADA, 
which deaminates adenosine and 2’-deoxyadenosine to inosine and 2 -  
deoxyinosine, respectively (Ozturk et al. 2008). Cellular uptake helps 
regulate the extracellular concentration of these purines and occurs via 
ENTs and CNTs (Fang et al. 1996). Intracellular adenosine and 2 -  
deoxyadenosine can be phosphorylated by adenosine kinase and 
successive purine kinases to nucleotides (Lloyd and Fredholm 1994).
Adenosine concentrations are known to significantly exceed 
physiological levels in states of hypoxia including those observed in the 
extracellular fluid of solid tumours (Blay et al. 1997) where it is 
suggested to play a role in stimulating angiogenesis (Ryzhov et al. 
2007). This increase in adenosine may also aid tumour development by 
functioning as an immunosuppressant (Linden 2006). Several studies 
have also suggested that adenosine can stimulate the growth of tumour 
and normal cell lines by mechanisms independent of 
immunosupression or angiogenesis and by both adenosine receptor- 
dependent and independent means (Lemmens et al. 1996; Mujoomdar 
et al. 2003; Jacques-Silva et al. 2004; Mujoomdar et al. 2004; Gessi et 
al. 2007).
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Despite evidence highlighting the role of adenosine in supporting 
tumour growth, numerous studies have identified adenosine and 2 ’- 
deoxyadenosine as inhibiting the growth of human breast, colon, 
gastric, ovarian and leukaemic cancer cell lines mostly via a mechanism 
requiring intracellular phosphorylation (Tanaka et al. 1994; Barry and 
Lind 2000; Saitoh et al. 2004; Hashemi et al. 2005). Other groups have 
identified non-specific intracellular mechanisms of action for adenosine 
in hepatocellular carcinoma cells (Wu et al. 2006) and in U973 cells 
(Schneider et al. 2001). The clinically used anti-cancer agent 
deoxycoformycin is an inhibitor of ADA and is suggested to work by 
increasing intracellular adenosine and 2 ’-deoxyadenosine nucleotides 
causing an imbalance of dNTP pools and inhibiting S- 
adenosylhomocysteine hydrolase. These effects lead to an impaired 
ability of the cell to synthesize and repair DNA, ultimately leading to 
either cellular quiescence or cell death (Fidias et al. 1996, Dillman 
2004). Further evidence that supports an intracellular mechanism of 
action comes from work with the PNA drugs cladribine, fludarabine and 
clofarabine that are all known to work by intracellular phosphorylation, 
and completely independently of adenosine receptor activation 
(Galmarini et at. 2001).
However, there is evidence that the anti-cancer activity of adenosine 
and adenosine agonists is due to adenosine receptor activation via Ai 
(Colquhoun and Newsholme 1997; Sai et al. 2006), A2A (Merighi et al. 
2003) or A3 receptors (Yao et al. 1997; Fishman et al. 2000; Ohana et 
al. 2001; Panjehpour and Karami-Tehrani 2004; Lee et ai 2005; 
Panjehpour and Karami-Tehrani 2007; Bar-Yehuda et ai 2008; Kim et 
ai 2008). Interestingly, a number of studies have found that adenosine 
receptor agonists, particularly A3 receptor agonists such as CI-IB-MECA 
and IB-MECA, are able to induce apoptosis of various cancer cell lines 
via a mechanism independent of the A3 or any adenosine receptor (Lu 
et ai 2003; Cheung et ai 2006).
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There are conflicting reports pertaining to the effects of adenosine 
receptor activation and the endogenous compounds adenosine and 2’- 
deoxyadenosine being either tumour promoters or tumour suppressors 
via a variety of different mechanisms. Further elucidation and 
confirmation of the precise roles of the receptors and adenosine and 2’- 
deoxyadenosine may open up novel therapeutic options for the 
treatment of breast cancers.
3.2 Chapter Aims
The aim of this chapter was:
• To investigate the effects of adenosine and 2’-deoxyadenosine 
on the proliferation of breast cancer cell lines and elucidate their 
mechanisms of action
The specific objectives of this chapter were:
• To establish the expression of adenosine receptors and 
determine their involvement in cell proliferation.
• To investigate the effects of endogenous and exogenous 
adenosine and 2’-deoxyadenosine on breast cancer cell viability
• To determine the mechanisms of action of adenosine and 2’- 
deoxyadenosine
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3.3 Methods
The protocols for the MTS, Western blotting and MAPK assays were 
described in detail in Chapter 2.
3.3.1 MTS Assay
Cells were seeded at 5000 cells/well into 96 well plates and allowed to 
plate down overnight. Media was aspirated from the adherent cells and 
replaced with media containing combinations or single drugs or 
enzymes from ADA (2U/mL), inosine (100 pM), deoxycoformycin (1 
pM), CGS 15943 (1 pM) or 5-amino-5‘-deoxyadenosine (50 pM). 
Adenosine and 2’-deoxyadenosine (0.01 -  1000 pM) were used in the 
presence of 1 pM deoxycoformycin. Relevant media only, vehicle 
(DMSO 0.25%) and blank controls were included on each plate. Cells 
were then left for 96 hours at 37°C in 5% CO2 in a humidified 
atmosphere. The MTS assay was then performed as described (section
2.3.2).
3.3.2 Western Blotting
MCF-7 and MDAMB231 cell lysates were prepared from cells in 
logarithmic growth phase and protein quantified as described in 
sections 2.5.1 and 2.5.3, respectively. Routinely, 20 pg of protein were 
separated using SDS-PAGE and proteins were then transferred to 
nitrocellulose membrane using semi-dry immunoblotting (section 2.5.5). 
After blocking, membranes were incubated with the primary antibodies 
overnight at 4°C in 1% Blotto before being washed, probed with 
secondary antibodies, washed again and detected using ECL. The 
concentrations of primary and secondary antibodies are given below.
p-actin 1° 1:50,000
2° 1:50,000 anti-mouse
Ai 1° 1:2000
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2° 1:10,000 anti-rabbit
A2A 1° 1:1000
2 ° 1 :1 0 , 0 0 0  anti-rabbit
A2B 1° 1:1000
2 ° 1 :1 0 , 0 0 0  anti-rabbit
A3 1° 1:250
2 ° 1 :1 0 , 0 0 0  anti-rabbit
3.3.3 MAPK Assay
MCF-7 and MDAMB231 cells were quiesced as described (see Section 
2.2.5). Adenosine or 2’-deoxyadenosine (100 |j M )  and deoxycoformycin 
(1 pM) alone or in combination with the non-selective adenosine 
receptor antagonist CGS 15943 (1  pM) were added to the cells for the 
time periods indicated (0, 5, 10, 30 or 60 minutes) before being 
aspirated and lysis buffer added. Cells were then lysed and lysates 
subjected to SDS-PAGE and Western blotting as described (see 
Section 2.5). Controls of media only, DMSO (0.02%), CGS 15943 and 
deoxycoformycin alone were also included. The concentrations of 
primary and secondary antibodies are given below.
GAPDH 1° 1:50,000
2° 1:50,000 anti-mouse
phospho-ERK 1/2 1 ° 1:2000
2 ° 1 :1 0 , 0 0 0  anti-rabbit
total-ERK 1/2 1° 1:1000
2 ° 1 :1 0 , 0 0 0  anti-rabbit
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3.3.4 Data Analysis
All data are expressed as mean ± S. E M. except for the IC50 data which 
are expressed as the mean and the 95% confidence intervals (C.l.) 
Data were entered into GraphPad Prism V5.0b and graphs were 
plotted. IC50 values were calculated using non-linear curve regression 
with a fixed Hill slope according to the following formula:
„ DrtH/vw j. (Top - Bottom) y-Bottom +  ^ + 10(x-Logic*>
Where:
y = response
x = log (drug concentration)
Top = y value at the top of the plateau 
Bottom = y value at the bottom of the plateau
Comparisons between two groups were made using a Student’s t test 
and a one-way ANOVA was used for three or more groups with a 
Tukey-Kramer post hoc test if a significant difference was observed or a 
Bonferroni post hoc test when comparing only selected pairs of data. 
Probability values of less than 0.05 were considered statistically 
significant.
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3.4 Results
3.4.1 Expression of adenosine receptors in MCF-7 and MDAMB231 
cells
Western blotting was used to determine the expression of adenosine 
receptors in the MCF-7 and MDAMB231 cell lines. The band intensities 
were not quantified as only the expression of the receptors was sought.
The Ai receptor was present in both cell lines in apparently relative 
equal amounts (Figure 3.1 A) and appeared as a band with an average 
molecular mass of 35.3±0.5 KDa compared to the reported size of 36.5 
KDa.
The A2A receptor was present in both cell lines, seen as a band at 
43.9±1.2 KDa (expected molecular mass 44.7 KDa) (Figure 3.1 B) but 
appeared stronger in the MDAMB231 compared to the MCF-7 cells. 
Strong bands appeared consistently at ~49 and 32 KDa which 
appeared stronger in the MCF-7 cells compared to the MDAMB231 
cells. Other faint bands of high molecular mass >50 KDa frequently 
appeared in lysates from both cell lines.
The expression of the A2B was also equal apparently between the cell 
lines (Figure 3.1 C) and appeared as lone bands with a molecular mass 
of 37.6±0.6 KDa compared to the reported molecular mass of 36.3 KDa.
The A3 receptor was also present in both cell lines, but with an 
apparently stronger signal in the MCF-7 cells (Figure 3.1 D). Other 
bands were present at high molecular mass >50 KDa. Bands 
corresponding to the expected size of A3 receptor (36.2 KDa) appeared 
with a molecular mass of 35.7±0.5 KDa.
A (AO
50 KDa 
37 KDa
MCF-7 MDAMB231 B (A2A) MCF-7 MDAMB231
30 KDa -  
P-actm
--------------------------
50 KDa —>  
37 KDa —>
30 KDa —>
“ :  ~
P-actin
C ( A 2b)
50 KDa
MCF-7 MDAMB231
37 KDa
p-actin
D(A3)
50 KDa
37 KDa
P-actin
MCF-7 MDAMB231
Figure 3.1 The Expression of Adenosine Receptors in MCF-7 and 
MDAMB231 Cells
The expression o f the four adenosine receptors A-, (A), A 2a (B ) A 2b (C) and A3 
(D) were determined by Western blotting in the MCF-7 and MDAMB231 cell 
lines. Protein loading was confirmed by probing for (3-actin. Representative 
blots of three separate experiments are shown. The expected molecular 
masses of the receptors are A i 36.5 KDa, A2A 44.7 KDa (indicated by the 
arrow), A 2b 36.3 KDa and A3 36.2 KDa.
70
3.4.2 Effects of adenosine receptor antagonists on cell viability
To determine if endogenous activation of adenosine receptors was 
important for cell proliferation, selective receptor antagonists were used 
to block the receptors and cell viability was then determined with the 
MTS assay. The selective receptor antagonists used were SLV 320 
(Ai), SCH 442416 (A2a), PSB 603 (A2B) and MRS 1334 (A3) and were 
also used at selective concentrations for their receptors (100 nM; Klotz 
et al. 2000; Kalk et al. 2007).
In both cell lines, none of the selective receptor antagonists at these 
concentrations had any significant effect upon cell viability (Figure 3.2 A 
and B).
3.4.3 Effects of a non-selective adenosine receptor agonist on cell 
viability
Next to determine if exogenous activation of adenosine receptors could 
influence cell viability, the non-selective adenosine receptor agonist 
NECA (Klotz et al. 2000) was incubated with the cells and viability 
determined by the MTS assay.
In the MCF-7 cells, NECA significantly reduced cell viability by 
16.9±2.0% and 32.0±2.4% compared to control at 30 (p<0.05) and 100 
pM (p<0.001), respectively (Figure 3.3). At concentrations up to 100 
pM, NECA had no significant effect upon MDAMB231 cell viability 
(Figure 3.3).
3.4.4 Effects of manipulating endogenous adenosine and 2’- 
deoxyadenosine levels on cell viability
To investigate the function of endogenous adenosine and 2’- 
deoxyadenosine on cell viability, various agents were used to increase 
or decrease their metabolism.
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DMSO SLV SCH PSB MRS
Figure 3.2 The Effects of Selective Adenosine Receptor Antagonists on 
Cell Viability in MCF-7 and MDAMB231 Cells
The effects of the selective adenosine receptor antagonists (100 nM) SLV302 
(SLV; AJ, SCH442416 (SCH; A2A), PSB603 (PSB; A2B) and MRS1334 (MRS; 
A3) on cell viability in MCF-7 (A) and MDAMB231 (B) cells were determined by 
the MTS assay after 96 hours. Data are expressed as the mean of three 
separate experiments repeated in triplicate ± S. E M. Data were analysed 
using a one-way ANOVA and no significant differences were found.
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Figure 3.3 Effects of the Non-Selective Adenosine Receptor Agonist 
NECA on MCF-7 and MDAMB231 Cell Viability
The effects of the non-selective adenosine receptor agonist, NECA, on cell 
viability were investigated in the MCF-7 and MDAMB231 cell lines after 96 
hours using the MTS assay. Data are expressed as the mean of three 
separate experiments repeated in triplicate ± S.E.M. The dotted line indicates 
control (100%). Data were analysed using a one-way ANOVA and a 
Bonferroni post hoc test comparing selected pairs of means (between control 
and drug). *(p<0.05), ***(p<0.001) compared to control.
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ADA (2U/mL Lopes et al. 1999), the enzyme that metabolises 
adenosine and 2’-deoxyadenosine, significantly (p<0.001) reduced cell 
viability to 37.8±1.0% and 18.0±1.7% compared to control in the MCF-7 
and MDAMB231 cells, respectively (Figure 3.4). There was also a 
significantly greater reduction (p<0.001) in viability of MDAMB231 cells 
compared to MCF-7 cells with ADA treatment.
The ADA inhibitor, deoxycoformycin (1 pM) and adenosine metabolite 
inosine (1CX) pM) had no significant effects on cell viability in either the 
MCF-7 or MDAMB231 cells (Figure 3.4).
3.4.5 Effects of Exogenous adenosine and 2’-deoxyadenosine on 
cell viability
Next, the effects of adding exogenous adenosine and 2’- 
deoxyadenosine on cell viability were investigated. These studies were 
conducted in the presence of deoxycoformycin (1 pM) to inhibit the 
metabolism of adenosine and 2’-deoxyadenosine by ADA.
Adenosine was able to significantly reduce the number of viable MCF-7 
and MDAMB231 cells compared to control at concentrations £10 and 
£100 pM in the MDAMB231 and MCF-7 cells, respectively. 2’- 
Deoxyadenosine was able to significantly (p<0.001) reduce cell viability 
in MCF-7 and MDAMB231 cells at concentrations £30 pM compared to 
control (Figure 3.5 A and B). The IC50 values for adenosine in the MCF- 
7 and MDAMB231 cells were 139.7 pM (-90.1 -  369.4) and 17 pM (-7.7 
- 41.8), respectively. The IC50 values for 2’-deoxyadenosine in the MCF- 
7 and MDAMB231 cells were 46.6 pM (22.3 -  79.8) and 58.5 pM (3.7 -
113.3), respectively. There were no significant differences in the IC50 
values for either adenosine or 2’-deoxyadenosine compared to one 
another or between cell lines.
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Figure 3.4 Effects of Manipulating Endogenous Adenosine and 2’- 
Deoxyadenosine Levels on MCF-7 and MDAMB231 Cell Viability
The effects of manipulating endogenous adenosine and 2 ’-deoxyadenosine 
levels on MCF-7 and MDAMB231 cell viability was investigated using the MTS 
assay after 96 hours using adenosine deaminase (2U/mL; ADA), 
deoxycoformycin (1 pM; dCF) and inosine (100 pM). Data are expressed as 
the mean of three separate experiments repeated in triplicate ± S. E M. Data 
were analysed using a one-way ANOVA and a Tukey-Kramer post hoc test. 
*(p<0.001) compared to control (media only). *(p<0.001) compared to the 
MCF-7 cells.
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Figure 3.5 Effects of Exogenous Adenosine and 2 ’-Deoxyadenosine on 
MCF-7 and MDAMB231 Cell Viability
The effects of exogenous adenosine and 2 ’-deoxyadenosine in the presence 
of deoxycoformycin (1 pM) on MCF-7 (A) and MDAMB231 (B) cell viability 
were investigated using the MTS assay after 96 hours. Data are the mean of 
three separate experiments repeated in triplicate ± S. E M. The dotted line 
indicates control (100%). Data were analysed with a one-way ANOVA and 
Tukey-Kramer post hoc test. **(p<0.01), ***(p<0.001) compared to control.
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3.4.6 Effects of the adenosine receptor antagonist CGS 15943 on 
adenosine and 2’-deoxyadenosine activity on cell viability
The non-selective adenosine receptor antagonist CGS 15943 (1 pM; 
Klotz et al. 2000) was used to determine if the effects on cell viability of 
adenosine and 2’-deoxyadenosine were mediated through adenosine 
receptor activation.
In the MCF-7 cells (Figure 3.6 A) adenosine and 2’-deoxyadenosine 
(100 pM) significantly reduced cell viability compared to control to 
52.8±4.8% and 94.2±1.5%, respectively. In the presence of CGS 
15943, cell viability was reduced to 75.9±5.5% and 90.5±2.3% 
compared to control for adenosine and 2’-deoxyadenosine, 
respectively. CGS 15943 significantly inhibited the reduction in cell 
viability induced by adenosine (p<0.05, n=3) but not 2’-deoxyadenosine 
in this cell line.
In the MDAMB231 cells (Figure 3.6 B), adenosine and 2’- 
deoxyadenosine both alone and in the presence of CGS 15943 
significantly (p<0.05 and p<0.001) reduced cell viability compared to 
control. There was, however, no difference between adenosine and 2’- 
deoxyadenosine alone compared to these compounds in combination 
with CGS 15943.
3.4.7 Effect of adenosine and 2’-deoxyadenosine on ERK 1/2 
phosphorylation
The effects of adenosine and 2’-deoxyadenosine (100 pM; plus 1 pM 
deoxycoformycin) on ERK1/2 phosphorylation were investigated in 
MCF-7 and MDAMB231 cells alone, and in the presence of the non- 
selective adenosine receptor antagonist CGS 15943 (1 pM).
In the MCF-7 cells, there were relatively consistent levels of 
phosphorylated ERK1/2 in the media only, CGS, deoxycoformycin, 2 -  
deoxyadenosine and 2’-deoxyadenosine plus CGS treatment groups
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over time. Treatment with adenosine (in the presence of 
deoxycoformycin) increased ERK1/2 phosphorylation compared to the 
media group from 5 minutes up to 30 minutes treatment and this effect 
was reduced with the addition of CGS 15943 (Figure 3.7).
In the MDAMB231 cells phosphorylation of ERK1/2 was consistent over 
time in the media, CGS 15943 and deoxycoformycin alone treatment 
groups. ERK1/2 phosphorylation decreased over time with adenosine 
and 2’-deoxyadenosine (in the presence of deoxycoformycin) both 
alone and in combination with CGS 15943 (Figure 3.7).
3.4.8 Effects of the adenosine kinase inhibitor S'-amino'-S’- 
deoxyadenosine on adenosine and 2’-deoxyadenosine activity on 
cell viability
To examine the role of the purine phosphorylating enzyme, adenosine 
kinase in the actions of adenosine and 2’-deoxyadenosine on cell 
viability, the adenosine kinase inhibitor 5’-amino-5’-deoxyadenosine (50 
pM; Barry and Lind 2000) was used.
In the MCF-7 cells, (Figure 3.8 A) adenosine and 2’-deoxyadenosine 
(100 pM) significantly reduced (p<0.001) cell viability compared to 
control to 50.7±0.1% and 22.73±1.6%, respectively. In the presence of 
the kinase inhibitor, viability was significantly reduced (p<0.001) to 
61.8±2.9% and 71.5±5.8% compared to control for adenosine and 2’- 
deoxyadenosine, respectively. In both cases, the presence of the 
kinase inhibitor significantly reduced the action of adenosine (p<0.01) 
and 2’-deoxyadenosine (p<0.001) on cell viability but viability was still 
significantly reduced (p<0.001) compared to 5’-amino-5’- 
deoxyadenosine alone.
In the MDAMB231 cells (Figure 3.8 B), cell viability was significantly 
reduced when treated with adenosine (p<0.01) and 2’-deoxyadenosine 
(p<0.001) compared to control by 30.4±5.9% and 50.4±2.5%, 
respectively.
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Figure 3.6 Effects of the Adenosine Receptor Antagonist CGS 15943 on 
Adenosine and 2 ’-Deoxyadenosine Activity on Cell Viability
The effects of adenosine and 2 ’-deoxyadenosine (100 pM) on cell viability 
were investigated in the presence of the non-selective adenosine receptor 
antagonist, CGS 15943 (1 pM) using the MTS assay after 96 hours in MCF-7
(A) and MDAMB231 (B) cells. All adenosine and 2 ’-deoxyadenosine data are 
in the presence of deoxycoformycin (1 pM). Data are the mean of three 
separate experiments repeated in tnplicate ± S. E M, analysed with a one-way 
ANOVA and Tukey-Kramer post hoc test. *(p<0.05), ***(p<0.001) compared to 
control. **(p<0.01), ***(p<0.001) compared to CGS alone. A(p<0.05) 
compared to adenosine alone.
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Figure 3.7 Effect of Adenosine and 2 ’-Deoxyadenosine on ERK 1/2 
Phosphorylation in MCF-7 and MDAMB231 Cells
The effects of media alone, CGS 15943 (1 pM), deoxycoformycin (1pM), 
adenosine and 2 ’-deoxyadenosine (100pM) plus deoxycoformycin alone or in 
the presences of CGS 15943 on the phosphorylation of ERK 1/2 in quiesced 
MDAMB231 and MCF-7 cells by Western blotting. Representative blots are 
shown from three independent experiments. GAPDH was used to confirm 
protein loading and a representative blot of total ERK 1/2 is also shown.
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In the presences of the kinase inhibitor, the actions of adenosine were 
not significantly different compared to adenosine alone. The inhibition of 
cell viability by 2’-deoxyadenosine was significantly reduced (p<0.01) in 
the presence of the kinase inhibitor to 79.6±4.4% of control when 
compared to 2’-deoxyadenosine alone, but cell viability was still 
significantly reduced compared to 5’-amino-5'-deoxyadenosine alone, 
however.
3.4.9 Effects of saturation of dCK on the anti-cancer activity of 
adenosine and 2’-deoxyadenosine
Next, to see if the pyrimidine salvage pathway enzyme, dCK, was 
involved in the anti-cancer activity of adenosine and/or 2- 
deoxyadenosine, the enzyme was saturated with its natural substrate 
2’-deoxycytidine (100 pM; Joachims etal. 2008).
In both the MCF-7 and MDAMB231 cells, the presence of 2 - 
deoxycytidine did not significantly alter the level of inhibition caused by 
adenosine or 2’-deoxyadenosine (Figure 3.9 A and B) when compared 
to either compound alone.
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Figure 3.8 Effects of the Adenosine Kinase Inhibitor 5 ’-Amino-5’- 
Deoxyadenosine on Adenosine and 2 ’-Deoxyadenosine Activity on Cell 
Viability
The effects of adenosine and 2 ’-deoxyadenosine (100 pM) on cell viability 
were investigated in the presence of the adenosine kinase inhibitor, 5 ’-amino­
s ’-deoxyadenosine (5’AD; 50 pM) using the MTS assay after 96 hours in MCF- 
7 (A) and MDAMB231 (B) cells. All adenosine and 2’-deoxyadenosine data 
are in the presence of deoxycoformycin (1 pM). Data are the mean of three 
separate experiments repeated in triplicate ± S. E M, analysed with a one-way 
ANOVA and Tukey-Kramer post hoc test. *(p<0.05), **(p<0.01), ***(p<0.001) 
compared to control. *p(<0.05),**(p<0.01), ***(p<0.001) compared to 5 ’AD 
alone. AA(p<0.01), AAyYp<0.001) compared to adenosine or 2'-deoxyadenosine 
alone.
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Figure 3.9 Effects of 2 ’-Deoxycytidine on Adenosine and 2’- 
Deoxyadenosine Activity on Cell Viability
The effects of adenosine and 2 ’-deoxyadenosine (100 pM) on cell viability 
were investigated in the presence of 2 -deoxycytidine (dCyt; 100 pM) to 
saturate dCK using the MTS assay after 96 hours in MCF-7 (A) and 
MDAMB231 (B) cells. All adenosine and 2 ’-deoxyadenosine data are in the 
presence of deoxycoformycin (1 pM). Data are the mean of three separate 
experiments repeated in triplicate ± S.E M, analysed with a one-way ANOVA 
and Tukey-Kramer post hoc test. **(p<0.01), ***(p<0.001) compared to control. 
*(p<0.05), ***(p<0.001) compared to dCyt alone.
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3.5 Discussion
The aim of this chapter was to determine the expression of adenosine 
receptors and their function in the regulation of MCF-7 and MDAMB231 
cell viability. The effects of manipulating adenosine and 2’- 
deoxyadenosine levels on the viability of these cells were also 
investigated.
3.5.1 Adenosine receptors are expressed in both the MCF-7 and 
MDAMB231 cell lines.
The first aim of this study was to determine the expression of adenosine 
receptors in the MCF-7 and MDAMB231 cell lines directly at the protein 
level with Western blotting.
Figure 3.1 very clearly shows that all four adenosine receptors are 
expressed in both the MCF-7 and MDAMB231 cell lines. Single bands 
were seen for the Ai, A2B and A3 receptors which are strongly 
suggestive of high antibody specificity for the respective proteins. The 
bands were sized to confirm specificity and all closely matched the 
expected molecular mass for each receptor. Blots probed for the A2A 
receptor, however, consistently showed the presence of more than one 
band. Strong bands appeared at -48-50 KDa, much stronger than the 
expected band at 44 KDa, which may suggest that the A2A receptor 
migrates at a higher MW than expected on SDS-PAGE gels. Piersen et 
al. (1994) confirmed that the A2A receptor has multiple glycosylation 
sites and, due to this, frequently migrates at 45-50 KDa on SDS-PAGE 
gels. It is probable that the majority of the A2A receptors are 
glycosylated, but the receptor also exists in an unglycosylated form.
Previous reports had suggested that the expression of the Ai receptor 
could be mediated by ERa in ER-positive MCF-7 cells (Lin et al. 2010). 
However, it appears here that this is not the case as MCF-7 and ER- 
negative MDAMB231 cells express equal amounts of Ai receptor. 
Furthermore, decreased expression of Ai, A2A and A3 mRNA in rats
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following ovariectomy, and thus depletion of oestradiol, suggests the 
role of ER in regulation of subtypes of adenosine receptors 
(Rose’Meyer et al. 2003). Limited conclusions should be drawn from 
this study, however, due to difference of species.
The expression of adenosine receptors in breast cancer has been 
investigated previously, but with contrasting findings. Whilst some 
studies found that MCF-7 cells did not express A3 adenosine receptors 
(Lu et al. 2003; Cheung et al. 2006), Panjehpour and Karami-Tehrani 
(2007) found a population of these receptors expressed in this cell line. 
This study also identified the expression of the other three receptors in 
MCF-7 and MDAMB468 breast cancer cell lines. Cheung et al. (2006) 
had previously demonstrated a lack of expression of Ai, A2B and A3 
adenosine receptors in T47D, MDAMB231 and SKBR-3 cells, but MCF- 
7 cells had both A2A and A 2b receptors. Experiments by a previous Ph D 
student in the Welsh School of Pharmacy (Clark 2004) found that MCF- 
7 cells (from a different source to the ones used in this thesis) 
expressed Ai, A2B and A3 receptors abundantly, as did T47D and 
MDAMB231 cells. However, none of these cells appeared to express 
A2A receptors.
These data highlight the differential expression of adenosine receptors 
in the same cell lines from different groups and therefore it is difficult to 
compare the results from this thesis with other studies. The variation in 
expression seen could be due to the different methods used or the 
variability of the cells from different sources.
3.5.2 Adenosine receptors have a limited role in the proliferation of 
breast cancer cells
The role of these adenosine receptors in cell proliferation was 
investigated next. Yao et al. (1997) had found that A3 receptor 
antagonists induced apoptosis in leukaemia cell lines, and protection 
from this could be achieved by low concentrations of A3 receptor
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agonists. They suggested that low level adenosine protected the cells 
via sustained activation of the A3 receptor. In contrast to this, Synowitz 
et al. (2006) showed that basal A1 receptor activity by endogenous 
adenosine retarded glioblastoma cell growth and that removal of this 
activity resulted in tumour proliferation.
Treatment of both MCF-7 and MDAMB231 cells with selective 
adenosine receptor antagonists (100 nM; Klotz et al. 2000; Kalk et al. 
2007) had no effect upon cell viability indicating that endogenous 
activation of adenosine receptors is not required for maintaining cell 
viability. In section 3.4.6 the non-selective antagonist CGS 15943 also 
had no effect upon cell viability further confirming these data. These 
results do not, however, negate the role of adenosine receptors in 
tumour development in vivo. For instance, under states of hypoxia, 
activation of adenosine receptors is suggested to protect cells from 
hypoxic damage (Fredholm 2000; Johansson et al. 2001). Therefore, 
adenosine receptor antagonism may be beneficial in tumours in vivo 
where hypoxia occurs. Similarly, adenosine receptor activation in cells 
of the immune system that are normally involved in destroying cancer 
cells such as natural killer and other T cells, can inhibit their anti-cancer 
function (Raskovalova etal. 2006).
The effects of adenosine receptor activation on cell viability were then 
investigated. Numerous reports have shown that adenosine receptor 
activation by the endogenous ligand adenosine, and selective and non- 
selective agonists causes apoptosis or reduced proliferation in a 
number of different cancer cells (Tey et al. 1992; Kohno et al. 1996; 
Colquhoun and Newsholme 1997; Yao et al. 1997; Fishman et al. 2000; 
Ohana et al. 2001; Merighi et al. 2002; Lee et al. 2005; Sai et al. 2006; 
Panjehpour and Karami-Tehrani 2007; Bar-Yehuda et al. 2008; Kim et 
al. 2008).
In the present study, the non-selective agonist, NECA was used to 
activate adenosine receptors and cell viability was then measured.
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There was no effect on cell viability in the MDAMB231 cells with NECA 
at concentrations up to 100 pM indicating that adenosine receptor 
activation does not influence cell proliferation or death. However, at 
concentrations of 30 and 100 pM, NECA significantly reduced cell 
viability in the MCF-7 cells by 20 and 30%, respectively. As NECA has 
Ki values in the low nanomolar range for , A2A and A3, and in the low 
micromolar range for the A 2b receptor (Klotz et al. 2000) these effects 
are likely to be non-selective effects. This could be tested with an 
adenosine receptor antagonist to see if the effects of NECA could be 
blocked. However, this is unlikely to have much clinical potential as 
such high concentrations of NECA would probably affect adenosine 
signalling elsewhere and so was not investigated further.
3.5.3 Endogenous adenosine and/or 2’-deoxy adenosine are 
essential for normal cell function.
It was then decided to focus the studies on the effects of the 
endogenous molecules, adenosine and 2’-deoxyadenosine.
The effects of eliminating adenosine and 2’-deoxyadenosine from the 
cells and surrounding matrix were investigated using ADA, the enzyme 
responsible for metabolism of adenosine and 2’-deoxyadenosine by 
deamination into inosine and 2’-deoxyinosine, respectively (Baflales et 
al. 1999). Adenosine deaminase is found mostly as a cytostolic 
enzyme, but is also attached to the outer cell membrane anchored by 
the CD26 membrane protein (Romanowska et al. 2007).
The addition of adenosine deaminase (2U/mL; Lopes et al. 1999) 
produced a highly significant reduction in viable cells compared to 
control in both MCF-7 and MDAMB231 cell lines by 60 and 80%, 
respectively. This inhibition was significantly greater in the MDAMB231 
cells compared to the MCF-7 cells, suggesting that removal of 
adenosine/2’-deoxyadenosine is significantly more detrimental to cell 
function in these cells. 2’-Deoxyadenosine is a better substrate for ADA
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than adenosine (Km 34 and 48 pM, respectively; Wiginton et al. 1981) 
and is therefore likely that the addition of ADA to the extracellular 
environment is depleting deoxynucleotides more readily than adenosine 
levels.
These data are consistent with the role of adenosine and 2’- 
deoxyadenosine as precursors to vital molecules such as ATP and 
cAMP, and for DNA synthesis and repair. The difference between the 
two cell lines could possibly be explained by the MDAMB231 cells being 
more metabolically active and thus requiring a higher turnover of ATP 
and increased DNA synthesis. Turturro et al. (2004) found that 
MDAMB231 cells have increased basal lactate production compared to 
MCF-7 cells, indicating an increase in glycolysis and thus metabolic 
activity which may explain these data.
An alternative explanation for these data is that the effects seen are not 
due to depletion of adenosine or 2,-deoxyadenosine, but rather a build 
up of the metabolites inosine or 2’-deoxyinosine, respectively. This 
hypothesis was tested by the addition of a high concentration (100 pM) 
of inosine to the cells. As inosine had no effect on cell viability in either 
cell line, the reduction in cell viability is likely to be a result of 
adenosine/2’-deoxyadenosine depletion.
3.5.4 Increasing endogenous adenosine and 2’-deoxyadenosine 
levels does not affect cell viability
Deoxycoformycin is a clinically used drug in the treatment of non- 
Hodgkin’s lymphoma, B-cell chronic lymphocytic leukaemia and 
Waldenstrdm’s macroglobulinemia (Ho and Hensel 2006). 
Deoxycoformycin is an irreversible inhibitor of ADA and was used in this 
study to investigate what effects increasing the endogenous 
concentration of adenosine and 2’-deoxyadenosine would have on cell 
viability.
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Deoxycoformycin at a concentration of 1 pM (Aye et al. 1982) had no 
effect upon cell viability in either MCF-7 or MDAMB231 cells. This 
indicates that accumulation of adenosine or/and 2’-deoxyadenosine is 
not sufficient to affect the viability of these cell lines. It would have been 
interesting to be able to quantify the accumulation of adenosine and 2’- 
deoxyadenosine in these cells. A HPLC method was tested but the 
results proved inconsistent and it was not pursued.
These data show that increasing endogenous adenosine and 21- 
deoxyadenosine levels do not affect cell viability. Ogawa et al. (2000) 
found similar results in isolated hairy cell leukaemia cells with 
deoxycoformycin, but in the presence of 10 pM 2’-deoxyadenosine, cell 
viability was reduced by almost 10-fold compared to 2’-deoxyadenosine 
alone. This point suggests that deoxycoformycin should be investigated 
in the presence of exogenous adenosine or 2’-deoxyadenosine.
3.5.5 Exogenous adenosine and 2’-deoxyadenosine significantly 
reduces cell viability
There have been numerous studies suggesting that increasing 
exogenous levels of adenosine and 2’-deoxyadenosine can lead to an 
inhibition of cell proliferation and result in cell death. This has been 
demonstrated in a number of cell lines to occur by an intracellular 
mechanism (Tanaka et al. 1994; Barry and Lind 2000; Saitoh et al. 
2004; Schneider et al. 2001; Hashemi et al. 2005; Wu et al. 2006). A 
number of studies have also identified an extracellular mechanism of 
action in cell lines (Kohno et al. 1996; Colquhoun and Newsholme 
1997; Yao et al. 1997; Fishman et al. 2000; Ohana et al. 2001; Merighi 
et al. 2003; Panjehpour and Karami-Tehrani 2004; Lee et al. 2005; Sai 
et al. 2006; Panjehpour and Karami-Tehrani 2007; Bar-Yehuda et al. 
2008; Kim etal. 2008).
In preliminary studies, adenosine and 2’-deoxyadenosine alone had no 
effect on cell viability, probably due to their metabolism by ADA. This
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has been demonstrated previously in other breast cancer cell lines 
(Hashemi et al. 2005) and Weisman et al. (1988) had also found that 
125 pM adenosine was completely metabolised to inosine when added 
to fibroblasts in 8 hours. Therefore, for all studies involving adenosine 
and 2’-deoxyadenosine, 1 pM deoxycoformycin was used to inhibit the 
activity of ADA. The metabolism of adenosine and 2’-deoxyadenosine 
by intracellular phosphorylation was not inhibited because this is one of 
the proposed mechanisms of action of adenosine/2’-deoxyadenosine 
toxicity (Hashemi etal. 2005).
Adenosine was able to reduce the number of viable MCF-7 and 
MDAMB231 cells, but at a 10-fold lower concentration in the 
MDAMB231 cells (10 pM). There were no significant differences 
between the IC50 values of adenosine, however. Similarly, there was no 
difference in the activity of 2’-deoxyadenosine on cell viability in either 
cell line nor when compared to the activity of adenosine. In both the 
MCF-7 and MDAMB231 cells, concentrations of 2’-deoxyadenosine £30 
pM significantly reduced cell viability. Hashemi et al. (2005) also found 
that adenosine and 2’-deoxyadenosine inhibited the growth of MCF-7 
and MDAMB436 (ER-negative) breast cancer cells with equal potency 
but at concentrations £250 pM.
The extracellular concentration of adenosine in most tissues is between 
10-200 nM under normal physiological function (Daines et al. 2003). 
Under states of hypoxia, extracellular adenosine levels can increase up 
to 40 pM (Schubert et al. 1994). In a mouse model of solid tumours, 
extracellular adenosine reached 2.5 pM, and in the presence of an ADA 
and adenosine kinase inhibitor, reached 13 pM (Blay et al. 1997). On 
this basis, neither adenosine nor 2’-deoxyadenosine are likely to be 
effective anti-cancer drugs as the concentrations that could be 
maintained in the extracellular fluid are unlikely to be sufficient to 
reduce cell viability.
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The role of adenosine in tumour function should not be discarded, 
however, as it is known to influence tumour fate by stimulating 
angiogenesis, increasing tumour motility and is an immunosuppressant 
at hypoxic concentrations (Blay et a/.1997; Lindon 2006, Merighi et al. 
2007; Ryzhov et al. 2007). Also, determining the mechanism of action 
of adenosine and 2’-deoxyadenosine may provide insights into novel 
pathways that can be targeted for future use. It may also provide an 
insight into how the clinically used adenosine and 2’-deoxyadenosine 
analogues, cladribine, clofarabine and fludarabine, may work in these 
cells.
Interestingly there appeared to be a biphasic response to adenosine in 
both cell lines that did not occur with 2’-deoxyadenosine. The actions of 
adenosine in the MDAMB231 cells appear to be saturated at 30 pM and 
at 100 pM in the MCF-7 cells. This effect could be explained in two 
ways, either different mechanisms of action between adenosine and 2 -  
deoxyadenosine or, adenosine requires conversion to 2’- 
deoxyadenosine and this step is rate-limiting. The mechanisms of 
action of adenosine and 2’-deoxyadenosine are discussed in the next 
section.
3.5.6 Effects of adenosine are part-mediated by adenosine 
receptor activation in the MCF-7 cells
There is a disagreement in the literature regarding the role of adenosine 
receptor activation, with most studies suggesting a role in initiating 
apoptosis (Kohno et al. 1996; Colquhoun and Newsholme 1997; Yao et 
al. 1997; Fishman et al. 2000; Ohana et al. 2001; Merighi et al. 2003; 
Panjehpour and Karami-Tehrani 2004; Lee et al. 2005; Sai et al. 2006; 
Panjehpour and Karami-Tehrani 2007; Bar-Yehuda et al. 2008; Kim et 
al. 2008). In contrast Hashemi et al. (2005) previously demonstrated 
that the cytotoxicity caused by adenosine and 2’-deoxyadenosine in 
MCF-7 cells was independent of adenosine receptor activation. 
However, studies by Panjehpour and Karami-Tehrani (2004 and 2007)
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demonstrated that A3 adenosine receptor activation by selective 
agonists and adenosine caused apoptosis in MCF-7 and MDAMB468 
cells.
In both the MCF-7 and MDAMB231 cells, pre-treatment with the non- 
selective adenosine receptor antagonist, CGS 15943, had no effect 
upon 2’-deoxyadenosine activity on cell viability. This was expected as 
2’-deoxyadenosine is not an agonist for adenosine receptors (Schrier et 
al. 2001). Similarly, CGS 15943 had no effect upon the action of 
adenosine in the MDAMB231 cells, indicating a non-receptor mediated 
mechanism of action for adenosine in these cells. However, CGS 15943 
did significantly attenuate the effects of adenosine in the MCF-7 cells, 
but not completely, indicating that the effects of adenosine on cell 
viability are mediated in part by adenosine receptor activation, but 
adenosine is also working by another mechanism. The use of selective 
antagonists could help elucidate which receptor(s) adenosine is 
activating to produce this response. Although most evidence suggests 
the A3 receptor is primarily responsible for initiating apoptosis or 
decreasing cell viability (Kohno et al. 1996; Fishman et al. 2000; Ohana 
et al. 2001; Panjehpour and Karami-Tehrani 2004; Lee et al. 2005; 
Panjehpour and Karami-Tehrani 2007; Bar-Yehuda et al. 2008; Kim et 
al. 2008), there is evidence to show the involvement of A1 (Tey et al. 
1992; Colquhoun and Newsholme 1997; Sai et al. 2006) and A2A 
receptors (Merighi et al. 2002) in these processes.
To further this work, the effects of adenosine and 2’-deoxyadenosine on 
adenosine receptors were investigated by looking at their effects on 
ERK1/2 phosphorylation. Adenosine receptors are known to be 
positively coupled to the ERK 1/2 pathway in naive and adenosine 
receptor transfected cell lines (Feoktistov et al. 1999; Seidel et al. 1999; 
Fredholm et al. 2000; Robinson and Dickenson 2001; Zhang and Liu 
2002; Hammarberg et al. 2003; Schulte and Fredholm 2003; Rivo et al. 
2007). The data clearly show that the MDAMB231 cells have increased
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basal ERK 1/2 signalling compared to MCF-7 cells, and this has been 
shown previously (Chen et al. 2009).
In the MCF-7 cells, adenosine was able to increase ERK 1/2 
phosphorylation compared to control, and in the presence of CGS 
15943, this effect was reduced. In contrast, 2’-deoxyadenosine did not 
influence the phosphorylation of ERK 1/2, consistent with the fact that it 
is not a ligand for adenosine receptors (Schrier et al. 2001). This 
strongly suggests that adenosine activates adenosine receptors in 
MCF-7 cells and is consistent with the cell viability data. It is interesting, 
however, that adenosine receptor activation-induced ERK 1/2 
phosphorylation is correlated with a decrease in cell viability considering 
the role of ERK 1/2 is generally associated with mitogenic signalling 
(Schulte and Fredholm 2003; Fang and Richardson 2005). However, 
numerous studies have also implicated transient ERK 1/2 activation in 
the initiation stages of apoptosis (Mohr et al. 1998; Blagosklonny 1999; 
Ishikawa and Kitamura 1999).
When the effects of adenosine and 2’-deoxyadenosine were 
investigated in the MDAMB231 cells, both adenosine and 2’- 
deoxyadenosine greatly reduced ERK 1/2 phosphorylation compared to 
control. As CGS 15943 did not antagonise these effects it can be 
assumed that these effects are adenosine receptor-independent. Whilst 
it has been shown previously that adenosine receptor activation by 
adenosine and various receptor agonists can decrease ERK 1/2 
signalling (Dubey et al. 2005; Jijon et al. 2005; Tan et al. 2006; Merighi 
et al. 2007; Bieber et al. 2008), this does not appear to be the case 
here.
Adenosine monophosphate-activated protein kinase (AMPK) controls 
cellular energy metabolism. Activation of AMPK encourages the cell to 
produce ATP for energy whilst reducing ATP-consuming processes, 
including cell proliferation and division (Towler and Hardie 2007). 
Adenosine has been demonstrated to activate AMPK in gastric cancer
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and hepatoma cell lines (Saitoh et al. 2004; Aymerich et al. 2006) and 
Baumann et al. (2007) found that activation of AMPK inhibited the 
phosphorylation of ERK. The exact role of AMPK in the inhibition of 
ERK signalling is still unclear, but it may explain the findings in the 
MDAMB231 cells described here.
3.5.7 The effects of 2' -deoxyadenosine on cell viability are 
mediated by intracellular phosphorylation by adenosine kinase
As the effects of 2’-deoxyadenosine, and some of the effects of 
adenosine on cell viability were not mediated by adenosine receptor 
activation, the role of intracellular phosphorylation was investigated.
Several studies have established that intracellular phosphorylation of 
adenosine or 2’-deoxyadenosine by adenosine kinase is responsible for 
the anti-proliferative mechanisms of action in a variety of cancer and 
normal tissue cell lines. Toxicity is suggested to arise from the 
accumulation of the nucleotide triphosphate that causes an imbalance 
of intracellular nucleotides, inhibition of ribonucleotide reductase, 
inhibition of S-adenosylhomocysteine hydrolase and DNA base pair 
mismatches. These effects ultimately lead to impaired repair and 
synthesis of DNA leading to apoptosis or cellular quiescence (Tanaka et 
al. 1994; Wakade et al. 1995; Kulkami et al. 1998; Barry and Lind 2000; 
Schreir et al. 2001; van der Weile et al. 2002; Saitoh et al. 2004; 
Hashemi et al. 2005). Furthermore, the anti-cancer actions of the 
clinically used analogues cladribine, clofarabine and fludarabine, which 
are 2’-deoxyadenosine analogues, are known to be due to 
phosphorylation to their triphosphate derivatives (M£nsson et al. 1999; 
Bonate et al. 2006).
The adenosine kinase inhibitor 5’-amino-5’-deoxyadenosine (50 pM 
Barry and Lind 2000) was used to inhibit the actions of this enzyme. 
Alone, 5’-amino-5’-deoxyadenosine had no significant effect on either 
cell line indicating that the cells can probably switch from the salvage
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pathway to the de novo pathway (see Figure 1.5, Chapter 1.4.1) in 
order to produce purine nucleotides (Hatse etal. 1999).
In both cell lines, in the presence of 5’-amino-5’-deoxyadenosine, the 
anti-cancer activity of 2’-deoxyadenosine was significantly attenuated, 
implying strongly that 2’-deoxyadenosine requires the action of 
adenosine kinase to impart its anti-cancer activity. This is most likely a 
direct effect of phosphorylation on 2’-deoxyadenosine by adenosine 
kinase to dAMP. Camici et al. (1995) and Giannecchini et al. (2003) 
both identified phosphorylation by adenosine kinase as an essential 
step in the toxicity of 2’-deoxyadenosine in colon cancer cells, as did 
Hashemi et al. (2005) in breast cancer cells. Interestingly, the effects of 
adenosine were significantly attenuated, albeit less so than with 2’- 
deoxyadenosine, in the presence of 5’-amino-5’-deoxyadenosine in the 
MCF-7 cells, but not in the MDAMB231 cells. This implies that 
adenosine also requires phosphorylation by adenosine kinase in MCF-7 
cells which has been reported previously (Tanaka et al. 1994; Wakade 
et al. 1995; Kulkami et al. 1998; Barry and Lind 2000; Schreir et al. 
2001; van der Weile et al. 2002; Saitoh et al. 2004). As the anti-cancer 
activity of 2’-deoxyadenosine in the MDAMB231 and MCF-7 cells, and 
adenosine in the MCF-7 cells was not completely attenuated by S’- 
amino-S’-deoxyadenosine, it may indicate another mechanism of action 
behind adenosine and 2’-deoxyadenosine toxicity. Alternatively,' it is 
possible that other routes of phosphorylation are also contributing as 
the concentration of 5’-amino-5’-deoxyadenosine used here should be 
sufficient to inhibit completely the activity of adenosine kinase (Sinclair 
etal. 2001).
The reasons for the differences observed here between adenosine and 
2’-deoxyadenosine in combination with the adenosine kinase inhibitor 
are unclear. Giannecchini et al. (2003) demonstrated that S’-amino-S’- 
deoxyadenosine inhibited the formation of dATP, but not ATP and 
confirmed that it is indeed dATP and not ATP accumulation that is toxic
to cells. Whilst 2’-deoxyadenosine must clearly go via a route of 
adenosine kinase phosphorylation to dATP, it appears that adenosine 
does not. It is possible that adenosine is phosphorylated by another 
kinase to AMP. As the purine analogues cladribine and clofarabine are 
phosphorylated by dCK to their monophosphates, it is possible that dCK 
is also phosphorylating adenosine here. However, the addition of 2’- 
deoxycytidine sufficient to competitively inhibit the action of dCK (100 
pM; Joachims et al. 2008) had no effect on adenosine or 2’- 
deoxyadenosine toxicity in either cell line. This implies that dCK does 
not phosphorylate adenosine or 2’-deoxyadenosine.
The anti-cancer action of adenosine in the MCF-7 cells may be 
mediated by both adenosine receptor activation and intracellular 
phosphorylation. However, the action of adenosine in the MDAMB231 
cells appears to be mediated by neither of these mechanisms. There 
have been other proposed mechanisms of action of adenosine in 
mediating apoptosis including inhibition of methyltransferases (Rounds 
et al. 1998; Hermes et al. 2008) or direct initiation of caspase 3 activity 
(Wti et al. 2006). The latter may also explain the differences seen 
between the MCF-7 and MDAMB231 cells as MCF-7 cells are caspase 
3-deficient but MDAMB231 cells are not (Yang et al. 2007) so 
adenosine may be mediating its effects via caspase 3 activation in the 
MDAMB231 cells. Further investigation of the mechanisms of action of 
adenosine and 2’-deoxyadenosine is needed.
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3.6 Conclusion
Both the MCF-7 and MDAMB231 cell lines express Ai, A2A, A2B and A3 
adenosine receptors at the protein level but the data indicate the limited 
role of direct adenosine receptor ligands as a treatment for breast 
cancer.
Whilst endogenous adenosine and 2’-deoxyadenosine were 
demonstrated to be essential for normal cell function, exogenous 
administration, although decreasing cell viability in both cell lines, would 
have little direct clinical potential against breast cancer.
In deciphering the mechanisms behind adenosine and 2’- 
deoxyadenosine toxicity, activation of adenosine receptors was 
important for adenosine activity in the MCF-7 cells, as was intracellular 
phosphorylation by adenosine kinase, suggesting a dual mechanisms of 
action of adenosine in these cells. The action of 2’-deoxyadenosine 
appeared to be mediated mostly by intracellular phosphorylation.
In the MDAMB231 cells, phosphorylation of 2’-deoxyadenosine by 
adenosine kinase was also essential for its function, but this was not the 
case with adenosine. However, both adenosine and 2’-deoxyadenosine 
reduced ERK 1/2 phosphorylation independently of adenosine receptor 
activation suggesting a novel mechanism of action of these compounds 
in this cell line. This may be linked to the phosphorylation mechanism of 
2 ’-deoxyadenosine but a definitive answer remains to be elucidated.
These data show that intracellular phosphorylation of 2’- 
deoxyadenosine is effective at reducing cell viability. Whilst 2’- 
deoxyadenosine is unlikely to have much benefit clinically, the 2 ’- 
deoxyadenosine analogues cladribine and clofarabine are very effective 
against haematological malignancies clinically and also require internal 
phosphorylation for their activity. Therefore, the effects of these 
analogues were investigated in the next chapter.
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Chapter 4: Pharmacological Investigation of the Activity 
of PNAs in Breast Cancer Cells
4.1 Introduction
PNAs represent a significant number of anti-cancer drugs used clinically 
and adenine PNAs include deoxycoformycin (ADA inhibitor), cladribine, 
fludarabine and clofarabine (halogenated analogues).
Halogenated PNAs require active transport across the plasma 
membrane via nucleoside transporters (NTs) (King et al. 2006) and are 
then phosphorylated primarily by dCK to the monophosphate. They are 
then sequentially phosphorylated by a purine monophosphate kinase 
and a nucleoside purine diphosphate kinase to the biologically active di- 
and triphosphate forms, respectively (Lotfi et al. 1999; M&nsson et al. 
1999; Galmarini et al. 2001).
The triphosphate forms of fludarabine, cladribine and clofarabine are all 
potent inhibitors of ribonucleotide reductase (Griffig et al. 1989; 
Bontemps et al. 2000; Galmarini et al. 2001; Cerqueira et al. 2005; 
Bonate et al. 2006) which results in a decrease in available dNTPs for 
DNA synthesis and repair and results in cell cycle arrest or apoptosis. 
These PNA can also be inserted into the DNA template leading to DNA 
strand breakage and inhibition of DNA polymerases which can initiate 
apoptosis (Huang et al. 1990; Huang and Plunkett 1991; Bontemps et 
al. 2000; Genini et al. 2000a; Bonate et al. 2006).
Several other mechanisms have also been attributed to the cytotoxic 
effects of these drugs including disruption of mitochondrial membrane 
potential (Marzo et al. 2001), inhibition of DNA ligase and DNA primase 
(Catapano et al. 1991; Yang et al. 1992), activation of PARP and 
subsequent depletion of NAD+ and ATP (Pettitt et al. 2000) and direct 
interaction and release of various mitochondrial apoptosis-inducing 
molecules including cytochrome C, AIF, caspase 9 and APAF 1 (Xie 
and Plunkett 1996).
98
Clinically, these drugs are used in the treatment of various 
haematological malignancies including hairy cell leukaemia, chronic 
lymphocytic leukaemia, Waldenstrdm’s macroglobulinaemia, acute 
leukaemia and non-Hodgkin’s lymphoma (Bryson et al. 1993; Fidias et 
al. 1996; Lenz et al. 2004; Faderl et al. 2005; Ho and Hensel 2006; 
Robak and Robak 2007). Their action against solid tumours is less well 
documented. However, gemcitabine, which is a pyrimidine NA and has 
similar mechanisms of action to the PNA, is active against a wide 
variety of solid tumours (Kroep et al. 2002). Few in vivo studies of 
clofarabine in solid tumours have been undertaken but Kantarjian et al. 
(2003) identified that in 13 patients with solid tumours treated with 
clofarabine, including breast (n=7), no specific response to clofarabine 
was achieved. However, they did note that one metastatic breast 
cancer patient (undefined breast cancer) did regain stable disease 
levels for 9 months on clofarabine treatment, suggesting some benefit. 
Cunningham et al. (2005), in a study of 57 patients with solid tumours 
(pancreatic, lung, colorectal, prostate, bladder and laryngeal, but not 
breast cancer) stated that clofarabine was well tolerated by patients, 
and was showing good clinical activity against a number of different 
tumours.
Several studies have looked at the effects of clofarabine in vitro in a 
variety of solid tumour cell lines including colon, pancreatic, renal, lung 
and melanoma cell lines and also in a number of mice models in vivo. 
Their studies identified good activity with IC50 values in the high nM 
range and curative to moderate activity in mouse solid tumour xenograft 
models (Takahashi et al. 1999; Waud et al. 2000). Hashemi et al. 
(2003; 2004) investigated cladribine activity in MDA-MB-468 and MCF-7 
cells breast cancer cells, respectively. The studies identified cladribine 
as being able to reduce cell viability and induce apoptosis in both cell 
lines, however, at relatively high pM concentrations.
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In the previous chapter, 2’-deoxyadenosine was found to significantly 
reduce cellular viability and this was attributed to intracellular 
phosphorylation by adenosine kinase. Analogues of 2,-deoxyadenosine 
already in the clinic are desirable for therapeutic use based upon their 
high tolerability profiles compared to standard cytotoxics. There is 
therefore a need to investigate these drugs further in solid tumours, 
including breast cancer, to evaluate their potential for such use.
4.2 Chapter Aims
The aims of this chapter were.
• To determine the pharmacological activity of clinically used NAs 
against a variety of human breast cancer cell lines, and the 
control leukaemia cells, HL60.
• To investigate the mechanism(s) of action of these drugs using 
pharmacological methods.
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4.3 Methods
The protocols for the MTS, cell growth and annexin V apoptosis assay 
are described in detail in Chapter 2.
4.3.1 MTS Assay
Cells were seeded at 5000 cells/well into 96 well plates and allowed to 
plate down overnight. Media was aspirated from the adherent cells and 
replaced with drug-containing media. Concentration-response curves 
were produced for clofarabine, cladribine, fludarabine and gemcitabine 
at concentrations between 0.1 nM and 100 pM. For the 2’-deoxycytidine 
(100 pM) and hydroxyurea (300 pM) assays, 1 pM of clofarabine and 
cladribine and 10 pM of fludarabine were used. Relevant media only, 
vehicle (DMSO; highest concentration was 0.5%) and blank media (no 
cells) controls were included on each plate. Cells were then left for 96 
hours (apart from the time course assay) at 37°C in 5% CO2 in a 
humidified atmosphere. The MTS assay was then performed as 
described earlier (section 2.3.2).
4.3.2 Annexin V FACS Apoptosis Assay
Cells were seeded into 25 cm2 cell culture flasks and allowed to plate 
down overnight. The media was then replaced with media only, vehicle 
(DMSO: 0.005%) or 1 pM clofarabine and cells were left for 96 hours at 
37°C in 5% CO2 in a humidified atmosphere. After this time, detached 
cells were collected by centrifugation, and cells still attached were 
detached using trypsin/EDTA. All cells were collated together, washed 
in PBS twice and then resuspended in annexin V binding buffer and 
passed through a 21G needle. Annexin V and PI were then added and 
the cells were immediately analysed using the FL1 and FL2 channels 
on the flow cytometer as described (section 2.4.3).
The data are expressed as a % of cells positively stained for annexin V 
or/and PI, corrected for the vehicle (clofarabine treated -  DMSO
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vehicle). This accounts for any effect the vehicle is having, and also any 
false positives caused by processing the samples.
4.3.3 Cell Growth Assay
Cells were seeded into 24 well plates and allowed to settle overnight. 
The media was then changed the next day and cells allowed to grow for 
the required amount of time, 24, 48 and 96 hours. At each time point, 
cells were harvested with trypsin/EDTA, suspended as a single cell 
suspension and counted in a Beckman Coulter Counter.
4.3.4 Data Analysis
All data are expressed as mean ± S.E.M. except for the IC50 data which 
are expressed as the mean and the 95% C.l. Data were entered into 
GraphPad Prism V5.0b and graphs were plotted. IC50 values are the 
50% inhibition between the top and bottom of the curve. They were 
calculated using non-linear curve regression with a fixed Hill slope 
according to the following formula:
„ or.nnm , (Top - Bottom) y -  Bottom +  ^ ^ ^q<x-Logic*)
Where:
y = response
x = log (drug concentration)
Top = y value at the top of the plateau 
Bottom = y value at the bottom of the plateau
Comparisons between two groups were made using a Student’s t test 
and a one-way ANOVA was used for three or more groups with a 
Tukey-Kramer posf hoc test if a significant difference was observed or a 
Bonferroni posf hoc test when comparing only selected pairs of data. 
Probability values of less than 0.05 were considered statistically 
significant.
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4.4 Results
4.4.1 Molecular profile of breast cancer cell lines
A literature search was carried out firstly to identify the molecular profile 
of the different breast cancer cell lines used for this study. The data for 
this are expressed in Table 4.1 and are adapted from Liang et al. (2005) 
and Neve et al. (2006). Three ER-positive and three ER-negative cell 
lines, two of which were triple negative breast cancer (TNBC) cell lines 
(MDAMB231 and MDAMB436), were used. Two Her2 overexpressing 
cell lines are also included, BT 474 and SKBR-3.
4.4.2 Activity of clofarabine in breast cancer cell lines
Concentration-response curves show the effects of clofarabine on cell 
viability against the different cell lines (Figure 4.1 A). The IC50 values for 
clofarabine in the ER-positive breast cancer cell lines were significantly 
higher compared to the HL60 cells (p<0.01) and ER-negative cells 
(p<0.05) by 15 and 8-fold, respectively (Figure 4.1 B). There were no 
differences between the IC50 values or % efficacy of clofarabine at 1 pM 
in the ER-negative cell lines compared to the HL60 cells. The % 
efficacy of clofarabine at 1 pM was significantly reduced (p<0.05) in the 
MCF-7 cells compared to the HL60, MDAMB231 and MDAMB436 cell 
lines. It was also significantly reduced (p<0.05) in the BT 474 cells 
compared to the HL60 and MDAMB436 cells (Figure 4.1 B). There was 
no significant difference in the % efficacy at 1 pM of clofarabine 
between the T47D cells and ER-negative and HL60 cells.
4.4.3 Activity of cladribine and fludarabine in MCF-7, MDAMB231 
and HL60 cell lines
The activity of the older generation PNAs, cladribine and fludarabine, 
were then investigated. The effects were only studied in the ER-positive 
and ER-negative cell lines, MCF-7 and MDAMB231, respectively, as 
well as the HL60 cell line.
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Cell Line ER PR Her2 p53 Class Type
MCF-7 + + - + Lu IDC
T47D + + - Lu IDC
BT 474 + + + Lu IDC
MDAMB231 - - - +M BaB AC
MDAMB436 - - - - BaB IDC
SKBR-3 - - + + Lu AC
Table 4.1 Molecular Profile of Breast Cancer Cell Lines.
The table describes the molecular profiles of the six different breast cancer 
cell lines used in this chapter with data taken from the literature rather than 
experimental work undertaken during this thesis. Data collated from (Liang et 
al. 2005; Neve etal. 2006).
ER -  Oestrogen Receptor
PR -  Progesterone Receptor
Her2 -  Epidermal Growth Factor Receptor 2
p53 -  Tumour Suppressor Protein, p53
Class -  Gene cluster profile. Lu = Luminal; BaB = Basal Type B
Type -  Cancer Type; IDC =  invasive ductal carcinoma; AC =  adenocarcinoma
+  indicates the presence of the protein; - absence of the protein; +M is protein present
but dysfunctional/mutated
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O 80-
&  40-
0.001
-m- MCF-7 
T47D 
BT 474 
-©- MDAMB436 
SKBR-3 
-B - MDAMB231 
HL60
Cell Line IC&0 values (nM) % Efficacy at 1 pM IC^ value change
MCF-7 336 (2 5 2 -4 1 9 )* * * 44.6 (0.8)*1 15.6
T47D 315 (100 -  530)*** 69.0 (7.4) 15.8
BT 474 308 (-69 -  685)*** 46.4 (5.4)*2 15.4
MDAMB231 37 (-11 - 8 5 ) 77.2 (4.6) 2.0
MDAMB436 45 ( -3 2 -1 2 1 ) 81.6 (2.4) 2.2
SKBR-3 45 (31 -1 2 0 ) 71.1 (1.4) 2.2
HL60 20 (-14 -  54) 82.9 (10.1) -
Figure 4.1 Effect o f Clofarabine on Breast Cancer Cell Viability
A shows the concentration-response curve of the cell lines to clofarabine after 
96 hours treatment. The table (B) gives the ICso values (95% C.i), the % 
response of control to clofarabine at 1 pM (S. E M) and the fold change in ICso 
values compared to HL60 cells. Data are expressed as the mean of at least 
three independent experiments, repeated in thplicate. * (p < 0 .0 5 ), * * (p < 0 .0 1 )  
compared to HL60 cells; P(p < 0 .0 5 )  compared to ER-negative cell lines. 
1(P < 0 .0 5 )  compared to MDAMB231 and MDAMB436 cells; 2(p < 0 .0 5 )  
compared to MDAMB436 cells. Data were analysed with one-way ANOVA and 
the Tukey-Kramer post hoc test. Closed symbols (ER-positive cells); open 
symbols (ER-negative cells).
105
Concentration-response curves show the activity of cladribine (Figure
4.2 A) and fludarabine (figure 4.3 A) against these cell lines.
The IC50 value of cladribine in the MCF-7 cells was significantly greater 
(p<0.01) compared to the MDAMB231 and HL60 cell lines by 11 and 9- 
fold, respectively. At 0.1 pM, the efficacy of cladribine was also 
significantly lower (p<0.05) in the MCF-7 cells compared to the 
MDAMB231 and HL60 cells (Figure 4.2 B). There were no significant 
differences between the MDAMB231 and HL60 cells in either the IC50 
values or % efficacy.
The IC50 values of fludarabine in the MCF-7 and MDAMB231 cells were 
significantly greater (p<0.001 and p<0.01, respectively) compared to the 
HL60 cells by 103 and 57-fold, respectively. The IC50 value of 
fludarabine in the MDAMB231 cells was significantly lower (p<0.05) 
compared to the MCF-7 cells. The efficacy of fludarabine at 10 pM was 
significantly greater (p<0.001) in the HL60 cells compared to both the 
MCF-7 and MDAMB231 cell lines (Figure 4.3 B).
4.4.4 Activity of gemcitabine in MCF-7 and MDAMB231 cells
The activity of the pyrimidine NA, gemcitabine, was then investigated in 
the MCF-7 and MDAMB231 cell lines. Concentration-response curves 
show the effects of gemcitabine in these cell lines (Figure 4.4 A).
The IC50 values of gemcitabine and efficacy at 1 pM are shown in 
Figure 4.4 B. The efficacy of gemcitabine was significantly smaller 
(p<0.01) at 1 pM in the MCF-7 compared to the MDAMB231 cells but 
there were no significant differences between the IC50 values.
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MCF-7
MDAMB231
HL60
Concentration (^iM)
B
Cell Line IC50 value (nM) % Efficacy at 0.1 pM
ICM value 
change
MCF-7 513(58-968)** 6.1 (1.8)* 9
MDAMB231 46 (-11 -103 ) 57.1 (7.3) 0.8
HL60 57 (-46 -160) 44.9 (10.9) -
Figure 4.2 Effect of Cladribine on MCF-7, MDAMB231 and HL60 Cell 
Viability
A shows the concentration-response curve of the cell lines to cladribine in 
MCF-7, MDAMB231 and HL60 cell lines after 96 hours treatment. The table
(B) gives the ICso values (95% C.I.), the % response of control to cladribine at 
0.1 pM (S.E M) and the fold change in ICso values compared to HL60 cells. 
Data are expressed as the mean of at least three independent experiments, 
repeated in triplicate. *(p<0.05), **(p<0.01) compared to MDAMB231 and 
HL60 cells. Data were analysed with one-way ANOVA and the Tukey-Kramer 
post hoc test. Closed symbols (ER-positive cells); open symbols (ER-negative 
cells).
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MCF-7
MDAMB231
HL60
Concentration (|iM)
B
Cell Line IC^ values (jiM) % Efficacy at 10 mM
IC^ value 
Change
MCF-7 13.6(6.6-20.6)*** 38.2 (4.0)*** 103.1
MDAMB231 7.5 (4.0 -11.1)*** 51.7 (3.2)*** 57.1
HL60 1.3 (0 .4 -0 .2 ) 99.0 (0.5) -
Figure 4.3 Effect of Fludarabine on MCF-7, MDAMB231 and HL60 Cell 
Viability
A shows the concentration-response curve of the cell lines to fludarabine in 
MCF-7, MDAMB231 and HL60 cell lines after 96 hours treatment. The table 
(B) gives the ICso values (95% C.I.), the % response of control to fludarabine 
at 10 pM (S.E.M) and the fold change in ICso values compared to HL60 cells. 
Data are expressed as the mean of at least three independent experiments, 
repeated in triplicate. **(p<0.01), ***(p<0.001) compared to HL60 cells. 
*(p<0.05) compared to MCF-7 cells. Data were analysed with one-way 
ANOVA and the Tukey-Kramer post hoc test. Closed symbols (ER-positive 
cells); open symbols (ER-negative cells).
108
AO 1001 
•fa *■
o  80- - m -  MCF-7 
-B- MDAMB231•4—o 60-
^  40-
!5£ 20-
0.0001 0.001 0.01 0.1 1 10
Concentration (jtM)
B
Cell Line IC5Q values (nM) % Efficacy at 1 pM
MCF-7 1.1 (0.8 -1 .3 ) 64.4 (2.7)**
MDAMB231 2.5 (-0.4 -  5.3) 86.3 (0.4)
Figure 4.4 Effect of Gemcitabine on MCF-7 and MDAMB231 Cell Viability
A shows the concentration-response curve of cell lines to gemcitabine in MCF- 
7 and MDAMB231 cell lines after 96 hours treatment. The table (B) gives the 
ICso values (95% C.L) and the % response to gemcitabine at 1 pM (S.E M). 
Data are expressed as the mean of at least three independent experiments, 
repeated in triplicate. **(p<0.01) compared to MDAMB231 cells. Data 
analysed with a two-tailed Students t test. Closed symbols (ER-positive cells); 
open symbols (ER-negative cells).
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4.4.5 Effects of clofarabine on induction of apoptosis in MCF-7 and 
MDAMB231 cell lines
To investigate the effects of clofarabine on the induction of apoptosis in 
MCF-7 and MDAMB231 cells, the annexin V apoptosis assay was used.
Figure 4.5 A-F shows representative dot plots obtained from FACS 
analysis of MCF-7 (A-C) and MDAMB231 (D-F) cells stained with 
annexin V and PI. In each cell line, the control and DMSO plots were 
similar, but there was an increase in annexin V and PI staining after 
treatment with clofarabine, represented by increases in counts in the 
lower and upper right quadrants, respectively.
Figure 4.6 shows a graphical representation of these data. The annexin 
V+ve/PI-ve cells stained positive for annexin V but not PI, typical of 
early apoptosis while the annexin V- and Pl-positive cells are typical of 
late apoptosis or necrosis. After treatment with clofarabine, 18.0±2.8% 
and 9.7±1.7% cells were in early and late apoptosis in the MCF-7 cells, 
respectively, compared to 37.3±4.8% and 28.9±2.5% in the MDAMB231 
cells, respectively. There were significant increases in both early 
apoptosis (p<0.05) and late apoptosis/necrosis (p<0.001) in 
MDAMB231 cells compared to MCF-7 cells.
4.4.6 Growth curves of breast cancer cell lines
The growth rates of the six breast cancer cell lines were investigated in 
order to determine if growth rate was correlated with activity of the PNA.
The MDAMB231 cells had the fastest growth rate followed by MCF-7 
and T47D cells (Figure 4.7). The MDAMB436, BT 474 and SKBR-3 
cells had reduced growth rates in comparison. No statistics were 
compiled as this study was carried out only once.
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Figure 4.5 Dot Plots o f Annexin V/PI Apoptosis Assay with FACS 
Analysis
These dot plots are representative examples (n = 3-4) of dot plots obtained 
from FACS analysis of annexin V/PI-stained MCF-7 (left) and MDAMB231 
(right) cells treated with media alone (top), 0.05% DMSO (middle) or 1 pM 
clofarabine (bottom) for 96 hours. Log PI staining is on the FL2 channel (Y 
axis) and log annexin V staining is on the FL1 channel (X axis). Each plot 
shows 10,000 counts. Upper left quadrant = Pl+ve/annexin V-ve; upper right 
quadrant = Pl+ve/annexin V+ve; lower left quadrant = Pl-ve/annexin V-ve; 
lower right quadrant = Pl-ve/annexin V+ve.
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Figure 4.6 Annexin V/PI Apoptosis Assay with FACS Analysis on MCF-7 
and MDAMB231 Cells A fte r Treatment with 1 pM Clofarabine
MCF-7 and MDAMB231 cells were treated with 1 pM clofarabine for 96 hours 
before staining with annexin V and PI and subsequent FACS analysis. 
Annexin +ve/PI-ve cells stained positive for annexin V but not PI. Annexin 
+ve/PI+ve cells stained positive for both annexin V and PI. The data were 
corrected for vehicle control (treated cells -  DMSO vehicle) to correct for any 
false positives caused by the methodology. Data are expressed as the % of 
cells from 10,000 counts (n = 3-4) ± S.E M. *(p<0.05), ***(p<0.001) compared 
to the MCF-7 cells analysed by a two-tailed Student's t test.
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Figure 4.7 Cell Growth Assay of Breast Cancer Cells
Breast cancer cells, seeded at 10,000 cells per well in 24 plates were counted 
24, 48 and 96 hours after seeding using a Beckman Z2 Coulter Counter. The 
data are expressed as the mean of triplicate wells from a single experiment 
and hence no error bars or statistics are presented. The ER-positive cell lines 
are depicted with closed symbols and ER-negative cell lines are represented 
by open symbols.
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4.4.7 Effects of dCK saturation on the activity of PNAs
The action of PNA is dependent upon primary phosphorylation by dCK 
(MSnsson et al. 1999). This was investigated in the MCF-7 and 
MDAMB231 cell lines by saturating the enzyme with its natural 
substrate, 2’-deoxycytidine (100 pM) prior to the addition of clofarabine, 
cladribine (1 pM) or fludarabine (10 pM).
Neither the DMSO vehicle nor 2’-deoxycytidine alone had any 
significant effect on cell viability compared to control in either cell line 
(Figure 4.8 A and B).
In the MCF-7 cells (Figure 4.8 A) cell viability was significantly 
(p<0.001) reduced to 57.1 ±4.1%, 42.8±1.1% and 48.8±0.5% with 
fludarabine, cladribine and clofarabine, respectively, compared to 
control. In the presence of 2’-deoxycytidine, cell viability was reduced to 
only 93.4±1.0%, 96.8±1.5% and 95.3±0.8% for fludarabine, cladribine 
and clofarabine, respectively, compared to control and these were 
significantly different to fludarabine, cladribine and clofarabine alone.
In the MDAMB231 cells (Figure 4.8 B) cell viability was significantly 
(p<0.001) reduced to 37.0±2.5%, 18.1 ±2.5% and 24.1 ±3.1% with 
fludarabine, cladribine and clofarabine, respectively, compared to 
control. In the presence of 2’-deoxycytidine, cell viability was reduced to 
94.9±0.8%, 80.8±3.1% and 75.3±3.2% for fludarabine, cladribine and 
clofarabine, respectively. Fludarabine plus 2’-deoxycytidine was not 
significantly different compared to control, but cladribine and clofarabine 
plus 2’-deoxycytidine were significantly (p<0.001) reduced compared to 
control. In the presence of 2’-deoxycytidine, the activity of fludarabine, 
cladribine and clofarabine on cell viability was significantly reduced 
(p<0.001) compared to each drug alone.
The cladribine analogue 5’-deoxy-2’-deoxychloroadenosine (Figure 4.9 
A) cannot be phosphorylated due to modification at C5 on the ribose
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and is thus inactive. There was no significant effect of this drug 
compared to control at concentrations up to 100 pM (Figure 4.9 B).
4.4.8 Effects of hydroxyurea of PNA activity
The influence of the ribonucleotide reductase inhibitor, hydroxyurea 
(300 pM) on the efficacy of fludarabine (10 pM), cladribine (1 pM) and 
clofarabine (1 pM) was then investigated using the MTS assay.
The DMSO vehicle (0.05%) had no significant effect on cell viability in 
either cell line. Alone, hydroxyurea significantly (p<0.001) inhibited cell 
viability to 63.7±1.9% and 36.6±1.3% of control in the MCF-7 and 
MDAMB231 cells, respectively (Figure 4.10 A and B).
In the MCF-7 cells (Figure 4.10 A), cell viability was significantly 
reduced (p<0.001) compared to control by fludarabine (57.1 ±4.1%), 
cladribine (42.8±1.1%) and clofarabine (48.8±0.5%). In combination 
with hydroxyurea, viability was further reduced to 29.5±1.5%, 
33.7±2.4% and 38.4±0.9% compared to control for fludarabine, 
cladribine and clofarabine, respectively. These values were significantly 
reduced compared to control (p<0.001), PNA (p<0.05) and hydroxyurea 
alone (p<0.05).
In the MDAMB231 cells (Figure 4.10 B), cell viability was significantly 
reduced (p<0.001) compared to control by fludarabine (36.1 ±3.1%), 
cladribine (18.1 ±2.5%) and clofarabine (24.1 ±3.1%). In combination 
with hydroxyurea, viability was further reduced to 23.2±0.4% by 
fludarabine, which was significantly reduced compared to control 
(p<0.001), fludarabine alone (p<0.05) and hydroxyurea alone (p<0.05).
In combination with hydroxyurea, no significant difference was observed 
in cell viability with cladribine (22.0±1.6% of control) or clofarabine 
(22.9±1.7% of control) compared to each drug alone. Cell viability was 
significantly reduced compared to control (p<0.001) and hydroxyurea 
alone (p<0.05).
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Figure 4.8 Effect o f 2 ’-Deoxycytidine on PNA Activity
T h e  e ffec ts  o f 2 ’-deoxycytid ine  (dC yt; 1 0 0  p M ) on  the a n ti-c a n c e r ac tiv ity  o f  
f lu d a ra b in e  (1 0  f.iM), c ladrib ine  (1 p M ) a n d  c lo farab in e  (1 p M ) on M C F -7  (A ) 
a n d  M D A M B 2 3 1  (B) b re a s t c a n c e r  ce lls  d e te rm in e d  by th e  M T S  assay. D a ta  
a re  e x p re s s e d  as  %  o f v iab le  ce lls  c o m p a re d  to contro l a n d  a re  the m e a n  o f  
th re e  s e p a ra te  experim ents , re p e a te d  in trip licate ±  S .E  M. * * * (p < 0 .0 0 1 )  
c o m p a re d  to respective  N A  a lo n e; * * * ( p < 0 .0 0 1 )  c o m p a re d  to control. D a ta  
w e re  a n a ly s e d  with o n e -w a y  A N O V A  a n d  the T u k e y -K ra m e r p o s t hoc  test.
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Figure 4.9 Effects of 5’-Deoxy-2’-Chlorodeoxyadenosine on MCF-7 Cell 
Viability
The effects (B) of the cladhbine analogue, 5 ’-deoxy-2'-chlorodeoxyadenosine 
(A) on MCF-7 cell viability were determined by the MTS assay over 96 hours. 
Data are expressed as % of viable cells compared to control and are the mean 
of three separate experiments, repeated in triplicate ± S.E.M. No significant 
differences were observed.
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Figure 4.10 Effects o f Hydroxyurea on PNA Drug Efficacy
The effects of the ribonucleotide reductase inhibitor, hydroxyurea (HyU; 300 
pM) on the efficacy of fludarabine (FaraA; 10 f.j M ), cladribine (2CdA; 1 fjM) 
and clofarabine (2CIFaraA; 1 yM) in MCF-7 (A) and MDAMB231 (B) cells 
determined by the MTS assay. Data are expressed as % of viable cells 
compared to control (media only) and are the mean of three separate 
experiments, repeated in thplicate ± S.E.M. *(p<0.05) compared to respective 
NA alone; *(p<0.05) compared to hydroxyurea alone. V(p<0.001) 
compared to control. Data were analysed with one-way ANOVA and the Tukey- 
Kramer post hoc test.
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4.4.9 Effect of cladribine and clofarabine protides on cell viability
The effects of cladribine and clofarabine protides on cell viability were 
investigated in MCF-7 and MDAMB231 breast cancer cell lines. A 
description of the protide technology is given in section 4.5.9. The 
protide CdA1X is an analogue of cladribine, and CIFaralX and 
CIFara2Y are analogues of clofarabine.
In the MCF-7 cells (Figure 4.11 A), cladribine (p<0.01), clofarabine 
(p<0.001), CIFaralX (p<0.001) and CIFara2Y (p<0.001) at 1 pM 
significantly reduced cell viability compared to control. There was a 
significant reduction in the efficacy of CdA1X compared to cladribine 
(p<0.01), and CIFaralX compared to clofarabine (p<0.001). At 100 pM 
cladribine (p<0.01), CdA1X, clofarabine, CIFaralX and CIFara2Y 
(p<0.001) all significantly reduced cell viability compared to control. 
There was a significant improvement in CdA1X activity compared to 
cladribine (p<0.05) and significant increases in CIFaralX and CIFara2Y 
efficacies compared to clofarabine (p<0.001).
In the MDAMB231 cells (Figure 4.11 B), cladribine, clofarabine 
(p<0.001), CIFaralX, CIFara2Y (p<0.01) and CdA1X (p<0.05) at 1 pM 
all significantly reduced cell viability compared to control. At 100 pM, all 
the compounds significantly reduced (p<0.001) cell viability compared 
to control. There were significant decreases in the activity of CdA1X 
(p<0.01) and CIFara2Y (p<0.05) at 1 pM compared to their parent 
compounds. At 100 pM, CdA1X (p<0.01) and CIFaralX (p<0.001) and 
CIFara2Y (p<0.01) were all significantly more efficacious compared to 
their parent compounds.
4.4.10 Effects of clofarabine and cladribine protides over time
The effects of the protides on cell viability were studied over time to 
determine differential activity at different time points. Only one 
clofarabine protide was used, CIFara2Y, as this was the lead compound 
(personal communication, Prof. C. McGuigan).
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In the MCF-7 cells at 1|jM  for each drug (Figure 4.12 A), CdA1X had 
significantly reduced activity at 72 (p<0.05) and 96 (p<0.001) hours, 
compared to cladribine. Only at 96 hours was cell viability significantly 
reduced compared to control with cladribine (p<0.01). The activity of 
CIFara2Y was significantly reduced compared to clofarabine at 24 
(p<0.05) and 48 hours (p<0.01). Clofarabine reduced cell viability 
significantly at 24 (p<0.01), 48, 72 and 96 hours (p<0.001) compared to 
control. CIFara2Y reduced cell viability at 48 (p<0.05), 72 and 96 hours 
(p<0.01) compared to control.
In the MDAMB231 cell line at 1 pM (Figure 4.12 B) both cladribine and 
clofarabine significantly reduced cell viability at 48 (p<0.01), 72 and 96 
hours (p<0.001) compared to control. CdA1X reduced cell viability 
significantly compared to control (p<0.001) at 96 hours and the 
reductions at 72 and 96 hours were significant (p<0.001) for CIFara2Y. 
At 48 (p<0.01), 72 and 96 hours (p<0.001) CdA1X activity was 
significantly less than that of cladribine.
At 100 pM, in the MCF-7 cells (Figure 4.13 A), both parent compounds 
(p<0.05 at 24 hours, p<0.001 at 48, 72 and 96 hours) and both protides 
significantly reduced cell viability at 24, 48, 72 and 96 (p<0.001) hours. 
At 24 hours, CdA1X was significantly better than cladribine at reducing 
cell viability compared to control (p<0.001). At all time points, CIFara2Y 
was significantly more active than clofarabine at reducing cell viability
(p<0.001).
In the MDAMB231 cells (Figure 4.13 B), cladribine and CdA1X 
significantly reduced cell viability (p<0.01) compared to control at 48, 72 
and 96 hours. Clofarabine reduced cell viability compared to control 
significantly at 48 (p<0.05), 72 and 96 hours (p<0.001) as did CIFara2Y 
at all time points (p<0.001). At 24 hours, CIFara2Y caused a 
significantly greater reduction in cell viability than clofarabine (p<0.01).
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Figure 4.11 Effects of Cladribine and Clofarabine Protides on MCF-7 and 
MDAMB231 Cell Viability
The effects on cell viability of a cladribine protide, CdA1X and two clofarabine 
protides, CIFaralX and CIFara2Y, were investigated over 96 hours using the 
MTS assay in MCF-7 (A) and MDAMB231 (B) cells. Data are expressed as % 
of viable cells compared to control and are the mean of three separate 
experiments, repeated in triplicate ± S.E.M. *(p<0.05) compared to control; 
*(p<0.05) compared to parent compound. The level of significance for each 
point was not included on the graph for clarity, but is included in the text (see 
section 4.4.9). Data were analysed using a one-way ANOVA and the Tukey- 
Kramer post hoc test.
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Figure 4.12 Effects of 1 pM Cladribine, Clofarabine, CdA1X and CIFara2Y 
on MCF-7 and MDAMB231 Cell Viability Over Time
The effects of 1 fjM cladribine, clofarabine and their respective protides, 
CdA1X and CIFara2Y, on MCF-7 (A) and MDAMB231 (B) cell viability were 
investigated at 24 hour time intervals using the MTS assay. Data are 
expressed as % of viable cells compared to control and are the mean of three 
separate experiments, repeated in triplicate ± S.E.M. *(p<0.05) compared to 
control; **(p<0.05) compared to parent compound. The level of significance 
was not included on the graph for clarity, but is included in the text (see 
section 4.4.10). Data were analysed using a one-way ANOVA and the 
Bonferroni post hoc test with selected pairs of data.
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Figure 4.13 Effects of 100 yM Cladribine, Clofarabine, CdA1X and 
CIFara2Y on MCF-7 and MDAMB231 Cell Viability Over Time
The effects of 100 pM cladribine, clofarabine and their respective protides, 
CdA1X and CIFara2Y, on MCF-7 (A) and MDAMB231 (B) cell viability were 
investigated at 24 hour time intervals using the MTS assay. Data are 
expressed as % of viable cells compared to control and are the mean of three 
separate experiments, repeated in triplicate ± S.E.M. *(p<0.05) compared to 
control; *(p<0.05) compared to parent compound. The level of significance 
was not included on the graph for clarity, but is included in the text (see 
section 4.4.10). Data were analysed using a one-way ANOVA and the 
Bonferroni post hoc test with selected pairs of data.
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4.5 Discussion
The aim of this chapter was to investigate the pharmacological actions 
of PNA on cell viability in a variety of human breast cancer cell lines. 
These effects were also examined in the HL60 leukaemia cell line as a 
control. The mechanisms of activation and action of these drugs were 
also investigated.
4.5.1 Molecular profile of breast cancer cell lines
The first part of this study was to determine which cell lines should be 
used to investigate the activity of the NA. A range of breast cancer cell 
lines were chosen to represent some of the most common molecular 
phenotypes of breast cancer seen clinically. Cells were chosen based 
upon their ER status primarily to encompass those that are ER-positive 
and ER-negative. Cell lines were also chosen based on whether they 
overexpressed Her2 and their p53 status. The molecular phenotype of 
each of the six breast cancer cell lines can be seen in Table 4.1.
The HL60 human promyelocytic leukaemia cell line was chosen to 
serve as a positive control for the NA studies as the effects of PNAs 
have been studied in these cells previously (Santini et al. 1996; 
Stachnik et al. 2005; Parker et al. 2009). These cells were chosen as 
they are a model of acute leukaemia, a disease which these drugs are 
used effectively to treat in the clinic (Robak and Wierzbowska 2009).
4.5.2 Clofarabine has a differential effect on cell viability
In the HL60 cells, clofarabine was shown to be the most effective of 
these drugs in reducing cell viability and fludarabine the least so, data 
which correspond with the current literature (M&nsson et al. 1999; 
Bonate et al. 2006). Clofarabine was found to have an IC50 value of 20 
nM, similar to previous results of 37-40 nM (Lotfi et al. 1999; M&nsson 
et al. 1999). The IC50 values of cladribine and fludarabine were also 
similar to the literature, 57 nM compared with 41 nM and 1.3 pM
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compared with 1.9 pM, respectively (Mansson et al. 1999). These data 
show that the PNA are working as expected and validate the 
experimental protocol.
The effects of clofarabine were investigated in the six breast cancer cell 
lines. The most striking effect observed was the significant differences 
in potency observed between ER-positive and ER-negative breast 
cancer cells. In ER-positive breast cancer cell lines, clofarabine had 
IC50 values of approximately 300 nM, compared to values of 
approximately 40 nM in the ER-negative cell lines. Whilst clofarabine 
was significantly less potent in these ER-positive cells compared to the 
HL60 cells, it was equally potent in the ER-negative cells compared to 
the HL60 cells. These data imply that clofarabine may have potential for 
clinical use in ER-negative breast cancers as less drug would be 
needed to produce a significant effect.
To further these studies, the efficiency of clofarabine to reduce cell 
viability at a concentration achievable clinically in plasma was 
determined. A concentration of 1 pM was chosen as clinical data 
suggested that, at the end of an infusion of the drug, clofarabine 
reached a median plasma concentration between 1 and 1.5 pM in 
patients treated with the maximal tolerated dose (Gandhi et al. 2003; 
Jeha et al. 2004; Faderl et al. 2005).
Clofarabine was equally efficacious at 1 pM in the ER-negative cell 
lines compared to the HL60 cells. This further suggests that clinically, 
clofarabine has potential for use against ER-negative breast tumours. In 
two ER-positive cell lines, MCF-7 and BT 474, clofarabine was 
significantly less efficacious compared to the HL60 cells at 1 pM. 
However, the efficacy of clofarabine in the T47D cells at 1 pM was 
equal to that observed in the ER-negative and HL60 cells. This 
difference is interesting because it means that whilst clofarabine is less 
potent in the T47D cells compared to the ER-negative cells, it is equally 
effective.
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When discussing potency (IC50) and efficacy at 1 pM, it is important to 
keep clear the distinctions between the two. The % efficacy at 1 pM is 
an important measurement as it suggests how the drugs might respond 
clinically at a concentration that could be achieved in patients. It gives 
an indication of how many of the tumour cells are likely to be killed by 
the drugs which is of clinical importance. However, this is not the 
maximal efficacy and is by definition, an 'arbitrary’ unit at 1 pM. The 
potency (IC50 value) is a better indicator of the effects of these drugs in 
vitro as it takes into account the whole concentration-response curve. 
Therefore, this thesis will focus upon the potency of these drugs in this 
in vitro system and differences between cell lines will be discussed 
primarily as the differences in IC50 values.
These results support the concept that ER-negative tumours are more 
responsive to cytotoxic chemotherapy than ER-positive tumours, with 
TNBC being even more sensitive than Her2 overexpressing, ER- 
negative tumours (Gluz et al. 2009). Similarly, tumours belonging to the 
basal sub-type and those that are poorly differentiated and have a high 
proliferation index tend to be more sensitive to cytotoxic chemotherapy 
(Faneyte et al. 2003; Berry et al. 2006; Guarnari et al. 2006; Anders and 
Carey 2008). Various reasons have been proposed as to the cause of 
this, such as expression of P-glycoprotein, multi-drug resistance 
proteins and the bcl-2 proto-oncogene (Kerr 1995).
Overexpression of Her2 tends to predict a more aggressive phenotype, 
and this is associated with an increased de novo resistance to a 
standard chemotherapeutic regime of cyclophosphamide, methotrexate 
and 5’-fluorouracil (Stal et al. 1995; Pettitt et al. 2001). However, those 
Her2 overexpressing tumours show increased sensitivity to 
anthracycline, anthracycline plus taxane and doxorubicin therapy (Paik 
et al. 1998; Thor et al. 1998; Zhang and Liu 2008) compared to tumours 
with normal levels of Her2. Induction of Her2/ER cross-talk has been 
demonstrated to cause resistance to anti-hormone drugs previously
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(Shou et al. 2004). There is no correlation with Her2 status and potency 
of clofarabine in these cell lines, however.
The tumour suppressor, p53, is often implicated in dictating 
chemotherapy efficacy. Galmarini et al. (2003a) found that p53-null 
colon cancer cells were more susceptible to the cytotoxic activity of 
cladribine compared to their p53 wild-type counterparts and suggested 
that the p53 status of a tumour dictated the apoptotic pathway induced. 
There was, however, no correlation observed here between p53 status 
and the effect of clofarabine, suggesting that p53 status and sensitivity 
to PNA in breast cancer cells does not correlate.
BRCA1 has also been demonstrated to have differential effects on 
chemotherapy responsiveness, depending upon the type of drug used 
(Quinn et al. 2003). However, of the six breast cancer cell lines tested 
here, only the MDAMB436 are reported to be BRCA1 -mutated (Elstrodt 
et al. 2006) and so there was no obvious correlation between BRCA1 
status and clofarabine potency.
4.5.3 Effects of cladribine and fludarabine on cell viability
The effects of cladribine in the MCF-7, MDAMB231 and HL60 cells 
were similar to that seen with clofarabine, albeit with a ~1.5-fold 
decrease in overall potency. These data suggest that cladribine and 
clofarabine may have similar mechanisms of action against these 
breast cancer cell lines, although clofarabine is more potent.
Fludarabine showed the least activity against MCF-7 and MDAMB231 
cells when compared to cladribine and clofarabine. It also had less 
activity in the HL60 cells compared to the other two drugs. The reasons 
for this are unknown, but this result has been shown previously in the 
literature (Mansson et al. 1999; Marzo et al. 2001). This differential 
effect may be due to phosphorylation to the active phosphorylated 
compounds as cladribine and clofarabine are more efficiently 
phosphorylated (Gandhi et al. 2006; Harned and Gaynon 2008). This,
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however, is unlikely as phosphorylation by dCK is not rate-limiting in the 
action of clofarabine and cladribine.
Alternatively, the differential potency of inhibition of ribonucleotide 
reductase or DNA polymerase may account for these effects. 
Clofarabine and cladribine are 10-fold more potent inhibitors (65 nM) of 
ribonucleotide reductase compared to fludarabine. Fludarabine is a 
more potent inhibitor of DNA polymerase-a (Ki = 0.7 pM) than cladribine 
and clofarabine (Ki = 3.5 and 4.7 pM, respectively). Fludarabine and 
cladribine are also relatively potent inhibitors of DNA polymerase-p (Ki 
= 5.8 and 42 pM, respectively) whereas clofarabine was less so (Parker 
et al. 1988; Parker et al. 1991; Xie and Plunkett 1995; Xie and Plunkett 
1996; Parker et al. 1999; Gandhi et al. 2003; Larson and Venugopal 
2009). These data therefore suggest that inhibition of DNA polymerase- 
a is less detrimental to the cells than inhibition of ribonucleotide 
reductase and depletion of dNTP pools.
Unlike the effects seen with cladribine and clofarabine, there was a 
highly significant difference between the effects of fludarabine in the 
MDAMB231 cells compared with the HL60 cells. This further suggests a 
different mechanism of action of fludarabine compared to cladribine and 
clofarabine and may also indicate that the HL60 cells are more sensitive 
to inhibition of DNA polymerase-a than the MDAMB231 cells.
Alternatively, clofarabine has been shown to alter the transmembrane 
potential of mitochondria and release of mitochondrial apoptotic factors 
and this was not seen with fludarabine. This may explain the effects on 
cell viability observed (Carson et al. 1992; Genini et al. 2000a; Perez- 
Galen et al. 2002; Bonate et al. 2006). However, Klopfer et al. (2004) 
stated that both cladribine and fludarabine are able to induce apoptosis 
by a mitochondrial cell death pathway and so this is less likely.
Clofarabine boasts the most clinical potential compared to cladribine 
and fludarabine being both a potent inhibitor of ribonucleotide reductase
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and DNA polymerase (Tseng et al. 1982; Parker et al. 1991). 
Physiologically, besides being resistant to degradation by ADA, it is also 
the most acid-stable compound, the most lipophilic and is also resistant 
to bacterial nucleoside phosphorylase (Zhenchuk et al. 2009). 
Clofarabine also has a slower elimination rate compared with cladribine. 
These features suggest it is more stable in the body and less likely to 
be broken down to toxic metabolites like 2-chloroadenine, therefore, 
reducing side effects, and increasing its duration of action. Based upon 
the data here, and the beneficial properties of clofarabine over 
cladribine and fludarabine clinically, clofarabine was chosen to study in 
more depth throughout the rest of this thesis.
4.5.4 Effect of gemcitabine on cell viability
Gemcitabine is a pyrimidine NA and, in combination with paclitaxel, has 
recently been approved for the treatment of metastatic breast cancer in 
patients who have relapsed and had prior adjuvant/neo-adjuvant 
chemotherapy (NICE guidelines, 2007). Its activity against the MCF-7 
and MDAMB231 cells was investigated to compare with the PNA in 
vitro.
Interestingly, gemcitabine had IC50 values of 1.1 and 2.5 nM in the 
MCF-7 and MDAMB231 cells, respectively. This is a significant increase 
(MCF-7 p<0.01 and MDAMB231 p<0.05) in the activity of gemcitabine 
compared to the clofarabine by 300- and 16-fold in the MCF-7 and 
MDAMB231 cells, respectively.
Unlike pyrimidine analogues, the rate limiting-step for clofarabine and 
cladribine activity is the conversion of the monophosphate to the 
diphosphate, and not primary phosphorylation by dCK (Gandhi et al. 
2003). The differences observed between clofarabine and gemcitabine 
may therefore be a consequence of high expression of dCK in these 
cell lines. Similarly, gemcitabine is more potent inhibitor or the various
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subunits of ribonucleotide reductase than PNA and this may account for 
the increased potency.
Despite the potency differences between gemcitabine and clofarabine, 
clofarabine should not be overlooked as a potential treatment of breast 
cancer. Gemcitabine is rapidly deactivated by cytidine deaminase and 
has a very short in vivo half-life of 8 minutes (Abbruzzese et al. 1991). 
In order to accumulate intracellular gemcitabine triphosphate, plasma 
concentrations of gemcitabine must be £10^M (Zucchetti et al. 2004).
Deoxycytidine triphosphate and gemcitabine triphosphate (dFdCTP) are 
negative feedback regulators of dCK. Concentrations of these 
metabolites of 25 pM can cause greater than 90% inhibition of the 
primary phosphorylation of gemcitabine by dCK (Gandhi and Plunkett 
1990; Bouffard et al. 1993; Veltkamp et al. 2008) and may explain why 
dFdCTP formation is saturated at plasma concentrations in a similar 
range in vivo (15-20 pM) (Abbruzzese et al 1991).
Taken together, these data suggest that clinically plasma 
concentrations in the range of 10 -  20 pM are optimal for accumulation 
of the active metabolite of gemcitabine, dFdCTP. The data herein 
suggest that at 1 pM there was no significant cytotoxic difference 
observed between gemcitabine and clofarabine in the MDAMB231 
cells. Therefore, although gemcitabine may have better in vitro potency, 
in vivo, clofarabine may be just as effective as gemcitabine. This data 
may be clinically relevant regarding de novo and acquired resistance to 
gemcitabine. Resistance to gemcitabine has been suggested to occur 
via dCK deficiency (Jordheim et al. 2006; Ohhashi et al. 2008), but the 
data in this thesis suggest that clofarabine activity is not defined by dCK 
levels, opening the door for clofarabine in the event of gemcitabine 
resistance (see Chapter 5). Similarly it has also been demonstrated that 
cells resistant to cladribine were not resistant to gemcitabine or 
cytarabine (Schirmer et al. 1998) further suggesting that cross­
resistance may not occur.
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4.5.5 Clofarabine induces apoptosis in MCF-7 and MDAMB231 
cells
To determine if clofarabine was causing apoptosis, flow cytometry with 
annexin V and propidium iodide staining was performed. After treatment 
with 1 pM clofarabine for 96 hours, there was an increase in the amount 
of annexin V staining in both MCF-7 and MDAMB231 cell lines 
compared to media when normalised to 0.05% DMSO vehicle control. 
This indicates that clofarabine can cause apoptosis in both these cell 
lines, confirming the cytotoxic nature of clofarabine against cancer cells. 
Numerous studies have shown this, albeit in leukaemia cell lines (Leoni 
et al. 1998; Genini et al. 2000a; Genini et al. 2000b; Takahashi et al. 
2002; Bonate et al. 2006; Zhang et al. 2009). This is the first example of 
clofarabine inducing apoptosis in breast cancer cells at clinically 
relevant concentrations. Hashemi et al. (2003; 2004) suggested that 
cladribine was able to cause apoptosis in MCF-7 and MDAMB436 cells, 
respectively, but this was only demonstrated at concentrations >25 pM 
that are not clinically relevant.
Clofarabine was shown to cause a significant increase in both early and 
late apoptotic cells in the MDAMB231 cells, compared to the MCF-7. 
These data further confirm the MTS results, suggesting that clofarabine 
is more active in the MDAMB231 cells compared to the MCF-7 cells. It 
would also be interesting to see if similar differences were observed in 
the other breast cancer and HL60 cell lines to confirm the MTS data.
4.5.6 The growth rate of breast cancer cells does not influence 
PNA potency
The differences in the activity of the PNA in the different breast cancer 
cell lines could be due to their rate of proliferation as cells that are 
undergoing more rapid division will have an increased need for DNA 
synthesis. This was investigated by determining the proliferation rates 
of each of the six breast cancer cell lines in preliminary experiments.
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It can clearly be seen that there was no particular correlation observed 
between growth rate and the activity of the NA cladribine and 
clofarabine. The MDAMB231 cells were the fastest growing, and the 
ER-negative, Her2 over-expressed SKBR-3 cells were the slowest. The 
MCF-7 and T47D cells grew at a slightly reduced rate compared to the 
MDAMB231 cells, but were both faster than the BT 474, MDAMB436 
and SKBR-3 cells.
4.5.7 PNA require phosphorylation by dCK for their activity
PNA are prodrugs that require intracellular phosphorylation by a 
nucleoside kinase to become active. The main enzyme responsible for 
this reaction for both purine and pyrimidine analogues is dCK (Lotfi et 
al. 1999; Parker et al. 1999; Mansson et al. 2003; van der Wilt et al. 
2003). dCK is a rate-limiting enzyme in the nucleoside salvage pathway 
as it catalyses the first phosphorylation reaction with 2’-deoxycytidine, 
its natural substrate (Hatzis et al. 1998) although it can also 
phosphorylate both 2’-deoxyadenosine and 2’-deoxyguanosine (van der 
Wilt et al. 2003). Thymidine kinase and deoxyguanosine kinase have 
also been implicated in the primary phosphorylation of NA, although to 
a significantly lesser extent (Mansson et al. 1999; van der Wit et al. 
2003).
There is no specific inhibitor of dCK but Bilgeri et al. (1993) and 
Joachims et al. (2008) were able to show that micromolar 
concentrations of the natural substrate, 2’-deoxycytidine, could 
competitively inhibit the activity of dCK in vitro. For this study an 
increased concentration of 100 pM of 2’-deoxycytidine was used 
compared to the 50 pM in the previous study by Joachims et al. (2008) 
on murine thymocytes. Cancer cells tend to have increased levels of 
dCK, so an increased concentration was used to account for this (van 
der Wit et al. 2003).
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In both the MCF-7 and MDAMB231 cells, pre-treatment with 2’- 
deoxycytidine significantly reduced the action of all three purine 
analogues compared to the activity of the analogues alone. In the MCF- 
7 cells there was no significant difference observed between control, 2’- 
deoxycytidine alone and drug plus 2’-deoxycytidine, suggesting that 
dCK is the sole enzyme involved in activation of these drugs. However, 
in the MDAMB231 cells, in the presence of 2’-deoxycytidine, there was 
still a significant reduction in cell viability with cladribine and clofarabine, 
but not for fludarabine. This suggests that fludarabine is solely 
phosphorylated by dCK, but other enzymes may be involved in the 
phosphorylation of cladribine and clofarabine. However, this 
involvement is likely small due to the minor differences observed. This 
could be due to thymidine or deoxyguanosine kinase (Mansson et al. 
1999; van der Wilt et al. 2003).
An analogue of cladribine, 5’-deoxy-2’-chlorodeoxyadenosine, (a 
generous gift from Professor Chris McGuigan, Welsh School of 
Pharmacy) was used to further these studies. This analogue, has the 
hydroxyl replaced at the 5’ position on the sugar moiety with a methyl 
group (see Figure 4.9 A). The substitution impairs the ability of this 
molecule to be phosphorylated at this position, rendering it a 
nucleoside. As the action of cladribine and other analogues is 
dependent upon phosphorylation, this drug should be inactive against 
cells. Even at 100 pM, 5’-deoxy-2’-chlorodeoxyadenosine had no 
significant effect on cell viability in the MCF-7 cells. These data show 
further that cladribine at least, must be phosphorylated at the 5’ position 
to be active.
4.5.8 Hydroxyurea influences the action of PNAs
Hydroxyurea is a clinically used ribonucleotide reductase inhibitor that 
works by scavenging the tyrosyl free radical essential for redox found 
on the RRM2 and p53R2 subunit (Sneeden and Loeb 2004). It has 
been shown to inhibit the growth of cancer cells both in vitro and in vivo
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(Juul et al. 2010). It has also been shown to increase the efficacy of NA 
by decreasing intracellular dNTP pools allowing a greater accumulation 
of NA into DNA (Sato et al. 1984; Bhalla et al. 1991; Kano et al. 2000; 
Zhou et al. 2002; Karp et al. 2008). The effects of hydroxyurea were 
investigated in combination with PNA to examine potential for 
combination treatment and to help elucidate pharmacologically the role 
of ribonucleotide reductase in PNA drug activity in these cells.
A concentration of 300 pM hydroxyurea was used as this was found to 
be the IC50 value (Yang et al. 2001; Rajwade et al. 2009) and has been 
used previously to inhibit the actions of the RRM2 subunit and 
ribonucleotide reductase activity in vitro (Kuo et al. 2003).
In both MCF-7 and MDAMB231 cells, hydroxyurea inhibited cell viability 
by 40 and 60% compared to control, respectively, meaning that 
inhibition of ribonucleotide reductase reduces cell survival significantly. 
The significant difference (p<0.001; two-tailed Student’s t test) between 
the two cell lines could be explained by an increase in ribonucleotide 
reductase RRM2 or p53R2 subunit expression in the MCF-7 cells 
compared to the MDAMB231 cells and has been suggested before as a 
mechanism of resistance to hydroxyurea (Zhang et al. 2009).
In combination with hydroxyurea, fludarabine significantly decreased 
cell viability compared to fludarabine or hydroxyurea alone by 30 and 
15% in the MCF-7 and MDAMB231 cells, respectively. This is probably 
an additive effect rather than synergistic effect and has been suggested 
previously (Sato et al. 1984; Kano et al. 2000). It is likely that the 
decrease in free dNTP pools by hydroxyurea encourages fludarabine 
incorporation into DNA leading to strand breakage and cell death 
(Bhalla et al. 1991; Kano et al. 2000; Zhou et al. 2002; Karp et al. 
2008). It also suggests that fludarabine primarily works by a mechanism 
independent of inhibition of ribonucleotide reductase
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In the MCF-7 cells, there was a small but significant increase in efficacy 
of cladribine and clofarabine in combination with hydroxyurea compared 
to each analogue alone, although this increase in efficacy was 3-fold 
lower than that observed with fludarabine. There was no difference 
observed between these groups in the MDAMB231 cells. These data 
imply that cladribine and clofarabine are primarily working via inhibition 
of ribonucleotide reductase, and this could be due to their more potent 
inhibition of this enzyme than fludarabine (Parker et al. 1991). As 
cladribine and clofarabine were still having some effect in the MCF-7 
cells, this could be explained by an increase in ribonucleotide reductase 
activity in these cells, and so is not fully inhibited by hydroxyurea. 
Alternatively hydroxyurea may be having a non-specific effect and has 
been shown to inhibit ERK and JNK signalling, inhibits the action of 
catalase and is known to influence iron uptake and expression of 
transferrin receptors (Chitamber and Wereley 1995; Park et al. 2001; 
Juul etal. 2010).
These data with hydroxyurea should be interpreted with caution as the 
effects seen may not be due to inhibition of p53R2 or RRM2. To confirm 
these studies, investigating changes in the dNTP pool would help 
identify a ribonucleotide reductase-specific mechanism. Similarly, the 
use of a different inhibitor would be useful. Triapine is a new 
ribonucleotide reductase inhibitor that works in the same way as 
hydroxyurea, but shows vastly improved specificity and has an IC 5 0  
value of 112 and 144 nM for p53R2 and RRM2, respectively (Shao et 
al. 2004; Karp et al. 2008). The fact that hydroxyurea is producing such 
pronounced effects alone may be skewing the data in combination with 
the NA.
4.5.9 Effects of protides on cell viability
Nucleoside prodrugs represent a novel way of delivering NA drugs and 
have potential as new therapeutics. Their aim is to by-pass the rate- 
limiting and adverse steps in the parent NA modifications, with the
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ultimate result of increased or new activity against cancers and viruses 
(Wagner et al. 2005). There was a two-fold aim to using prodrugs in this 
thesis; to establish if prodrugs of the NA have potential as new 
therapeutics against breast cancer and secondly, to help elucidate 
mechanism(s) of action of the parent compounds in breast cancer cells 
in vitro. For intellectual property reasons neither the structures or 
specific details of any of the prodrugs can be disclosed in this thesis. 
The prodrugs used in this thesis are based upon phosphoramidate 
technology where the protective groups are amides or esters and for 
consistency will be called protides throughout.
Protides are monophosphates of the parent nucleoside and therefore 
can benefit from bypassing primary phosphorylation by dCK (Congiatu 
et al. 2005). Although the rate-limiting step is not primary 
phosphorylation by dCK for PNA (Xie and Plunkett 1995; Albertioni et 
al. 1998; Lotfi et al. 1999), it is still a necessary step. As the nucleotide 
cannot pass through the plasma membrane due to its charge, 
protecting groups are added to mask this charge and allow it to diffuse 
freely through the membrane. The protecting groups are then cleaved 
off inside the cell by cellular esterases and amidases to reveal the 
nucleotide monophosphate. The generic structure of a protide of 
cladribine is shown in Figure 4.14. n h ,
o
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Figure 4.14 Generic Structure of a Cladribine Protide
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Concentration-response curves for the various protides and the parent 
compounds were investigated including an inactive concentration of the 
parent compounds (0.1 and 0.01 pM for the MCF-7 and MDAMB231 
cells, respectively). In both cell lines, and for all the protides, none had 
any significant effect on cell viability at these lowest concentrations. 
Only at 100 pM were the protides significantly better than the parent 
compounds in both cell lines. Importantly, at clinically achievable 
concentrations of cladribine (0.1 pM) and clofarabine (1 pM), there was 
no significant improvement in the activity of the protides. This is 
possibly due to low levels of esterases or amidases to cleave the 
protecting groups and reveal the nucleotide.
These data strongly suggest that these protides are unlikely to have 
clinical potential as against breast cancer. A key features of NA to 
support their clinical use is their selectivity for cancerous cells due to 
the increased levels of dCK in cancer cells compared with normal cells 
(Eriksson et al. 1994; van der Wilt et al. 2003; Hubeek et al. 2005). By 
by-passing this primary phosphorylation they lose this selective feature 
which could lead to increased effects on normal tissue, therefore 
increasing side effects for the patient. Similarly, by being able to diffuse 
through the membrane, the expression of NT are less important for the 
protides. Malignant cells have been identified as having increased 
levels of NT compared to normal cells, which may help to explain the 
increased sensitivity of these cells to NA (Mackey et al. 1998; 
Pennycooke et al. 2001; Zhang et al. 2007). Again by-passing this, the 
protides lose another selective feature that may increase side effects.
In help determine the mechanism(s) of action of the parent NA, time 
course profiles were set up with these drugs and the protides. It was 
hypothesised that the protides may work faster than the parent 
compounds, regardless of their efficacy at 96 hours. Cell viability was 
determined at 24 hour intervals for clofarabine, cladribine and two 
protides, CdA1X and CIFara2Y at 1 pM (a clinically relevant
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concentration) and at 100 pM as this was the only concentration that 
the protides had any beneficial effect over the parent compounds.
In both the MCF-7 and MDAMB231 cell lines, there was no 
improvement observed with either protide when compared to their 
respective parent compound at 1 pM at any time interval, and they were 
significantly less effective at various time points. These effects could be 
due to low expression of cellular esterases or amidases. What these 
data highlight is that neither cellular entry nor conversion to the 
monophosphate are rate-limiting steps in the activity of cladribine or 
clofarabine in the MCF-7 or MDAMB231 cell lines.
When the effects of the protides were studied at 100 pM, CIFara2Y and 
CdA1X resulted in a 90 and 70% reduction in cell viability, respectively, 
after 24 hours in the MCF-7 cells. Compared to the parent compounds, 
this is significantly greater. After 96 hours treatment with CIFara2Y, 
there was no significant alteration in cell viability compared to 24 hours. 
This was expected as nearly all of the cells were dead after only 24 
hours. However, after 48 hours treatment with CdA1X, there was a 20% 
increase in the number of viable cells compared to 24 hours. This 
suggests that the MCF-7 cells are able to recover somewhat after the 
initial insult.
The reason for this is unknown, but it is possible that the protide 
oligophosphates accumulate more rapidly than their parent compounds 
resulting in rapid cell death. Whereas with the parent compounds, the 
cells can clear or deactivate the cytotoxic oligophosphate before they 
build up to a significantly cytotoxic level due to their slow accumulation.
Alternatively, repair of the DNA insult may be able to occur with the 
parent compounds, but the rapid accumulation of toxic oligophosphates 
from the protides may be too quick for DNA repair process to begin. 
The wild-type p53 in MCF-7 cells may support this argument. 
Furthermore, the recovery of the MCF-7 cells at 48 hours after CdA1X
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treatment also suggests an adaptive feature of the MCF-7 cells after the 
initial insult that could be repair of the DNA. As the MDAMB231 cells 
have mutated p53 and mutated DNA repair mechanism(s), the rate of 
accumulation of cytotoxic oligophosphates is perhaps less relevant and 
may explain why even at higher concentrations of the drugs, there was 
no increase in effect as the effects are already saturated.
The dramatic cytotoxic effects seen in the MCF-7 cells at high 
concentrations of the protides could be due to accumulation of the 
protecting groups cleaved from the protide to unmask the nucleotide. 
Although it cannot be stated what these groups are, literature searches 
have revealed that high concentrations of these metabolites can cause 
cytotoxicity in a variety of cancer cell lines in culture. This could be 
investigated by treating the cells with these metabolites and measuring 
their cellular accumulation with HPLC, and their cytotoxicity with viability 
assays.
In the time course experiments the significant difference at 100 pM 
between the clofarabine protides and clofarabine was not observed as 
before (section 4.4.8). This is probably due to inter-experimental 
variability, as there is only an 8% difference between the results at 96 
hours in section 4.4.9 and 4.4.10. These data suggest that, in the 
MDAMB231 cells, increasing the concentration of protide or parent 
analogue is not going to increase the anti-cancer activity of either 
compound dramatically over shorter time periods than 96 hours. This 
could be because at 1 pM either the activation enzymes, 
monophosphate or diphosphate purine kinases, and/or the cellular 
targets of these oligophosphates are saturated.
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4.6 Conclusion
The aim of this chapter was to investigate the activity and action of PNA 
in human breast cancer cell lines in vitro.
Clofarabine was the most potent of the three PNA tested in breast and 
leukaemia cell lines. It was also more potent in ER-negative compared 
to ER-positive cell lines, and its potency in these ER-negative cells was 
comparable to the activity seen in the HL60 leukaemia cell line. 
Cytotoxic activity of the PNA is also dependent upon phosphorylation by 
dCK. These data indicate the potential for the use of clofarabine in ER- 
negative breast cancers.
The differences in potency of clofarabine between the ER-negative and 
ER-positive cells was not addressed in this chapter. However, based 
upon the pharmacological profiles of the other PNA and the 
ribonucleotide reductase inhibitor, hydroxyurea, differences in the 
expression and activity of ribonucleotide reductase may be a plausible 
explanation. Similarly, the differential effects were not attributed to the 
rate of proliferation or different molecular phenotypes of these cells, 
besides ER status.
Results obtained with clofarabine and cladribine protides indicated that 
these novel agents are unlikely to be of clinical use but did, however, 
suggest that neither intracellular phosphorylation to the 
monophosphate, nor cellular entry are rate-limiting steps in the 
effectiveness of clofarabine or cladribine.
The differences observed between ER-positive and ER-negative cells 
raised further questions that are addressed in the next chapter. Here, 
studies were carried out to try and identify the causes of this increased 
resistance in the ER-positive cells using molecular biological 
techniques, with particular focus on the MCF-7 and MDAMB231 cells.
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Chapter 5: Mechanisms of Increased Resistance to 
Clofarabine in ER-Positive Breast Cancer
5.1 Introduction
In the previous chapter, a correlation between ER status and the 
potency of PNAs were identified. Although still sensitive to clofarabine 
at clinically relevant concentrations (~300 nM), the ER-positive tumours 
were 8-fold more resistant to the action of clofarabine than the ER- 
negative tumours. PNA have not been widely studied in solid tumours 
and so there is no data on mechanisms of resistance to these drugs in 
solid tumour cell lines. There are, however, a large number of studies 
that have looked at the resistance of PNA in leukaemia and other cell 
lines of haematological malignancies. The vast majority of these data 
look at acquired resistance to the drugs rather than de novo resistance 
as is the case here, and again means that direct comparisons are 
difficult to make. These studies are useful, however, as they suggest 
rational mechanisms and targets that could be identified in solid 
tumours.
Three proposed routes of resistance to PNA have been suggested in 
the literature (Galmarini et al. 2001);
1. Insufficient accumulation of the active triphosphate due to
a. decreased dCK expression
b. increased expression of cN-ll
c. decreased nucleoside influx, or increased efflux.
2. Decreased ability of the triphosphate to affect DNA or dNTP 
pools from
a. increased/altered ribonucleotide reductase expression
b. altered DNA polymerase activity
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3. Defective induction of the apoptosis pathway
It was decided to focus the work on the three most common 
mechanisms studied to date looking at the expression of dCK, cN-ll and 
ribonucleotide reductase.
dCK is an essential enzyme in PNA activity as it catalyses the first, but 
not rate-limiting phosphorylation to the monophosphate (M&nsson et al. 
1999; Gandhi et al. 2003). Its loss is frequently implicated in resistance 
to both purine and pyrimidine NAs both in vivo (Kawasaki et al. 1993; 
Kakihara et al. 1998; Kroep et al. 2002) and in vitro (Orr et al. 1995; Bai 
etal. 1998; Dumontet etal. 1999; Lotfi etal. 1999; Mansson etal. 1999; 
Gourdeau et al. 2001; M&nsson et al. 2003).
The role of increased cN-ll expression in PNA resistance has been 
suggested by numerous studies (Carson et al. 1991; Kawasaki et al. 
1993; Schirmer et al. 1998; Dumontet et al. 1999; Lotfi et al. 2001; 
Yamamoto et al. 2007) and high levels of this enzyme have been 
associated as a prognostic indicator in acute myeloid leukaemia 
patients (Galmarini et al. 2001; Galmarini et al. 2003b)
Increased activity or lack of the inhibitory effects of NAs on 
ribonucleotide reductase has been reported as a cause of NA 
resistance. Caras and Martin (1988) showed that mutations in the 
allosteric regulatory site of RRM1 can cause inhibition of the feedback 
regulation by dATP. Increased activity of ribonucleotide reductase is 
thought to cause resistance to NAs due to an increase in dNTPs that 
can out-compete NAs in other areas such as insertion into DNA or 
acting as false substrates for DNA polymerases (Parker et al. 1991). 
Several studies have suggested that increased ribonucleotide 
reductase expression and activity causes resistance to NAs (Carson et 
al. 1992; Dumontet et al. 1999; Goan et al. 1999; Minsson et al. 1999; 
Davidson etal. 2004; Jordheim etal. 2005; Ferrandina etal. 2010).
142
The expression of dCK, cN-ll and ribonucleotide reductase was 
investigated at the genomic level by looking at RNA expression, and 
then at the protein level with Western blotting both to confirm the basal 
expression and determine clofarabine-induced changes in expression.
5.2 Chapter Aims
The aim of this chapter was:
• To use molecular biological and pharmacological tools to 
investigate the increased resistance to clofarabine in ER-positive 
compared to ER-negative breast cancer cell lines.
The specific objectives of this chapter were to:
• Use real-time PCR to investigate RNA levels of genes 
associated with clofarabine activity including dCK, cN-ll and the 
subunits of ribonucleotide reductase, RRM1, RRM2 and p53R2.
• Use Western blotting to confirm data observed with PCR and to 
look at differential expression of proteins after treatment with 
clofarabine.
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5.3 Methods
The detailed protocols for the SYBR Green, real-time PCR and Western 
blotting are described in chapter 2.
5.3.1 RT-PCR
RNA extracted from six breast cancer cell lines (MCF-7, T47D, BT 474, 
MDAMB231, MDAMB436 and SKBR-3) and HL60 cells was reverse 
transcribed to cDNA. Using gene-specific primers and a DNA Master 
SYBR Green I kit, specific cDNA sequences were amplified in a 
LightCycler 2.0 RT-PCR system (Roche Applied Science, Burgess Hill, 
UK) under the following conditions:
Program: Denaturation Cycles: 1
Segment
Number
Target
Temperature
(°C)
Hold
Time
(sec)
Slope
(°C/sec)
Acquisition
Mode
1 95 600 20 None
Program: Amplification Cycles: 35
Segment
Number
Target
Temperature
(°C)
Hold
Time
(sec)
Slope
(°C/sec)
Acquisition
Mode
1 95 10 20 None
2 56 8 20 None
3 72 7 20 Single
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Program: Melting Curve Cycles: 1
Segment
Number
Target
Temperature
(°C)
Hold
Time
(sec)
Slope
(°C/sec)
Acquisition
Mode
1 95 0 20 None
2 65 15 20 None
3 95 0 0.1 Continuous
Program: Cooling Cycles: 1
Segment
Number
Target
Temperature
(°C)
Hold
Time
(sec)
Slope
(°C/sec)
Acquisition
Mode
1 40 30 20 None
The Ct values for each gene in each cell line were determined 
automatically using the second derivative maximum method in the 
LightCycler v3.5 software (Roche Applied Science, Burgess Hill, UK). 
All data were normalised to GAPDH expression to control for any 
differences in the starting amount of RNA. REST software was used to 
calculate the expression of each gene relative to the expression in the 
HL60 cells. Therefore, all data are expressed as fold change from the 
HL60 cells.
Gel electrophoresis was used to confirm amplicon size as described in 
section 2.6.5 and visualised under UV illumination.
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5.3.2 Western blotting
Cell lysates were prepared from cells in logarithmic growth phase and 
protein quantified as described in sections 2.5.1 and 2.5.3, respectively. 
To determine the effects of clofarabine cells were treated with the 
appropriate concentrations for the time period indicated in normal 
growth media. Media only and vehicle controls were also included. 
Routinely, 10 pg of protein were separated using SDS-PAGE and 
proteins were then transferred to nitrocellulose membrane using semi­
dry immunoblotting (section 2.5.5). After blocking, membranes were 
incubated with the primary antibody overnight at 4°C in 1% Blotto 
before being washed, probed with secondary antibodies, washed again 
and detected using ECL. The concentrations of primary and secondary 
antibodies are given below.
P-actin 1° 1:50,000
2° 1:50,000 anti-mouse
cN-ll 1° 1:2000
2° 1:10,000 anti-rabbit
p53R2 1° 1:2000
2° 1:10,000 anti-rabbit
Densitometry was used to semi-quantitate protein levels and analysed 
using ImageJ software (NIH, USA). Data were normalised to p-actin to 
control for protein loading.
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5.3.3 Data Analysis
REST software (REST, Germany) was used to calculate the relative 
expression of genes compared to the HL60 cells and their significance 
using a pair-wise fixed reallocation randomisation test from the PCR 
data. No statistics could be performed to compare the expression 
between the breast cancer cell lines. This is because the REST 
software and the relative quantification methods do not allow for 
statistics to be performed in a cross-wise manner, but only between the 
genes of interest (GOI) in samples compared to the control (HL60 cells 
in this instance). See section 2.6.6.
Statistical analyses were carried out in GraphPad Prism V5.0b. 
Comparisons between two groups were done using a Student’s t test, 
and a one-way ANOVA was used for three or more groups with a 
Tukey-Kramer post hoc test if a significant difference was observed 
between the three or more groups. If only selected means were 
compared than the Bonferroni correction method was used. Probability 
values of less than 0.05 were considered statistically significant. 
Correlations between IC50 values and gene expression were 
determined in GraphPad Prism. The Pearson correlation coefficient (r) 
was calculated for each gene compared to the IC50 value as a Gaussian 
distribution was assumed but not calculated due to small sample sizes 
(n=7). Due to the low sample size, a Spearman’s Rank test was also 
used, which doesn’t assume normally distributed data and adds 
confidence to any significant results observed with Pearson’s 
correlation test. The results of the Spearman’s Rank test are not 
included in the results section, but are discussed in the relevant 
discussion sections of this Chapter.
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5.4 Results
5.4.1 RT-PCR validation
SYBR Green, RT-PCR was used to investigate the expression of genes 
associated with the action of PNA in the six breast cancer cell lines and 
the HL60 leukaemia cell line. The mRNA expression of dCK, cN-ll and 
the three subunits that form ribonucleotide reductase (RRM1, RRM2 
and p53R2) and GAPDH as a control were determined using primers 
specific for each of these genes.
Figure 5.1 A shows a representative fluorescence trace obtained from 
HL60 cells looking at the expression of all 5 target genes, and GAPDH 
as a positive control. Also shown are the minus reverse transcription (- 
RT) negative controls. Fluorescence signals were seen for all 6 genes 
indicating their presence. There was no increase in fluorescence above 
background for the -R T  controls. These data were consistent in the 
other cell lines and repeats of experiments.
Figure 5.1 B shows a representative trace of the melting curve analysis 
from the same samples as shown in figure 5.1 A. Single peaks were 
obtained for each of the 6 genes investigated indicating the presence of 
only one amplicon. The melting points were consistently 3-5 °C higher 
than expected (see table 2.1, section 2.6.1). There were no peaks 
present in the -R T control samples. Again, these data were consistently 
similar with repeats of experiments in all the cell lines.
It was then decided to look at the size of the amplicons to confirm 
correct amplification of the desired genes. The expected sizes of the 
amplicons are given in figure 5.2. It can be seen that there are single 
bands present in each lane that correspond to the expected size of 
each amplicon.
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Figure 5.1 Representative Graphs o f SYBR Green RT-PCR and Melting 
Curve Analysis
T h e  top  trace  (A ) is a  re p re s e n ta tiv e  e x a m p le  o f  H L 6 0  c D N A  a n d  su bsequent 
P C R  fo r  G A P D H , dC K , c N -ll, R R M 1 , R R M 2  a n d  p 5 3 R 2 . The n egative  controls  
a re  a lso  in c lu d e d  w h ich  w e re  H L 6 0  R N A  run u n d e r the s am e  conditions but 
m in u s  th e  re v e rs e  tran scrip tase  e n z y m e  ( -R T  control). T race  (B ) is the m elting  
c u rv e  a n a ly s is  from  th e s e  sam p les . S in g le  p e a k s  can  be o b served  in each  o f 
th e  c D N A  s a m p le s , b u t no p e a k s  a re  o b s e rv e d  in the - R T  controls.
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Figure 5.2 Representative Gel o f HL60 cDNA RT-PCR Amplicons 
Separated by Gel E lectrophoresis
The image is of HL60 cDNA run on the real-time PCR system without melting 
curve analysis, and the resulting amplicons were then separated using 
agarose gel electrophoresis and compared to a ladder of known base pair 
sizes. A GAPDH (220bp), B dCK (139bp), C cN-ll (195bp), D RRM1 (195bp), 
E RRM2 (120bp), F p53R2 (168bp) and G 100bp Ladder.
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5.4.2 Expression of dCK and cN-ll
Next, the genomic expression of dCK and cN-ll was investigated using 
the developed real-time PCR method. Figure 5.3 shows the fold 
expression of dCK and cN-ll compared to the HL60 cells for the six 
different breast cancer cell lines. It can be seen that MCF-7 cells 
express significantly (p<0.05) less dCK RNA than the HL60 cells. There 
were significant increases (p<0.05) in expression of dCK in the T47D 
and BT 474 cells compared to the HL60 cells.
There were significant (p<0.05) increases in cN-ll expression in the 
MCF-7, T47D, BT 474 and MDAMB231 cells compared to HL60 cells 
(Figure 5.4).
Correlations between gene expression and IC 5 0  values of clofarabine 
were investigated with Pearson’s correlation test (r). Figure 5.4 A shows 
there was no significant (p>0.05) correlation with dCK expression and 
I C 5 0  values. Figure 5.3 B, however, shows a significant (p<0.05) 
correlation between cN-ll expression and IC 5 0  values for clofarabine.
5.4.3 Basal protein expression of cN-ll
From the PCR data, it was decided to focus upon the gene that showed 
positive correlations with the IC50 data, cN-ll. Firstly, the basal 
expression of the cN-ll protein was determined to see if it correlated 
with the PCR data. These experiments were carried out in the MCF-7, 
MDAMB231 and HL60 cells only.
Figure 5.5 A shows a representative example of Western blot probing 
for cN-ll and p-actin as a loading control. Densitometry analysis was 
performed and showed a significant (p<0.05) increase in cN-ll protein 
levels in the MCF-7 cells (0.92±0.07) compared to the MDAMB231 
(0.42±0.02) and HL60 (0.18±0.05) cells.
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A Fold RNA Expression Compared to HL 60 Cells
(S.E.)
dCK cN-ll
MCF-7 0.53 (0.36-0.74)* 13.18 (3.52-44.53)*
T47D 1.63 (1.27-2.28)* 8.54(2.19-29.99)*
BT 474 1.62 (1.46-1.84)* 8.96(2.21 -31.81)*
MDAMB231 0.78 (0.71 -0.85) 8.07 (1.99-29.52)*
MDAMB436 0.94 (0.60- 1.37) 4.05 (1.05- 14.29)
SKBR-3 0.61 (0.43- 1.06) 2.41 (0.60 - 8.03)
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Figure 5.3 Fold Expression o f dCK and cN-ll RNA in Breast Cancer Cell 
Lines Compared to HL60 Cells
This figure (tabulated values A; graphical representation B) shows the fold 
difference in expression of dCK and cN-ll RNA in the six different breast 
cancer cell lines compared to the HL60 cells assessed by SYBR Green, real­
time PCR and REST software. The standard error (S.E.) are shown in 
brackets (A). The dotted line represents expression in HL60 cells (1). The data 
are the mean of three separate PCR experiments. *(p<0.05) upregulated 
compared to HL60 cells. *(p<0.05) downregulated compared to HL60 cells. 
Data were analysed with REST software with a pair-wise fixed reallocation 
randomisation test.
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Figure 5.4 Correlation of dCK and cN-ll RNA Expression in Breast Cancer 
Cell Lines with ICso values for Clofarabine
Figures 5.3 A and B show the correlations between the expression ofdCK and 
cN-ll, respectively, with the ICso values for clofarabine in the six breast cancer 
cell lines MCF-7, T47D, BT 474, MDAMB231, MDAMB436 and SKBR-3, and 
also the HL60 cells. Pearson’s correlation coefficient (r) was used to 
determine the significance of the correlation. p<0.05 was considered a 
statistically significant correlation.
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Figure 5.5 Basal Expression o f cN-ll Protein in MCF-7, MDAMB231 and 
HL60 Cells
Cell lysates (10 pg total protein) were subjected to SDS-PAGE 
electrophoresis, blotted and probed for cN-ll and p-actin as a loading control 
and a representative example is shown (A). Densitometry on scanned images 
was used to semi-quantitate the levels of cN-ll protein, and data were 
normalised to p-actin (B). Data are expressed as the mean of three separate 
experiments ± S.E.M. *(p<0.05) different to HL60 cells. *(p<0.05) different 
compared to MDAMB231 cells. Data were analysed with a one-way ANOVA 
and the Tukey-Kramer post hoc test.
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5.4.4 Expression of cN-ll after exposure to clofarabine
It was next decided to investigate whether the protein expression of cN- 
II was altered after exposure to clofarabine. Using densitometry 
analysis, no significant (p>0.05) differences in expression of cN-ll 
between clofarabine-treated (MCF-7 0.83±0.03 and MDAMB231 
0.99±0.10) and control cells were detected. (Figure 5.6).
5.4.5 Expression of ribonucleotide reductase subunits
The RNA expression of the three subunits that make up ribonucleotide 
reductase was investigated and data are shown in Figure 5.7 A and B.
Fold-expression of the RRM1 subunit was significantly (p<0.05) higher 
in all the cell lines, except for the SKBR-3 cells compared to the HL60 
cells. RRM2 gene expression in the BT 474 and MDAMB436 cell lines 
was significantly higher compared to the HL60 cell lines. MCF-7, T47D 
and BT 474 cells all had significantly increased (p<0.05) p53R2 RNA 
expression compared to the HL60 control cells. There was a significant 
decrease (p<0.05) in p53R2 protein observed in the SKBR-3 cells 
compared to the HL60 cells.
Figure 5.8 shows there was a highly significant (p<0.01) correlation 
between p53R2 expression and IC50 values for clofarabine, but not for 
RRM1 or RRM2.
5.4.6 Basal protein expression of p53R2
The expression of basal p53R2 protein was investigated next in MCF-7, 
T47D, MDAMB231 and HL60 cells. Figure 5.9 A shows a representative 
blot probed for p53R2 and p-actin.
Figure 5.9 B shows there were approximately equal amounts of p53R2 
protein in the MCF-7 (1.41 ±0.17) and T47D (1.37±0.11) cells which 
were significantly (p<0.05) greater compared to the MDAMB231 
(0.62±0.06) and HL60 (0.39±0.03) cells.
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Figure 5.6 Expression o f cN-ll A fte r Treatment with Clofarabine in MCF-7 
and MDAMB231 Cells
This figure shows the expression of cN-ll protein after treatment with media 
only, 0.05% DMSO or 1 pM clofarabine for 96 hours in MCF-7 (A and C) and 
MDAMB231 (B and D) cells. Representative blots are shown for MCF-7 (C) 
and MDAMB231 (D) cells. 10 pg total protein was subjected to SDS-PAGE 
electrophoresis, blotted and probed for cN-ll and p-actin. Densitometry on 
scanned images were used to semi-quantitate the levels of cN-ll protein, and 
data were normalised to p-actin (A and B), and then as a % of control (media 
only). Data are expressed as the mean of three separate experiments ± 
S.E.M. No significant (p>0.05) differences were observed. Data were analysed 
with a one-way ANOVA and the Tu key-Kramer post hoc test.
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A Fold mRNA Expression Compared to HL 60 Cells (S.E.)
RRM1 RRM2 p53R2
MCF-7 1.42 (1.29- 1.65)* 1 .16(0 .97- 1.32) 10.08 (5.10- 17.83)*
T47D 3.00 (2.82 - 3.20)* 2.43 (2.00-2.88) 7.60 (6.06-9.10)*
BT 474 2.00 (1 .87 -2 .22 )* 2.51 (2.19-2.97)* 4.45 (3.98 - 4.95)*
MDAMB231 2.53 (1.71 -3 .20)* 1.18 (0.99- 1.43) 1.69 (0.99-2.51)
MDAMB436 2.74 (1 .23-3 .18 )* 4.94 (4.38 - 5.84)* 2.31 (1.56-3.45)
SKBR-3 0.73 (0.61 - 0.88) 1.29(1 .06- 1.50) 0.40 (0.38-0.42)#
WM MCF-7
I I T47D
□ BT 474
□ MDAMB231
□ MDAMB436
□ SKBR-3
RRM1 RRM2 p53R2
Figure 5.7 Fold Expression o f RRM1, RRM2 and p53R2 RNA in Breast 
Cancer Cell Lines Compared to HL60 Cells
This figure (tabulated values A; graphical representation B) shows the fold 
difference in expression of RRM1, RRM2 and p53R2 RNA in the six different 
breast cancer cell lines compared to the HL60 cells assessed by SYBR 
Green, real-time PCR and REST software. The standard errors (S.E.) are 
shown in brackets (A). The data are the mean of three separate PCR 
experiments. Data were analysed with REST software with a pair-wise fixed 
reallocation randomisation test The dotted line represents expression in HL60 
cells (1). *(p<0.05) upregulated compared to HL60 cells. *(p<0.05)
downregulated compared to HL60 cells.
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Figure 5.8 Correlation of RRM1, RRM2 and p53R2 RNA Expression in 
Breast Cancer Cell Lines with ICso value for Clofarabine
A, B and C show the correlations between the expression of RRM1, RRM2 
and p53R2, respectively, with the ICso values for clofarabine in the six breast 
cancer cell lines MCF-7, T47D, BT 474, MDAMB231, MDAMB436 and SKBR- 
3, and also the HL60 cells. Pearson’s correlation coefficient (r) was used to 
determine the significance of the correlation. p<0.05 was considered a 
statistically significant correlation.
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Figure 5.9 Basal Expression o f p 53R2 Protein in MCF-7, T47D, 
MDAMB231 and HL60 Cells
Total ceil lysates (10 pg protein) were subjected to SDS-PAGE 
electrophoresis, blotted and probed for p53R2 and (3-actin as a loading control 
and a representative example is shown (A). Densitometry on scanned images 
was used to semi-quantitate the levels of p53R2 protein, and data were 
normalised to (3-actin (B). Data are expressed as the mean of three or four 
separate experiments ± S.E.M. *(p<0.05) different to HL60 cells. *(p<0.05) 
different compared to MDAMB231 cells. Data were analysed with a one-way 
ANOVA and the Tukey-Kramer post hoc test.
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5.4.7 Expression of p53R2 after exposure to clofarabine
Next, the expression of p53R2 was investigated in the MCF-7, T47D 
and MDAMB231 cells after clofarabine treatment. The results of the 
densitometry analysis are shown in Figure 5.10 for MCF-7 (A), T47D 
(B) and MDAMB231 (C). It can be seen that there was a significant 
(p<0.05) increase in p53R2 expression upon exposure to clofarabine in 
the MCF-7 cells (1.62±0.11) (Figure 5.10 A). Figure 5.10 C shows a 
significant (p<0.05) decrease in p53R2 expression (0.61 ±0.06) in the 
MDAMB231 cells treated with clofarabine compared to control. There 
was no significant change in p53R2 expression after clofarabine 
treatment compared to control in the T47D cells (Figure 5.10 B). 
Figures 5.10 D, E and F show representative blots probed for p53R2 
and p-actin in the MCF-7, T47D and MDAMB231 cells, respectively.
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Figure 5.10 Expression o f p 53R2 A fter Treatment with Clofarabine in 
MCF-7, T47D and MDAMB231 Cells
This figure shows the expression of p53R2 protein after treatment with media 
only, 0.05% DMSO or 1 pM clofarabine for 96 hours in MCF-7 (A and D), 
T47D (B and E) and MDAMB231 (C and F) cells. Representative blots are 
shown for MCF-7 (D), T47D (E) and MDAMB231 (F) cells. 10 pg total protein 
was subjected to SDS-PAGE electrophoresis, blotted and probed for p53R2 
and (3-actin. Densitometry on scanned images were used to semi-quantitate 
the levels of p53R2 protein, and data were normalised to /3-actin (A, B and C), 
and then as a % of control (media only). Data are expressed as the mean of 
three separate experiments ± S.E.M. *(p<0.05) different control. Data were 
analysed with a one-way ANOVA and the Tukey-Kramer post hoc test.
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5.5 Discussion
The previous chapter had identified a differential effect between PNAs 
in ER-positive and ER-negative breast cancer cell lines. The six breast 
cancer cell lines and the HL60 leukaemia cell line were first screened 
for RNA expression of 5 GO I related to PNA activation (dCK), 
metabolism (cN-ll) or activity (RRM1, RRM2 and p53R2) to identify any 
correlations with IC50 data. Western blotting was then used to further 
these data by looking at basal and drug-induced changes in protein 
expression of relevant genes.
5.5.1 Confirmation of RT-PCR method
PCR is widely used in molecular biology to assess the transcriptional 
state of a GOI and is the principal technique available to look at trace 
amounts of RNA (Heid et al. 1996). Real-time PCR was used as it has 
many advantages over standard ‘semi—quantitative’ PCR which looks 
at the end product by gel electrophoresis, including increased 
sensitivity, specificity, reproducibility and a wider quantification range 
(Pffafl et al. 2006). Perhaps the biggest advantage of real-time PCR is 
that the quantification of the amplification product occurs during 
exponential amplification, not as an end-point as with traditional ‘semi— 
quantitative’ PCR using gel-electrophoresis and densitometry analysis. 
(Lockey et al. 1998).
Quantitative real-time PCR depends upon comparing RNA copy 
numbers to a calibration curve and results provide an ‘absolute’ 
quantification. However, the standards for the GOI looked at in this 
study could not be acquired, therefore, a relative quantification system 
was used. This involves looking at differences in RNA expression from 
different samples or cell lines and comparing them to a control sample. 
In this instance, the HL60 cell line was chosen as the control sample 
and all data are expressed as fold-change from this. The data are also 
normalised to a constantly expressed housekeeping gene, in this
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instance, GAPDH, to control for any differences in starting quantity of 
RNA/cDNA and inter-experimental variability. As this relative 
quantification method can be used to compare data across multiple 
real-time PCR experiments and is used to investigate small changes in 
gene expression across samples (Pffafl et al. 2006) it was therefore 
used for these studies.
Figure 5.1 A shows a representative fluorescent trace of the five GOI 
and GAPDH from the HL60 cell line. It can be seen that increases in 
fluorescence are obtained for all 6 genes, indicating the HL60 cells 
were transcribing RNA from all six genes. GAPDH RNA was the most 
abundant, and cN-ll RNA was the most sparse.
To ensure that only RNA had been extracted from the cells and not 
DNA, controls were included in each experiment. These controls were 
treated the same as the samples, except during the reverse- 
transcription step, the reverse transcriptase enzyme was omitted which 
means that if only RNA was extracted, no cDNA would be produced. 
Therefore, during the PCR there should be no amplification as the 
primers will only bind to and amplify from DNA. These controls also 
served to confirm there were no contaminants in any of the reagents. It 
can be seen that there was no increase in fluorescence suggesting that 
no amplification took place and there was no contaminating DNA. This 
was done for all the samples in all the cell lines to confirm integrity. 
Subsequent PCR runs were completed with H2O controls where the 
cDNA was replaced with H2O to ensure that each PCR run was free 
from contaminants.
To confirm specific amplification of the correct sequence of DNA, 
melting curve analysis can be used with real-time PCR. This involves 
steadily heating the samples at the end of the amplification stage 
progressively to 95°C and determining the temperature at which the 
fluorescence signal rapidly deteriorates. This melting temperature (Tm) 
of an amplicon is the temperature at which the DNA strands separate
163
from one another and is determined by factors such as base pair 
composition, amplicon length and PCR conditions. The presence of a 
single peak in the melting curve analysis indicates only one amplicon is 
present, and the temperature at which this occurs helps to define what 
this amplicon is. Figure 5.1 B, shows the melting curve analysis from 
Figure 5.1 A. Single peaks are observed for each of the six GOI, 
indicating only one amplicon was present. No peaks were observed for 
the controls meaning that no amplicons were produced, confirming the 
data in Figure 5.1 A. However, the Tm observed were all 3-5 °C higher 
than the calculated Tm (see Table 2.1, section 2.6.1). This could be due 
to slight increases in potassium or sodium salts that caused an increase 
in the temperature needed to denature the double-stranded DNA. To 
confirm that these amplicons were in fact specific to the GOI, the PCR 
was rerun minus the melting curve analysis and the PCR products were 
separated and sized using gel electrophoresis. The sizes of the bands 
were compared to a 100bp ladder. The amplicons for the six genes 
were all at the correct size; GAPDH 200bp, dCK 139bp, cN-ll 195bp, 
RRM1 195bp, RRM2 120bp and p53R2 168bp. This confirmed that the 
fluorescence signals generated during the PCR were specific to the 
GOI.
5.5.2 The expression of cN-ll, but not dCK is correlated with the 
potency of clofarabine
The expression of dCK and cN-ll was investigated first as these are the 
two principle enzymes involved in PNA activation and metabolism 
(Bonate et al. 2006). There was a significant up-regulation of dCK gene 
expression in the T47D and BT 474 cell lines compared to the HL60 
cells, whereas the other breast cancer cell lines all had decreased dCK 
gene expression in comparison. Previous studies have identified that 
cells of lymphoid or myeloid origin have highest basal levels of dCK 
enzyme activity, compared to normal tissue or other cancers including 
head and neck, ovarian, pancreatic, lung and colon cancers. It is also
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known that solid tumours express higher levels of dCK compared to 
their normal, non-cancerous tissues (Eriksson et al. 1994; 
Spasokoukotskaja et al. 1995; van der Wilt et al. 2003). The data here 
suggest that some phenotypes of breast cancer may have increased 
levels of dCK expression compared with leukaemic cells. Confirming 
these data with Western blotting to look at the actual protein was 
attempted, however, the antibody used was poor and even at dilutions 
of 1.25 probing 50 pg of protein, no specific signal was found. As there 
was no correlation between dCK expression and the IC50 values for 
clofarabine, it was decided not to pursue this further. A Spearman’s 
Rank test confirmed no correlation between gene expression and IC50 
value (r=-0.04; p=0.96).
Although a significant number of studies have suggested a role for dCK 
in determining drug activity (Galmarini et al. 2003b) or resistance to 
PNA (Orr et al. 1995; Bai et al. 1998; Dumontet et al. 1999; Lotfi et al. 
1999; M£nsson et al. 1999; Gourdeau et al. 2001; Mansson et al. 
2003), the data here do not suggest this. Whilst dCK is clearly an 
important enzyme as shown in the previous chapter (see section 4.4.7), 
its genomic expression does not correlate with the potency of 
clofarabine. Correlations were not determined with fludarabine or 
cladribine as the effects of these drugs were only studied in two breast 
cancer cell lines. Similarly, these data are also supported by the protide 
data in the previous chapter. It was concluded that by-passing the 
primary phosphorylation by dCK did not improve the potency or efficacy 
of cladribine or clofarabine, suggesting that a) dCK is not rate-limiting, 
and b) dCK expression does not correlate with drug potency.
Studies by Stegmann et al. (1995) and Hapke et al. (1996) found that 
retroviral transfer of dCK genes into deficient cell lines, including MCF- 
7, increased sensitivity to cladribine, cytarabine and fludarabine. This 
suggests that although PNA resistance is probably determined mostly 
by other factors, the level of dCK may still contribute to PNA potency. It
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is possible that past a certain threshold, the level of dCK is no longer a 
deciding factor in PNA potency, which is supported by the fact that dCK 
is not rate-limiting (Gandhi et al. 2003).
As pyrimidine analogues activity are rate-limited by dCK, these data 
may explain the equal potency of gemcitabine in the previous chapter 
as there was little difference in the expression of dCK between MCF-7 
and MDAMB231 cells (0.25 -fold).
The level of the dephosphorylating enzyme, cN-ll was investigated next. 
There are limited data on the expression of cN-ll between normal and 
neoplastic tissues, and between cancer types. However, cN-ll is 
generally thought to be up-regulated in cancer cells compared to normal 
tissue (Vannoni et al. 2004; Suzuki et al. 2007), although studies by 
Rosi et al. (1998a; 1998b) found the opposite to be true.
Interestingly, there was a significant positive correlation observed 
(r=0.82) between increased levels of cN-ll RNA and decreased potency 
of clofarabine. Similarly, a Spearman’s Rank test also produced a 
significant correlation, further confirming these data (r=0.85; p=0.02). In 
order to confirm these data, the expression of the cN-ll protein was 
determined in the MCF-7, MDAMB231 and HL60 cell lines. Indeed 
these data are similar to those observed with the PCR. However, the 
difference in cN-ll protein levels between cell lines was not the same as 
the difference between RNA expression, suggesting that post- 
translational modifications may contribute to cN-ll activity and 
regulation. These data do, however, confirm further the role of basal 
cN-ll in increased resistance to clofarabine and PNA.
This idea has been suggested widely in the literature (Carson et al. 
1991; Kawasaki et al. 1993; Schirmer et al. 1998; Dumontet et al. 1999; 
Lotfi et al. 2001; Yamamoto et al. 2007). It has also been used as a 
prognostic indicator to activity of PNA analogues (Galmarini et al. 2001; 
Galmarini et al. 2003b) and gemcitabine (Seve et al. 2005; Qu et al.
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2007). Studies by Giovannetti et al. (2005) found that inhibition of cN-ll 
with diethylpyrocarbonate could increase the activity of gemcitabine in 
human lung and epidermoid carcinoma cell lines. These data may 
suggest a role for cN-ll as a prognostic indicator in determining PNA 
potency in breast cancer, should these drugs make it into the clinic as 
breast cancer therapeutics. Indeed, several studies have found that cN- 
II expression correlates with response to PNA in the clinic (Kawasaki et 
al. 1993; Galmarini etal. 2001; Galmarini etal. 2003b).
Determining the enzyme activity would also be useful to ensure that 
enzyme levels correlate with actual activity. Indeed, numerous studies 
have used this approach with dCK and cN-ll and found similar results 
between expression and activity (Kawasaki et al. 1993; Kawasaki et al. 
1996; Mansson et al. 1999; M&nsson et al. 2003). However, a study by 
Lotfi et al. (2006) found that there was no correlation between mRNA 
expression of dCK and dCK activity in isolated leukocytes from patients 
with B-cell leukaemia, suggesting post-translational modifications are 
central to dCK activity.
Also, determining the exact role of cN-ll in PNA resistance would be of 
use. Although it is widely assumed that overexpression of metabolising 
enzymes is related to direct metabolism of PNA, other studies have 
found that cN-ll overexpression modulates dNTP pools causing 
resistance. Cytarabine resistance has been associated with cN-ll 
overexpression, but it is not a substrate for cN-ll (Mazzon et al. 2003). 
However, Albertioni et al. (2005) found that degradation of fludarabine 
monophosphate is correlated with cN-ll activity, supporting the idea that 
cN-ll is acting via direct deactivation of PNA. This study also found a 
correlation between cladribine monophosphate degradation and cN-l 
activity, suggesting that activity of this nucleotidase is also involved in 
PNA deactivation.
cN-ll is allosterically activated by purine nucleotides, with ATP being the 
strongest activator, followed by dATP, but is also dependent upon the
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concentration of organic phosphate which acts to deactivate the 
enzyme (Wallden et al. 2007). It was decided to see if clofarabine could 
alter the expression of the cN-ll protein in the MCF-7 or MDAMB231 
cell lines. Ideally, one would look at the activity of the enzyme after 
treatment with clofarabine using enzyme kinetics studies. Due to time 
constraints these studies were not completed. Figure 5.6 shows that 
clofarabine (1 pM) had no effect on the expression of cN-ll in either cell 
line. This suggests that the role of cN-ll in resistance to clofarabine is 
dependent upon the basal expression of cN-ll enzyme, not by drug- 
induced changes. These data do not, however, suggest whether cN-ll is 
more or less active in response to clofarabine exposure and only limited 
conclusions can be made.
5.5.3 The expression of p53R2, but not RRM1 or RRM2 is 
correlated with the potency of clofarabine
Cladribine and clofarabine were both found to be more potent 
compared to fludarabine in the MCF-7 and MDAMB231 cell lines 
(chapter 4). dATP is an inhibitory allosteric effector and, by binding to 
the allosteric site on RRM1, inhibits the activity of ribonucleotide 
reductase (Jordan and Reichard 1998). PNA triphosphates have 
increased affinity for the RRM1 allosteric binding site compared to 
dATP and are thus powerful inhibitors of ribonucleotide reductase 
(Shao et al. 2006). As cladribine and clofarabine are 10-fold more 
potent inhibitors of ribonucleotide reductase than fludarabine (Parker et 
al. 1991) this suggests that inhibition of this enzyme is more critical to 
their mechanisms of action and also suggests that intracellular levels of 
this enzyme also help dictate sensitivity to NAs. The data from the 
previous chapter also highlighted a potential role of ribonucleotide 
reductase in determining potency of clofarabine and so the basal RNA 
expression of the three subunits of ribonucleotide reductase, RRM1, 
RRM2 and p53R2 was investigated next.
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The RRM1 subunit was significantly up-regulated in the MCF-7, T47D, 
BT 474, MDAMB231 and MDAMB436 cell lines compared to the HL60 
cells. There was no correlation between RNA expression and IC50 
values for clofarabine (r=0.23) suggesting that RRM1 expression is not 
a determining factor in clofarabine potency. A Spearman’s Rank also 
produced no significant correlation (r=0.27; p=0.56). Significant links 
between gemcitabine potency and RRM1 levels have been suggested 
previously where increased RRM1 levels correlated with increased 
resistance to gemcitabine in leukaemic, breast and pancreatic cancer 
cell lines (Davidson et al. 2004; Jordheim et al. 2005; Nakahira et al. 
2007). M£nsson et al. (2003) found that in CEM leukaemia cells 
resistant to clofarabine, cladribine and fludarabine, there was no 
change in expression of the RRM1 protein suggesting it is not involved 
in resistance. This highlights the potential differences in resistance 
mechanisms to different types of analogue, either purine or pyrimidine.
The RNA expression of RRM2 was significantly increased in the BT 474 
and MDAMB436 cell lines only. Again there was no correlation between 
expression of RRM2 and IC50 values for clofarabine (r=-0.02) 
suggesting that RRM2 expression is not a determining factor in 
clofarabine potency either. This was again confirmed with a Spearman’s 
Rank test (r=0.27; p=0.56). Studies by Mansson et al. (1999; 2003) 
found that fludarabine-resistant CEM cells had increased RRM2 subunit 
expression over their wild-type parental cell line, suggesting 
overexpression of RRM2 in fludarabine resistance. With the use of a 
ribonucleotide reductase inhibitor, didox, in combination with 
fludarabine, sensitivity to fludarabine in the fludarabine-resistant CEM 
cells was restored. This suggested that increased ribonucleotide 
reductase activity was contributing to fludarabine resistance. This has 
also been demonstrated in cells resistant to gemcitabine (Duxbury et al. 
2004; Giovannetti et al. 2005; Nakano et al. 2007). What these data 
highlight is the specific nature of NAs and their resistance mechanisms, 
where cells resistant to a particular NA are not necessarily resistant to
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1another NA by the same mechanism, particularly true for fludarabine 
and the two other analogues, cladribine and clofarabine. As such, 
resistance to NA should be approached in a cell and drug-specific 
manner.
When the expression of p53R2 was investigated, there was a significant 
up-regulation of this gene in the ER-positive breast cancer cells 
between 10- and 4-fold over the HL60 cells. Whereas the SKBR-3 cells 
had a 0.6-fold decrease in expression. When the genomic expression of 
p53R2 was correlated with IC50 values for clofarabine there was a 
highly significant positive correlation (r=0.90, p=0.005) showing 
increased expression correlates with decreased sensitivity. 
Nonparametric testing of this correlation with a Spearman’s Rank test 
further validated these data and found a significant correaltion (r=0.85; 
p=0.02). To confirm these data, the expression of the p53R2 protein 
was investigated in the MCF-7, T47D, MDAMB231 and HL60 cells. 
There were approximately equal amounts of p53R2 protein in the MCF- 
7 and T47D cells , 1.41 and 1.37 fold, respectively. The MDAMB231 
cells had less than 50% of this amount (0.62), and the HL60 cells even 
less (0.39). These data agree with the PCR data, although there is a 
difference in the ratio of protein expression between the cell lines 
compared with the PCR data, suggesting post-translational regulation of 
this enzyme subunit.
The basal expression of p53R2 could be linked to its role in supplying 
dNTPs to mitochondrial DNA synthesis as a study by Bourdon et al. 
(2007) found that p53R2 gene mutations and reduced function resulted 
in depletion of mitochondrial DNA. This theory is also suggested by 
Pontarin et al. (2007). It is known that p53R2 is constitutively expressed 
in cells regardless of their p53 status, p53 status is important only in its 
overexpression after DNA insult (Wang et al. 2009).
Previous studies have indentified a correlation between increased 
p53R2 expression and reduced invasion and metastatic potential in
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colon carcinoma tissue, and suppression of p53R2 increased invasion 
and migration (Liu et al. 2006; Liu et al. 2007). These data are in 
agreement with the results here where ER-negative tumours, which are 
more aggressive and show increased invasiveness, express 
significantly less p53R2 than ER-positive tumours. Okumura et al.
(2006), however, found that in patients with oesophageal squamous cell 
carcinoma, positive expression of p53R2 correlated significantly with 
increased tumour invasion, lymph node involvement and high grading of 
tumours compared with those deemed p53R2-negative. The data in the 
study here do not follow this pattern as ER-negative tumours are 
associated with tumours that have a histologically high grading 
(Rochefort et al. 2003). These data suggest that p53R2 expression and 
related cell grading or invasiveness is cell and/or cancer type- 
dependent and suggests that inferring data from one cancer type to 
another should be done with caution.
The expression of p53R2 was investigated after treatment with 
clofarabine for 96 hours. This expression was also investigated in the 
T47D cells as these cells are p53-mutated, but ER-positive and this 
would determine if p53R2 expression is p53-dependent. There was a 
60% increase in p53R2 expression over control following treatment with 
clofarabine in the MCF-7 cells. Although there was a 28% increase in 
p53R2 expression in the T47D cells compared to control, this was not 
significant. Interestingly, there was a significant 40% reduction in p53R2 
expression following treatment with clofarabine in the MDAMB231 cells. 
The reasons for this decrease in p53R2 expression are unclear and not 
readily explainable, but this decrease in p53R2 may explain the 
increase in sensitivity to clofarabine in these cells. One possibility is that 
clofarabine is disrupting the gene locus of p53R2 (chromosome 8q23.1; 
Smeds et al. 2001) causing mutation, DNA damage and ultimately 
affecting transcription. Mansson et al. (2003) found that clofarabine- 
resistant CEM cells showed increased structurally rearranged
171
4
chromosomes suggesting that clofarabine is able to disrupt the genome 
more efficiently than other PNAs.
These data indicate that in p53 wild-type cells (MCF-7), clofarabine can 
induce p53R2 expression but this expression cannot be induced in p53 
mutant cells, regardless of ER-status or basal expression (T47D and 
MDAMB231). These findings are consistent with the literature 
demonstrating an increase in p53R2 protein expression following DNA 
damage by cytotoxics or UV irradiation (Nakano et al. 2000; Tanaka et 
al. 2000; Barber et al. 2005; Tsai et al. 2006; Link et al. 2008).
Lin et al. (2007) observed an interesting response to DNA damaging 
agents in HC116 colon cancer cells that are p53-null. Their study found 
that the RRM2 subunit could effectively take the place of p53R2 and 
provide dNTP for DNA repair after treatment with cisplatin. This idea 
has been supported by Zhang et al. (2009) who found that 
camptothecin treatment up-regulated RRM2 expression and silencing of 
RRM2 enhanced DNA damage caused by camptothecin in MDAMB231 
cells. This may mean that that MDAMB231 cells are able to repair their 
DNA by RRM2-mediated mechanisms. If this is the case with 
clofarabine-induced DNA damage, then this suggests that the 
differential response to clofarabine is not solely mediated by DNA repair 
mechanisms, or lack thereof. Interestingly, the MDAMB436 cells 
showed over 4-fold higher expression of RRM2 compared to the 
MDAMB231 cells, yet they were equally susceptible to clofarabine, and 
neither the MDAMB231 nor the MDAMB436 cells should be able to 
induce p53R2 in response to DNA damage due to mutated or lack of 
p53, respectively. These data suggest that RRM2-mediated DNA repair 
does not affect clofarabine potency. This may be due to clofarabine- 
induced DNA damage not activating the repair signal initiated by 
checkpoint kinase 1 for RRM2-mediated DNA repair (Zhang etal. 2009) 
or that RRM2-mediated repair is drug-specific.
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As p53R2 expression is increased in response to DNA damage, and is 
involved in DNA repair, these data imply that the resistance to 
clofarabine is caused by DNA repair of the genomic insult. The fact that 
only the MCF-7 cells had an increase in p53R2 expression after 
clofarabine treatment further suggests that p53R2 is p53-dependent 
(Tanaka et al. 2000), and breast cancer cells with mutated p53 i.e. 
T47D and MDAMB231, are unable to initiate this response. This 
suggestion of p53R2-mediated resistance is supported by another 
factor. In the previous chapter, gemcitabine was identified as equally 
potent in both MCF-7 and MDAMB231 cells, suggesting a mechanism 
unique to gemcitabine that clofarabine does not induce/target. Wang et 
al. (2009b), found that gemcitabine diphosphate was able to inhibit 
p53R2, something not yet identified with clofarabine.
These studies have only touched the surface as to the role of p53R2 in 
determining sensitivity to PNA in human breast cancer cell lines and 
much work remains to investigate this relationship further. To confirm 
the role of either basal or inducible p53R2 in sensitivity to PNA, gene 
silencing or knockout studies would provide the most reliable answer to 
this. siRNA techniques have been used in the literature and show that 
knockout of p53R2 increases cancer cells’ susceptibility to cytotoxic 
agents and radiation treatments in vitro (Yanamoto et al. 2005; Devlin et 
al. 2008). Similarly, using more specific pharmacological inhibitors of 
ribonucleotide reductase than hydroxyurea (chapter 4) such as triapine 
would help clarify the role of ribonucleotide reductase as a whole in the 
mechanisms of action and resistance to clofarabine. Looking at basal 
and clofarabine-induced protein expression of p53R2 in the BT 474, 
MDAMB436 and SKBR-3 cells would also lend more weight to some of 
the arguments within this thesis.
Again using siRNA techniques, the role of cN-ll in determining 
resistance to clofarabine could be elucidated. If high expression of cN-ll 
is mediating, at least in part, the sensitivity of breast cancer cells to
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clofarabine, then its reduction should increase this sensitivity. It may 
also be useful to determine more accurately the quantification of the 
expression of dCK and cN-ll so that a ratio between them can be 
investigated. Real-time PCR could be used again, but using absolute 
rather than relative quantification methods utilising standards of dCK 
and cN-ll. Better antibodies against dCK could also be used to allow 
semi-quantitative measurements of this enzyme to be made.
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5.6 Conclusion
In this chapter the expression of enzymes related to the activity of 
clofarabine was investigated and related to the differential effects of 
clofarabine in ER-positive and ER-negative breast cancer cell lines.
There appears to be no correlation between the expression of the 
activating enzyme dCK and the potency of clofarabine. However, there 
was a positive correlation between the expression of cN-ll RNA and the 
differential potency of clofarabine and this was confirmed at the protein 
level in three cell lines also. Increased breakdown of clofarabine 
nucleotides by cN-ll may account for some of the reduced effects of 
clofarabine in the ER-positive breast cancer cell lines, compared to the 
ER-negative breast cancer cells and HL60 leukaemia cells.
There was a strong correlation between clofarabine potency and the 
expression of the p53-inducible R2 subunit, p53R2 and this was again 
confirmed at the protein level. Similarly, there was an increase in p53R2 
protein expression following exposure to clofarabine in the p53 wild- 
type MCF-7 cells, but not in two p53-mutant cell lines regardless of ER 
status (T47D and MDAMB231). These data suggest that p53R2 plays a 
role in determining sensitivity to clofarabine in breast cancer cell lines. 
This is probably due to increased DNA repair capabilities in cell lines 
expressing higher levels of p53R2.
These data need confirmation by further experimentation and are 
unlikely to be the only explanation for the resistance to clofarabine in 
ER-positive cells lines. There are probably multiple factors that 
contribute to the varying sensitivity of breast cancer cell lines to 
clofarabine. These data when compared with the literature, suggest that 
resistance to clofarabine and other NAs in different cell lines is 
mediated by different mechanisms.
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Chapter 6: The Role of ERK 1/2 in the Activity of Clofarabine in 
Breast Cancer Cells
6.1 Introduction
The MAPKs transduce extracellular signals with control over a variety of 
cellular responses that include cell growth, division, differentiation and 
apoptosis (Chen et al. 2001; Luttrell 2003; Schulte and Fredholm 2003). 
The ERK 1/2 pathway forms a cascade of kinases that activate each 
other in sequence and is amongst the most important for control of cell 
cycle progression, and is known to activate various proto-oncogenes 
(Fang and Richardson 2005). Deregulation of the ERK 1/2 pathway is 
associated with several human cancers including colorectal (Fang and 
Richardson 2005), acute leukaemia (Kim et al. 1999), thyroid (Shih et 
al. 2002) and breast cancer (Sivaraman et al. 1997; Mueller et al. 2000; 
Ma etal. 2001).
The importance of endogenous ERK 1/2 activity to the growth of breast 
cancers both in vivo and in vitro is more apparent in the more invasive 
and aggressive tumours, especially those deemed ER-negative. 
Studies have demonstrated increased ERK/MAPK activity in vivo in 
malignant breast cancers compared to normal breast tissue and benign 
tumours of the breast with further increases in ERK 1/2 activity in higher 
graded tumours (Sivaraman et al. 1997; Zhang et al. 2004). However, 
Milde-Langosch et al. (2005) found the opposite to be true in vivo, 
where high levels of phosphorylated ERK 1/2 were correlated to 
decreased reoccurrence and lower graded or metastatic breast 
cancers. In vitro, Chen et al. (2009) showed increased basal levels of 
phosphorylated ERK 1/2 in ER-negative tumours (MDAMB231, 
MDAMB436 and BT549) compared to ER-positive tumours (MCF-7, 
T47D and ZR-75-1). MDAMB231 cells, which exhibit high levels of 
constitutively activated ERK 1/2, were suggested to have increased 
cyclins (cyclin D1) and urokinase-type plasminogen activator 
expression that ultimately lead to increased proliferation and
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invasiveness (Seddinghzadeh etal. 1999). The increased levels of ERK 
1/2 signalling in ER-negative tumours are suggested to arise from 
overexpression of growth receptors such as EGFR that drive the 
proliferation of these cells (Eralp et al. 2008).
Increased basal ERK 1/2 signalling has been associated with increased 
resistance to chemotherapy (Eralp et al. 2008). Resistance to anti­
hormones such as tamoxifen has been indicated to occur via elevated 
ERK 1/2 signalling (Knowlden et al. 2003; Cui et al. 2006 and 
Massarweh et al. 2008). Elevated ERK 1/2 signalling has also been 
associated with resistance to microtubule inhibitors (MacKeigan et al. 
2000; McDaid and Horwitz 2001), DNA damaging agents (Hayakawa et 
al. 1999; Persons et al. 1999; Cui et al. 2000), topoisomerase inhibitors 
(Guise et al. 2001) and antimetabolites including NAs (Jarvis et al. 
1998; Smal et al. 2007). The ability to block the ERK 1/2 pathway and 
increase sensitivity of tumours to chemotherapeutics has led to the 
development of new, small-molecule inhibitors of various stages in the 
MAPK/ERK pathway that are in clinical trials (Kohno and Pouyssegur 
2006), including MEK inhibitors (AZD6624), Raf-1 inhibitors (sorafenib) 
and famesyltransferase inhibitors (tipifarnib) (Grant 2008). Smal et al.
(2007) had previously shown that pharmacological inhibition of ERK 1/2 
signalling in leukaemic cells increased the efficacy of cladribine 
significantly probably due to the removal of the pro-survival signals by 
ERK 1/2 (Platanias 2003). Increased ERK 1/2 signalling is associated in 
a similar way with breast cancers and, in particular with ER-negative 
and more aggressive tumours (Sivaraman et al. 1997; Chen et al.
2009).
The anti-cancer activity of MEK inhibitors is rather limited and they have 
proven to be relatively unsuccessful in clinical trials in breast cancer 
(Mirzoeva et al. 2009). However, in combination with direct anti-cancer 
agents and other chemotherapeutic agents that are used in the 
treatment of cancer, their use seems to potentiate the activity of these
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drugs in numerous tumour and cancer types (McDaid and Horwitz 
2001; Romerio and Zella 2002; Brantley-Finely et al. 2003; Li et al. 
2003b; Sun and Sinicrope 2005; Cusimano et al. 2007; Mirzoeva et al. 
2009; Xu etal. 2009).
There is a contrast in these current data as elevated ERK 1/2 signalling 
is associated with resistance to chemotherapeutic agents, yet, as 
shown in Chapter 4, the ER-negative cells with elevated ERK 1/2 
signalling are more sensitive to clofarabine and PNAs. Therefore, there 
is a need to understand better the role of ERK 1/2 signalling in relation 
to the activity of clofarabine in breast cancers.
6.2 Chapter Aims
The aim of this chapter was:
• to determine the role of ERK 1/2 in relation to the activity of 
clofarabine in MCF-7 and MDAMB231 breast cancer cells.
The specific objectives of this chapter were to:
• confirm basal expression of phosphorylated ERK 1/2 in MCF-7 
and MDAMB231 cells.
• investigate the effects of reducing ERK 1/2 signalling in both 
breast cancer cell lines, and determine if this has any effect on 
the activity of clofarabine.
• determine if clofarabine is able to activate or reduce ERK 1/2 
activity by looking for phosphorylation after treatment with 
clofarabine.
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6.3 Methods
The detailed protocols for the Western blotting and MTS assay are 
described in Chapter 2.
6.3.1 Western blotting
Cell lysates were prepared from cells in logarithmic growth phase and 
protein quantified as described in sections 2.5.1 and 2.5.3, respectively. 
To determine the effects of clofarabine or the MEK inhibitor, PD 98059 
(20 pM; Smal et al. 2007) on protein levels, cells were treated with the 
appropriate concentrations of the drug for 96 hours in normal growth 
media. Media only and vehicle controls (DMSO) were also included. 
Routinely, 10 pg of protein was separated using SDS-PAGE and 
proteins were then transferred to nitrocellulose membrane using semi­
dry immunoblotting (section 2.5.5). After blocking, membranes were 
incubated with the primary antibody and secondary antibodies and 
detected using ECL. The concentrations of primary and secondary 
antibodies used are given below.
GAPDH 1° 1:50,000
2° 1:50,000 anti-mouse
phospho-ERK1 /2 1 ° 1:2000
2° 1:10,000 anti-rabbit
total-ERK1/2 1° 1:1000
2° 1:10,000 anti-rabbit
Densitometry was used to semi-quantitate protein levels and analysed 
using ImageJ software (NIH, USA). The data are expressed as the 
densitometry value of ERK 1 and ERK 2 combined. All data were 
normalised to GAPDH to control for protein loading and to ensure
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consistency between the two cell lines, blots were analysed that had 
equal GAPDH intensity in both the MCF-7 and MDAMB231 cells.
6.3.2 MTS Assay
Cells were seeded at 5000 cells per well into 96 well plates and allowed 
to plate down overnight. The normal growth media was aspirated from 
the cells and replaced with clofarabine (0.01, 0.1 or 1 pM), PD 98059 
(20 pM) or a combination of both-containing media. Relevant media 
only, vehicle (DMSO 0.05%) and blank controls were included on each 
plate. Cells were then left for 96 hours at 37°C in 5% CO2 in a 
humidified atmosphere. The MTS assay was then performed as 
described (2.3.2).
6.3.3 Data Analysis
A two-tailed Student’s t test was used to compare two groups. 
Comparisons between three or more groups were carried out using a 
one-way ANOVA with a Tukey-Kramer post hoc test if a significant 
difference was observed between the three or more groups. Probability 
values of less than 0.05 were considered statistically significant.
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6.4 Results
6.4.1 Basal ERK 1/2 signalling in MCF-7 and MDAMB231 cells
Western blotting was used first to determine the basal level of ERK 1/2 
signalling in MCF-7 and MDAMB231 cells. This was done by probing 
blots for phosphorylated ERK 1/2 (T185-T202) as this is a measure of 
ERK 1/2 activity, and also for GAPDH as a loading control (Figure 6.1 
A). There was a significant (p<0.01) ~2.5-fold increase in basal levels of 
ERK 1/2 signalling in the MDAMB231 cells compared to the MCF-7 
cells (Figure 6.1 B).
6.4.2 Effects of MEK inhibition on MCF-7 and MDAMB231 cell 
viability
The MTS assay was used to determine if the MEK inhibitor, PD 98059 
had any significant effect on the viability of MCF-7 and MDAMB231 
cells after 96 hours of treatment. Neither DMSO nor PD 98059 had any 
significant effect on the growth of MCF-7 cells compared to control 
(Figure 6.2 A). Figure 6.2 B shows that DMSO had no significant effect 
on MDAMB231 cell growth compared to control. At 20 pM, however, PD 
98059 significantly (p<0.001) reduced viability to 82.4±1.0% of control.
Western blotting was then used to confirm that PD 98059 had reduced 
ERK 1/2 phosphorylation. Figures 6.2 C and D show that PD 98059 
clearly reduced the amount of phosphorylated but not total ERK 1/2 in 
MCF-7 and MDAMB231 cells, respectively. GAPDH was used to 
confirm protein loading.
6.4.3 Effects of MEK inhibition on clofarabine activity
Next, the effects of 20 pM PD 98059 on the activity of clofarabine were 
determined with the MTS assay in MCF-7 and MDAMB231 cells and 
are shown in figures 6.3 A and B, respectively. The data in these figures 
are expressed as a % of their respective controls. Clofarabine alone is 
as a % of control (media only) treated cells.
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Figure 6.1 Basal Levels of Phosphorylated ERK1/2 in MCF-7 and 
MDAMB231 Cells
The basal levels of phosphorylated ERK 1/2 were determined from MCF-7 and 
MDAMB231 cells in logahthmic growth by Western blot. Representative blots 
are shown (A) where 10 pg total protein was subjected to SDS-PAGE 
electrophoresis, blotted and probed for phosphorylated ERK 1/2, total ERK 1/2 
and GAPDH. Densitometry on scanned images were used to semi-quantitate 
the levels of phosphorylated ERK 1/2, and data were normalised to GAPDH 
(B). Data are expressed as the mean of three separate experiments ± S.E.M. * 
significantly (p=0.005) different to MDAMB231 cells analysed with a two-tailed 
Student's t test.
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Figure 6.2 Effects o f the MEK Inhibitor, PD98059 on MCF-7 and 
MDAMB231 Viability
M C F -7  (A ) a n d  M D A M B 2 3 1  (B ) ce lls  w e re  in c u b a te d  with m ed ia  only, 0 .0 5 %  
D M S O  o r  2 0  p M  P D  9 8 0 5 9  fo r 9 6  h ours  a n d  ce ll v iability w as a s s e s s e d  with 
th e  M T S  assay . M C F -7  (C ) a n d  M D A M B 2 3 1  (D ) cells  tre a te d  as  fo r A an d  B  
w e re  ly s e d  a n d  10 p g  o f  to ta l p ro te in  w as  su b jec ted  to S D S -P A G E  
e le c tro p h o re s is , b lo tted  a n d  p ro b e d  fo r  p h o sp h o ry la ted  E R K  1 /2  (p E R K  1/2), 
to ta l E R K  1 /2  (tE R K  1 /2 ) a n d  G A P D H . The M T S  data  a re  e x p re s s e d  a s  the  
m e a n  o f th ree  s e p a ra te  e x p e rim e n ts  re p e a te d  in trip licate  ±  S .E .M . W estern  
b lo t d a ta  a re  from  a s ing le  exp erim en t. *  significantly  (p < 0 .0 0 1 ) d ifferen t to 
co n tro l ce lls  a n a ly s e d  b y  o n e -w a y  A N O V A  with T u k e y -K ra m e r p o s t hoc  test.
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Clofarabine in the presence of PD 98059 is expressed as a % of PD 
98059 alone, to account for the significant effects of PD 98059 in the 
MDAMB231 cells. These data are presented in Figure 6.2 B and are 
from the same experiment. As DMSO, at concentrations up to 0.5%, 
had no significant effect on cell viability in either cell line (see Figure 
4.8, Chapter 4.4), a DMSO plus PD 98059 control was not included in 
the assay.
In the presence of PD 98059, there was no significant difference in the 
activity of clofarabine when compared to clofarabine alone in the MCF-7 
cells. Only at 1 pM clofarabine, both alone and in the presence of PD 
98059 was there a significant (p<0.01) difference compared to media 
and PD 98059 controls, respectively (Figure 6.3 A).
Figure 6.3 B shows that in the presence of PD 98059, there was a 
significant (p<0.001) reduction in the activity of clofarabine in the 
MDAMB231 cells at 0.1 and 1 pM of 16.2±2.3% and 15.5±1.3%, 
respectively, compared to clofarabine alone. At 0.1 and 1 pM 
clofarabine, both alone and in the presence of PD 98059, there was a 
significant reduction (p<0.001) in viable cells compared to media and 
PD 98059 controls, respectively.
6.4.4 Effects of clofarabine on ERK 1/2 phosphorylation
Finally, Western blotting was used to determine if clofarabine affected 
the phosphorylation of ERK 1/2 in MCF-7 and MDAMB231 cells. 
Figures 6.4 A and B show representative Western blots of the effects of 
clofarabine on phosphorylated and total ERK 1/2 in the MCF-7 and 
MDAMB231 cells, respectively. Figures 6.4 C and D shows the results 
of densitometry analysis of phosphorylated ERK 1/2 levels in MCF-7 
and MDAMB231 cells, respectively. Clofarabine had no significant 
effect on ERK 1/2 phosphorylation in either MCF-7 or MDAMB231 cells.
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Figure 6.3 Effects of the MEK inhibitor, PD 98059 on the Activity of 
Clofarabine on Cell Viability of MCF-7 and MDAMB231 Cells
The effect of the PD 98059 (20 fjM) on the activity of clofarabine on cell 
viability after 96 hours was determined by the MTS assay in MCF-7 (A) and 
MDAMB231 (B) cells. Solid line represents DMSO (0.005%), dashed line 
represents 20 pM PD 98059 alone. Data are expressed as the mean of three 
separate experiments repeated in triplicate ± S.E.M. *(p<0.01), **(p<0.001) 
significantly different compared to control. *(p<0.001) significantly different 
compared to clofarabine alone. Data analysed with two-way ANOVA followed 
by Bonferroni post hoc test. Clofarabine alone data are expressed as % of 
media (100%) control. Clofarabine + PD 98059 data are expressed as a % of 
PD 98059 alone.
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Figure 6.4 Effects o f Clofarabine on the Phosphorylation o f ERK1/2 in 
MCF-7 and MDAMB231 Cells
Levels of phosphorylated ERK 1/2 were determined by Western blot in MCF-7 
(A and C) and MDAMB231 (B and D) cells after treatment with media alone 
(control), 0.05% DMSO, 0.01 pM or 1 pM clofarabine for 96 hours. 
Representative blots are shown (A and B, MCF-7 and MDAMB231, 
respectively) where 10 pg total protein was subjected to SDS-PAGE 
electrophoresis, blotted and probed for phosphorylated ERK 1/2 (pERK 1/2), 
total ERK 1/2 (tERK 1/2) and GAPDH. Densitometry on scanned images were 
used to semi-quantitate the levels of pERK 1/2, and data were normalised to 
GAPDH (C and D, MCF-7 and MDAMB231, respectively). Data are expressed 
as the mean of three separate experiments ± S.E.M. No significant differences 
were detected with one-way ANOVA.
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6.5 Discussion
In Chapter 4, the differential effects of clofarabine and other PNAs on 
cell viability in ER-positive and ER-negative breast cancer cell lines 
were identified. In the subsequent Chapter, the expression of enzymes 
involved in the activation, metabolism and cellular targets of clofarabine 
was investigated. These studies identified a conceivable role of cN-ll 
and p53R2 in the differential effects of clofarabine, but it was suggested 
that these were unlikely to be the only reasons for these differences. 
There is a growing body of evidence that ERK 1/2 signalling influences 
sensitivity to cytotoxic chemotherapeutics, including NAs. Therefore, the 
role of ERK 1/2 signalling in sensitivity to clofarabine was investigated.
6.5.1 Basal ERK 1/2 activity is higher in MDAMB231 cells
The first experiment in this Chapter was to determine the basal activity 
of ERK 1/2 signalling in the MCF-7 and MDAMB231 cell lines. Western 
blotting was used to semi-quantitate the amount of phosphorylated ERK 
1/2 in both these cell lines, lysed during normal logarithmic growth in 
culture. These experiments showed clearly that the MDAMB231 cells 
have significantly more phosphorylated ERK 1/2 compared to the MCF- 
7 cells by ~2.5-fold. The amount of GAPDH in each cell line was fairly 
consistent which indicates that there was an equal amount of protein 
loaded and thus a fair comparison can be made.
Several other studies have identified an increase in basal ERK 1/2 
activity in MDAMB231 and ER-negative cell lines compared to MCF-7 
and other ER-positive cell lines in culture (Krueger et al. 2001; Ogata et 
al. 2001; Chen et al. 2009). Creighton et al. (2006) suggested that 
increased expression of ERK 1/2 causes loss of ERa, and the 
generation of an ER-negative phenotype. This elevated ERK 1/2 activity 
is often due to increased receptor tyrosine kinase expression including 
epidermal growth factor receptor (EGFR) and Her2 (Eralp et al. 2008; 
Toyama et al. 2008). The data herein are in agreement with the
187
literature and therefore help validate the subsequent experiments 
described in this Chapter.
An interesting study by Piao and colleagues found that p53R2 
interacted directly with MEK2, an upstream activator of ERK 1/2. Their 
study identified the role of p53R2 in suppressing MEK2 and ERK 1/2 
activity in lung cancer cell lines (Piao et al. 2009) and hypothesised that 
p53R2 expression might suppress the mitogenic potential of tumours. In 
the previous chapter, p53R2 expression was found to be higher in ER- 
positive tumours, and this is correlated with lower basal ERK 1/2 
signalling.
These data also suggest that increased basal ERK 1/2 signalling does 
not correlate with increased resistance to PNA in these breast cancer 
cell lines. ERK 1/2 signalling is associated with an increase in pro­
survival and transcription factor activation (Chen et al. 2001), and this 
increase has been shown to ‘protect’ cells against a variety of clinically 
used anti-cancer drugs including cisplatin, vinblastine, vincristine, 
paclitaxel, cladribine, doxorubicin and cytarabine (Jarvis et al. 1998; 
Hayakawa et al. 1999; Persons et al. 1999; Cui et al. 2000; MacKeigan 
et al. 2000; Guise et al. 2001; McDaid and Horwitz 2001; Stadheim et 
al. 2001; Brantley-Finley et al. 2003; Smal et al. 2007). These studies 
suggested that inhibition of the pro-survival ERK 1/2 signalling pathway 
‘primed’ cells for apoptosis, enhancing the effects of these commonly 
used cytotoxic agents that included DNA-damaging agents, anti­
metabolites, topisomerase inhibitors and microtubule inhibitors. 
Similarly, Normanno et al. (2006) found that resistance to the tyrosine 
kinase inhibitor gefitinib, was directly related to an increase in 
MEK/ERK 1/2 activity in MDAMB468 cells in particular. They found that 
inhibition of ERK 1/2 by PD 98059 synergistically increased the action 
of gefitinib. This was also seen in SKBR-3 and MDAMB361 cell lines, 
although only with an additive effect.
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However, the increase in basal ERK 1/2 signalling herein is associated 
with increased sensitivity to clofarabine and other PNA and is discussed 
in the following sections.
6.5.2 Pharmacological inhibition of ERK 1/2 decreases the activity 
of clofarabine in MDAMB231 cells
The previous experiment demonstrated that increased basal ERK 1/2 
signalling is not associated with increased resistance to PNA in MCF-7 
or MDAMB231 cells. However, this does not rule out the involvement of 
ERK 1/2 signalling in the activity of clofarabine or other PNA. The 
following experiments were designed to try and answer the question as 
to how or if ERK 1/2 signalling was involved in the action of clofarabine 
in the MCF-7 and MDAMB231 cell lines.
Initial studies characterised the response of the MEK inhibitor, PD 
98059, on the viability of MCF-7 and MDAMB231 cells in culture. MEK 
is an upstream kinase to ERK 1/2 that is directly involved in the 
phosphorylation of ERK 1/2. Therefore, through its inhibition, ERK 1/2 
phosphorylation is proportionally reduced. PD 98059 is widely used for 
this purpose as it does not inhibit other protein kinases at the 
concentration used here (Davies et al. 2000).
20 pM PD 98059 had no effect on the viability of MCF-7 cells. This 
suggests that ERK 1/2 signalling is not a key pathway for normal cell 
functioning in these cells. However, PD 98059 significantly decreased 
the amount of viable MDAMB231 cells by 20% compared to control 
suggesting a role for ERK 1/2 signalling in these cells which has been 
found previously (Seddighzadeh et al. 1999). This notion is supported 
by the elevated basal ERK 1/2 signalling observed in the MDAMB231 
cells, compared to the MCF-7 cells. In order to confirm that this effect 
on cell viability was due to decreased ERK 1/2 signalling, Western 
blotting was used to confirm ERK 1/2 knockdown following treatment 
with PD 98059. A substantial, albeit not maximal, decrease in
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phosphorylated ERK 1/2 in both MCF-7 and MDAMB231 cells was 
seen.
To determine the role that ERK 1/2 was playing in relation to clofarabine 
activity, MCF-7 and MDAMB231 cells were incubated with several 
concentrations of clofarabine alone, or clofarabine in combination with 
PD 98059. In the MCF-7 cells, no difference was observed between 
these two treatment schedules at any concentration strongly indicating 
that reduction of ERK 1/2 signalling has no bearing on the potency of 
clofarabine. As ERK 1/2 basal activity is minimal in MCF-7 cells, this 
strongly suggests that it is a relatively under-utilised pathway in normal 
cell functions, at least in vitro. ERK 1/2 signalling in ER-positive cells is 
not to be overlooked, however, as it has previously been demonstrated 
in ER-positive tumours that binding of estrodiol to the ERa receptor at 
the cell membrane can directly induce MAPK activation (Santen et al. 
2002) and data have shown that this increase in phosphorylated ERK 
1/2 can result in increased cellular proliferation (Peralta etal. 2006).
It is interesting to look at what effects increased ERK 1/2 signalling had 
on the MCF-7 cells. Although ERK 1/2 may not be involved in pro- 
survival ‘per se’ here, an increase in activity may affect clofarabine 
potency. Studies have identified an increase in ERK 1/2 signalling in 
breast cancer cells resistant to anti-hormones. Knowlden et al. (2003), 
Cui et al. (2006) and Massarweh et al. (2008) showed that MCF-7 cells 
made resistant to tamoxifen (TamR) had an increase in ERK 1/2 
signalling compared to their wild-type parental cell lines and that this 
signalling was important in cell growth. This feature has also been 
demonstrated with fulvestrant-resistant cells (Frogne et al. 2009). 
Testing clofarabine against these cell lines may give an insight into this 
possibility.
In the MDAMB231 cells in the presence of PD 98059, clofarabine 
activity was decreased compared to clofarabine alone at concentrations 
of 0.1 and 1 pM by -15%. This suggests that ERK 1/2 signalling
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accounts for part of the mechanism behind the anti-cancer activity of 
clofarabine in these cells and that ERK 1/2 sensitizes cells to the action 
of clofarabine for the cytotoxic action. Similar findings have identified 
the role of ERK 1/2 in sensitizing cells to other cytotoxic agents. 
Cisplatin-induced apoptosis was decreased following treatment of HeLa 
ovarian carcinoma cells with PD 98059 leading to reduced ERK 1/2 
signalling (Wang et al. 2000). They found that ERK 1/2 was initiating the 
apoptotic signal upstream of cytochrome C release and caspase 
activation. Also, Bacus et al. (2001) showed that paclitaxel-induced 
apoptosis was significantly reduced following ERK 1/2 phosphorylation 
inhibition by PD 98059 in MCF-7 cells. They found that paclitaxel 
induced G2/M cell cycle arrest and apoptosis, but in PD 98059 pre­
treated cells, paclitaxel only induced cell cycle arrest in the G2/M 
phase. This suggests that ERK 1/2 is involved in initiating the apoptotic 
cascade, with similar results suggested by Guise et al. (2001) in 
neuroblastoma cells treated with paclitaxel and doxorubicin. Similar 
results have also been shown with cisplatin and doxorubicin using renal 
epithelial cells, also identifying ERK 1/2 signalling upstream of Bax 
activation, cytochrome C release and caspase activation (Alexia et al. 
2004; Arany et al. 2004; Kim et al. 2005).
The reasons for this paradoxical ERK 1/2 signalling as an apoptosis 
inducer are unknown here. Although ERK 1/2 signalling is important for 
the growth of MDAMB231 cells, it may have dual functions. Most 
literature suggests ERK 1/2 as a pro-survival kinase (Chen et al. 2009), 
but studies have also suggested its role as an apoptosis inducer (Mohr 
et al. 1998; Blagosklonny 1998). Indeed Ishikawa and Kitamura (1999) 
suggested a dual-functioning role for ERK 1/2 as both necessary at 
basal constitutional levels in normal cell functioning, but temporary 
increases in ERK 1/2 signalling were involved in induction of apoptosis.
Clofarabine did not affect ERK 1/2 signalling directly, as active 
concentrations of clofarabine (1 pM) failed to increase or decrease
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levels of phosphorylated ERK 1/2 compared to controls in either MCF-7 
or MDAMB231 cells. One of the reasons for this could be due to the 
methods used. Western blotting using antibodies directed against a 
phosphorylation site is a widely used method for looking at the 
activation of signalling molecules. However, due to the high level of 
basal ERK 1/2 signalling in the MDAMB231 cells, a further increase in 
phosphorylation of ERK 1/2 may be missed by saturation of the assay. 
One way to overcome this would be to reduce basal activity of ERK 1/2 
by removal of exogenous growth factors and quiescing the cells. 
Although this method can be used to look at ERK 1/2 signalling over 
short time periods (see Chapter 3), it cannot be used for long periods 
here (over 96 hours) as the cells cannot cope with this deprivation of 
growth factors and die. However, clofarabine did not induce ERK 1/2 
phosphorylation in the MCF-7 cells, where basal levels are low. This 
suggests that clofarabine does not activate ERK 1/2 signalling directly, 
and that saturation of the assay was not masking the effects in the 
MDAMB231 cells. Methods such as ELISA are more sensitive and may 
be able to pick up the changes in ERK 1/2 phosphorylation more 
accurately and therefore could be used to confirm the data here.
Studies by Smal et al. (2007) and Conrad et al. (2009) both found that 
cladribine was able to induce ERK 1/2 phosphorylation in leukaemia cell 
lines. Fernandez-Calotti et al. (2006) was also able to demonstrate that 
fludarabine could activate ERK 2 in leukaemic cells. Pyrimidine NAs 
have also been demonstrated to increase ERK 1/2 phosphorylation 
including gemcitabine (Matsumoto et al. 2008), ganciclovir (Whartenby 
et al. 2002) and cytarabine (Jarvis etal. 1998; Stadheim etal. 2001).
Similarly, numerous other studies have found that other cytotoxics can 
induce phosphorylation of ERK 1/2 in cell lines that include MCF-7 and 
MDAMB231 cells, including doxorubicin, epirubicin cisplatin, ceramide, 
etoposide and paclitaxel (Hayakawa et al. 1999; Persons et al. 1999; 
Cui et al. 2000; MacKeigan et al. 2000; Bacus et al. 2001; Guise et al.
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2001; McDaid and Horwitz 2001; Boldt et al. 2002; Small et al. 2003). 
However, other studies have found that the same cytotoxics can 
decrease ERK 1/2 signalling in other cancer cell types (Amato et al. 
1998; Stone and Chambers 2000; Stadheim etal. 2001).
These data suggest that, as inhibition of ERK 1/2 signalling reduces 
clofarabine efficacy in MDAMB231 cells, and clofarabine does not affect 
ERK 1/2 signalling directly, one of the mechanisms behind clofarabine 
activity lies at a post-ERK 1/2 phosphorylation site. As suggested, ERK 
1/2 may be involved in the upstream activation of apoptosis (Ishikawa 
and Kitamura 1998; Wang et al. 2000; Zhuang and Schnellmann 2006) 
as a consequence of the cytotoxic mechanism of clofarabine. However, 
as clofarabine did not increase ERK 1/2 phosphorylation, this may 
suggest that the DNA damage caused by clofarabine may be affecting 
an intracellular target that relies on, and is downstream of ERK 1/2. 
Therefore, through ERK 1/2 inhibition, this target is no longer activated 
and less cell death is observed. Arany et al. (2004) showed that ERK 
1/2 inhibition inhibited caspase 3 activation, an effector caspase in the 
intrinsic apoptosis pathway. MCF-7 cells are known to be caspase 3- 
null, whereas MDAMB231 cells are not (Yang et al. 2007), which may 
explain the differences seen with PD 98059 and clofarabine treatment. 
This may then also explain why an increase in ERK 1/2 phosphorylation 
was not observed. Similarly, Bax, a member of the Bcl-2 proteins is a 
pro-apoptotic protein. It is translocated to the mitochondria upon 
apoptotic stimuli where it causes release of pro-apoptotic proteins such 
as cytochrome C and the activation of caspases (Chiu et al. 2003). 
Exposure to cisplatin or reactive oxygen species has been shown to 
increase Bax expression, consistent with apoptosis, but in the presence 
of ERK 1/2 signalling, a decrease in Bax is observed (Kim et al. 2005; 
Park et al. 2005).
A potential mechanism of ERK 1/2 signalling and its role in clofarabine- 
induced cell death is shown below (figure 6.5.1).
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Figure 6.5 Representation o f the Role o f ERK 1/2 Signalling in 
Clofarabine-lnduced Apoptosis in MDAMB231 Breast Cancer Cells
Clofarabine causes DNA damage, which leads to the initiation of apoptosis by 
the release or activation of apoptosis-inducing proteins. Some of these require 
either activation by ERK 1/2, or interaction with an ERK 1/2-dependent 
molecule. This then leads to apoptosis. Reduction in ERK 1/2 signalling 
removes this process therefore reducing apoptosis, although other processes 
that are ERK 1 /2-independent can still cause significant cell death.
These data suggest that breast cancer cell lines, at least in vitro, with 
higher basal ERK 1/2 activity are more susceptible to the actions of 
clofarabine. ERK 1/2 signalling, at least in part, appears to sensitize the 
cells to the cytotoxic action of clofarabine, and removal of the ERK 1/2 
pathway reduces the efficacy of clofarabine in MDAMB231 cells. It 
would be interesting to look at ERK 1/2 signalling in other breast cancer 
cell lines in relation to clofarabine efficacy and see if correlations appear 
with basal activity or inhibition of ERK 1/2 signalling. It would also be 
interesting to look at the precise mechanism by which ERK 1/2 
signalling is partly mediating clofarabine-induced apoptosis in 
MDAMB231 cells. Looking at the expression of caspases and pro-
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apoptotic proteins such as Bax after clofarabine treatment in the 
presence or absence of PD 98059 would help identify the key players at 
the stage between DNA damage, ERK 1/2 signalling and initiation of 
apoptosis. Similarly, it would also be interesting to look at the other 
MAPK including JNK and p38 as these have also been associated in 
similar ways to ERK 1/2 with activating and preventing apoptosis in 
relation to cytotoxic drugs (Fan and Chambers 2001).
What these data also suggest is the highly complex nature of ERK 1/2 
signalling in relation to cytotoxic drugs and strongly indicate the 
individual role of specific drugs in specific cell lines to this pathway. The 
ability to apply these data clinically is debatable due to the wide 
differences in ERK 1/2 signalling in normal tissues, and in different 
cancers. Gee et al. (2001) demonstrated a decrease in disease-free 
survival in breast tumours deemed positive for phosphorylated ERK 1/2 
compared to those deemed ERK 1/2-negative after the initiation of anti­
hormone therapy. Derin et al. (2008) also found that low levels of ERK 
1/2 signalling in ER-negative breast cancer were associated with 
anthracycline resistance and shorter survival rates. Interestingly, they 
found that those people with higher ERK 1/2 signalling also had shorter 
survival rates compared to reduced ERK 1/2 signalling after disease 
reoccurrence. These data may suggest a differential role of ERK 1/2 at 
different stages of tumour progression clinically. Interestingly, Boldt et 
al. (2002) identified no particular correlation with drug-induced MAPK 
activity and efficacies of cytotoxic drugs alone, or in combination with 
MAPK inhibitors. Their data suggest that MAPK inhibition can either 
increase or decrease the efficacy of cytotoxic drugs, and that the 
potential for using MAPK inhibitors would have to tailored to individual 
tumours, a view supported here.
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6.6 Conclusion
The data herein suggest there is no direct relationship between ERK 
1/2 signalling and clofarabine in the MCF-7 cells. However, these data 
do suggest that in MDAMB231 cells increased basal ERK 1/2 signalling 
is a feature that promotes the anti-cancer activity of clofarabine, and 
reducing ERK 1/2 signalling reduces the efficacy of clofarabine against 
these cells. The mechanism by which this is occurring was not 
elucidated in this study due to time constraints. As clofarabine did not 
alter ERK 1/2 signalling directly it is possible that clofarabine activity is 
partially dependent upon ERK 1/2 activity on another cellular process. 
Further work is therefore needed to help characterise the mechanism 
by which ERK 1/2 is related to the cytotoxic activity of clofarabine.
Clinically, these data suggest that inhibition of ERK 1/2 signalling may 
not be of clinical benefit when combined with cytotoxic chemotherapy, 
specifically with clofarabine. Although alone, ERK 1/2 inhibition did 
produce a small effect against MDAMB231 cells, it is unlikely that this 
has clinical potential as it was such a small effect. Looking at the 
relationship between ERK 1/2 signalling, and the efficacy of clofarabine 
could be used in the future to predict how likely a patient is to respond 
to clofarabine treatment. Further understanding of the molecular 
interplay between ERK 1/2 signalling and clofarabine efficacy could 
lead to development of novel therapies or treatment strategies to exploit 
these pathways.
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Chapter 7: General Discussion
7.1 Discussion
Breast cancer is a group of heterogeneous neoplasms that arise from 
the breast and is now the most common form of cancer in the UK, with 
an annual incidence of 45,000 new cases. Worldwide, there are over 
one million new cases of breast cancer diagnosed annually, with the 
highest incidences occurring in North America (Cancer Research UK,
2010). Despite falling death rates over the last 10 years, 12,000 people 
still die annually from breast cancer in the UK and it is now the second 
most common form of death from cancer after lung cancer in women 
(Cancer Research UK, 2010).
Current treatments for breast cancer depend upon the molecular status 
of the cancer, specifically whether they express ER and/or PR, and also 
the expression level of the Her2 receptor. Other factors are also taken 
into account such as age, general health and menopausal status. For 
those women with cancers that are ER-positive and/or Her2 
overexpressed, effective targeted therapies are available i.e. aromatase 
inhibitors and trastuzumab, respectively. TNBC, however, accounts for 
2 0 % of all newly diagnosed cases of breast cancer and there are 
currently no targeted chemotherapy options (Skliris et al. 2008).
Besides surgery and radiation, cytotoxic chemotherapy forms the basis 
of treatment for women with TNBC. Despite good initial response, 
reoccurrence is high and prognosis for these women is extremely poor 
(Carey et al. 2007). There is no standardised treatment regime but 
generally combination therapy is used including two or three agents 
from the taxanes (paclitaxel), anthracyclines (doxorubicin), alkalying 
agents (cyclophosphamide) and antimetabolites (5-fluorouracil and 
methotrexate) (Anders and Carey 2008; Gluz et al. 2009). The major 
limitations to these treatments are the development of significant 
toxicities and side effects including nausea, fatigue, mucosal toxicity,
197
hair loss and neurotoxicity that severely affect quality of life. Drugs such 
as taxanes and anthracyclines can also cause life-threatening side 
effects such as heart failure and the development of leukaemia (Shapiro 
and Recht 2001; Nowak et al. 2004). As such, there is a very obvious 
need for the development of new treatments for TNBC that are effective 
and also well tolerated by patients.
The adenosine system and adenosine analogues represent attractive 
targets for the development of new and novel therapies. Numerous 
studies have identified that adenosine receptor activation inhibits the 
growth of various tumours, including breast (Colquhoun and 
Newsholme 1997; Yao et al. 1997; Fishman et al. 2000; Ohana et al. 
2001; Merighi et al. 2003; Panjehpour and Karami-Tehrani 2004 and 
2007; Lee et al. 2005; Sai et al. 2006; Bar-Yehuda et al. 2008; Kim et 
al. 2008). The adenosine receptors, particularly the Ai and A3 receptors 
have also been shown to be upregulated in cancerous tissues over 
normal tissues, and this has been specifically demonstrated in breast 
cancers (Khoo et al. 1996; Madi et al. 2004; Gessi et al. 2007; Ahmad 
et al. 2009). There is therefore the potential that exploitation of these 
receptors could lead to novel treatments.
Adenosine analogues are widely used in the treatment of 
haematological malignancies. They are very effective, sometimes 
producing curative outcomes and are also well tolerated by patients 
without many of the side effects commonly associated with standard 
cytotoxic chemotherapy (Guchelaar et al. 1994; Selby et al. 1998; 
Seshadri et al. 2000; Rummel et al. 2002; Cooper et al. 2004; Jeha et 
al. 2004). There have only been limited studies in solid tumours but 
their potential is evident (Takahashi et al. 1999; Waud et al. 2000; 
Hashemi et al. 2003, 2004; Wang and Albertioni 2010).
The aim of this thesis was to explore the potential of adenosine and 
adenosine analogues to reduce the viability of breast cancer cell lines in 
vitro. The studies were mainly carried out on the two widely used MCF-
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7 (ER-positive) and MDAMB231 (ER-negative, TNBC) cell lines. Some 
studies were also extended using four other breast cancer cell lines to 
attempt to reflect the different phenotypes that exist in breast cancer.
Initial results demonstrated the expression of all four adenosine 
receptors in both the MCF-7 and MDAMB231 cell lines. However, 
antagonism of these receptors had no effect upon cell viability in either 
cell line suggesting endogenous activation of these receptors does not 
promote cell survival or proliferation. Furthermore, the non-selective 
adenosine receptor agonist, NECA, only reduced cell viability at 
concentrations far exceeding the Ki for adenosine receptors (between 
14 and 5000-fold; Klotz et al. 2000) and only in the MCF-7 cells. Further 
studies then identified that adenosine at a high concentration (100 pM) 
was able to reduce cell viability in the MCF-7 cells by a mechanism 
partly involving adenosine receptor activation, which also caused a 
transient increase in ERK 1/2 phosphorylation. However, there was no 
effect upon adenosine receptors in the MDAMB231 cells.
These results indicate that in the MDAMB231 cells, adenosine 
receptors are not involved in cell viability, nor can their activation induce 
apoptosis or cytostasis. In the MCF-7 cells, activation of the adenosine 
receptors can reduce cell viability significantly suggesting therapeutic 
potential. The high concentrations of NECA and adenosine needed to 
reduce viability, however, suggest that they would be of little clinical 
benefit due to the wide distribution and functions of adenosine receptors 
physiologically (Klinger et al. 2002; Borowiec et al. 2006). There are 
selective adenosine receptor agonists available that are more potent 
than NECA which may offer more feasible clinical options (Jacobson 
and Gao 2006). Indeed, the selective A3 receptor agonists CF101 (Ki =
1.1 nM) and CF102 are in phase I and II clinical trials for the treatment 
of colorectal cancer and hepatocellular carcinoma, alone and in 
combination with other cytotoxic drugs and are showing promising 
results with very limited side effects (Stemmer et al. 2004; Stemmer
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2009). Due to the increased expression of the A3 receptor on breast 
cancer cells over normal breast tissue (Madi et al. 2004), this may be a 
feasible target in breast cancer also. However, further work is needed to 
elucidate which receptor NECA and adenosine were activating.
Elimination of endogenous adenosine and 2’-deoxyadenosine with ADA 
caused a significant decrease in cell viability in both cell lines that was 
probably due to depletion of important precursor molecules such as 
ATP or cAMP. Localised elimination of adenosine and 2’- 
deoxyadenosine from the tumour microenvironment could be a useful 
therapy for solid tumours. Although it has been shown that gene 
therapy can restore ADA activity in ADA-deficient mice (Mortellaro etal. 
2006), it is unknown whether overexpression could be induced in 
humans, and specifically in tumour cells.
Inhibition of adenosine metabolism by the clinically used agent, 
deoxycoformycin did not influence cell viability in either cell line. 
Although deoxycoformycin is effective in the treatment of 
haematological malignancies (Dillman 2004), it does not appear to be 
as effective in the treatment of solid tumours, but this may be a 
consequence of the in vitro methods used. Ogawa et al. (2000) 
demonstrated that, whilst deoxycoformycin was very effective in treating 
hairy cell leukaemia in a patient, in vitro deoxycoformycin had no effect 
upon isolated leukaemia cells. When 10 pM 2’-deoxyadenosine was 
introduced, however, this combination of drugs had a significant effect 
upon reducing cell viability suggesting a source of 2 ’-deoxyadenosine 
other than the tumour cells is needed. This theory was tested here by 
the addition of adenosine and 2 ’-deoxyadenosine in the presence of 
deoxycoformycin which produced significant reductions in cell viability in 
both cell lines. The concentrations of adenosine and 2’-deoxyadenosine 
in plasma after treatment with deoxycoformycin are in the order of 13 
and 27 pM, respectively (Venner et al. 1981). In solid tumours, 
adenosine levels peak at 13 pM in the presence of deoxycoformycin
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and adenosine kinase inhibitors (Biay et al. 1997). As concentrations 
greater than these are needed here to influence cell viability 
significantly in the MCF-7 and MDAMB231 cells, deoxycoformycin is 
unlikely to be useful against breast cancer tumours clinically.
The mechanisms of action of adenosine and 2’-deoxyadenosine were 
investigated next, as these compounds could offer new pathways to 
exploit as treatments for breast cancer. In the MCF-7 cells adenosine 
was working by activation of adenosine receptors and also by 
intracellular phosphorylation by adenosine kinase. In the MDAMB231 
cells, however, the mechanism of action of adenosine was by neither of 
these mechanisms. Both adenosine and 2’-deoxyadenosine in the 
MDAMB231 cells were able to reduce ERK 1/2 phosphorylation in an 
adenosine receptor-independent manner, which may account for some 
of the effects on cell viability. However, in Chapter 6, it was 
demonstrated that the MEK inhibitor PD 98059 had a lesser effect on 
cell viability than adenosine or 2’-deoxyadenosine did here. This 
suggests that alternative mechanisms are also induced.
In both the MCF-7 and MDAMB231 cells, 2’-deoxyadenosine reduced 
cell viability by a mechanism requiring the action of adenosine kinase 
and this has been described previously in breast, colon and gastric 
cancer cell lines (Camici et al. 1995; Giannecchini et al. 2003; Hashemi 
et al. 2005). The phosphorylation of 2’-deoxyadenosine to the mono- 
and ultimately the triphosphate is most likely mediating these effects. 
Indeed, dATP has been shown to cause dNTP imbalance by inhibition 
of ribonucleotide reductase causing base pair mismatching in DNA and 
ultimately leading to apoptosis (Tanaka et al. 1994; Wakade etal. 1995; 
Fidias etal. 1996; Barry and Lind 2000; Hashemi etal. 2005).
The intracellular action of 2’-deoxyadenosine (with deoxycoformycin), 
however, did suggest that stable analogues of this compound already in 
the clinic could be cytotoxic to these breast cancer cell lines and so 
their activity was investigated next.
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The clinically used PNA clofarabine and cladribine had nM potency 
against a range of breast cancer cell lines. Fludarabine was less active 
with IC50 values in the pM range in MCF-7 and MDAMB231 cells. 
Clofarabine was able to induce apoptosis in the MCF-7 and 
MDAMB231 cell lines at a clinically effective dose (1 pM) confirming its 
cytotoxic effects. All three drugs require intracellular phosphorylation by 
dCK, consistent with the literature (Parker et al. 1991; Lotfi et al. 1999; 
M£nsson etal. 1999; Galmarini et al. 2001). Clofarabine and cladribine 
were shown to work primarily through ribonucleotide reductase 
inhibition whereas fludarabine was less dependent upon inhibition of 
this enzyme. These results are consistent with the differential potencies 
of these drugs for inhibiting this enzyme (Parker et al. 1991) and could 
explain the differential effects of these drugs on cell viability. 
Phosphorylation by dCK and transport across the membrane were 
identified as not being rate-limiting steps in the action of clofarabine and 
cladribine using phosphoramidate analogues.
Clofarabine is the most promising of these agents based upon its 
potency here and also preferential pharmacodynamics including 
increased oral bioavailability, increased resistance to 
degradation/metabolism, increased cellular retention and its inhibitory 
action on both DNA polymerase and ribonucleotide reductase (Tseng et 
al. 1982; Parker et al. 1991; Zhenchuk et al. 2009). Clofarabine was 
therefore the focus of subsequent studies.
Interestingly, these results demonstrated a differential effect of the PNA 
between ER-positive and ER-negative breast cancers, with the drugs 
being significantly more potent in the latter. Most interestingly, however, 
was that clofarabine was equally potent in the ER-negative cells 
compared to the HL60 leukaemia cell line in this experimental protocol. 
As clofarabine is used successfully against leukaemia (Robak and 
Wierzbbowska 2009), this strongly demonstrates its potential for its 
clinical application in this difficult to treat phenotype of breast cancer.
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As clofarabine is effective even as a low dose regime against acute 
leukaemia (Bonate et al. 2006; Choi and Foss 2006), the excellent 
potency of clofarabine against the ER-negative cells suggests that low 
doses may be sufficient to reduce tumour burden whilst further reducing 
potential side-effects. The excellent potency also highlights its potential 
use in combinational therapy.
Whilst the ER-positive cells were less sensitive to the effects of 
clofarabine, it may still be useful as an adjuvant therapy for this type of 
breast cancer as potency was in the 300 nM range. Also, the efficacy of 
clofarabine at 1 pM in the T47D (ER-positive, Her2 normal expressed, 
p53-mutant) cells was equal to that of the leukaemia cells, suggesting 
that this phenotype may gain benefit from clofarabine treatment. This 
may be useful in cases of metastatic or hormone-resistant breast 
cancer, which almost always occurs upon disease reoccurrence after 
treatment of patients with advanced disease with anti-hormones (Goss 
and Strasser 2002).
Investigating the mechanisms behind the differential effect of 
clofarabine in ER-negative and ER-positive breast cancer cells revealed 
that these differences were not artefacts of cellular proliferation rates.
RT-PCR and Western blotting studies focused on investigating the 
expression of the activating and metabolising enzymes dCK and cN-ll, 
respectively, and ribonucleotide reductase as these enzymes are 
frequently implicated in the development of resistance (Carson et al. 
1991; Kawaski et al. 1993; Bai et al. 1998; Schirmer et al. 1998; 
Dumontet et al. 1999; Lotfi et al. 1999 and 2001; Mansson et al. 1999 
and 2003; Gourdeau et al. 2001; Davidson et al. 2004; Jordheim et al. 
2005; Yamamoto etal. 2007; Ferrandina etal. 2010).
Results indicated that increased basal levels of the metabolising 
enzyme cN-ll were correlated with a decrease in the potency of 
clofarabine. The expression of dCK, however, was not correlated with
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clofarabine potency. This is most likely due to increased metabolism of 
clofarabine triphosphate to the inactive forms. This may have clinical 
implications and be able to serve as a prognostic indicator as to which 
patients are most likely to respond to clofarabine treatment as 
suggested previously (Galmarini et al. 2001; Galmarini et al. 2003b). 
Similarly, cN-ll may serve as a therapeutic target for pharmacological 
inhibition to potentiate the action of PNAs.
There was also a correlation between increased expression of p53R2 
and decreased potency of clofarabine at the RNA level, and this was 
also confirmed at the protein level in several cell lines. Interestingly, 
after exposure to clofarabine, p53R2 expression was increased in the 
p53-wild type MCF-7 cells, but not in the p53-mutant T47D or 
MDAMB231 cell lines. These data strongly indicate that both basal and 
drug-induced expression of p53R2 can influence clofarabine potency in 
this panel of breast cancer cell lines. Although the mechanism behind 
these effects was not investigated here, it is probable that clofarabine- 
mediated DNA damage can induce p53R2 expression, which is able to 
produce dNTPs to repair the damage and out-compete clofarabine for 
incorporation into DNA (Tanaka et al. 2000; Barber et al. 2005; Tsai et 
al. 2006; Link etal. 2008).
Interestingly, 80% of TNBC are associated with mutated or null p53 
function (Sorlie et al. 2001). Whilst p53 mutant tumours have generally 
been regarded as more resistant to cytotoxic chemotherapy, the activity 
of clofarabine may favour p53 mutants due to its role in inducing p53R2 
in p53 wild-type cells.
Previous studies had shown that increased basal ERK activity was 
associated with resistance to various cytotoxic agents, including NAs 
(Jarvis etal. 1998; Hayakawa etal. 1999; Persons etal. 1999; Cui etal. 
2000; MacKeigan et al. 2000; McDaid et al. 2001; von Giese et al. 2001 
Smal et al. 2007; Eralp et al. 2008). This was interesting as ER-
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negative cells are associated with an increase in basal ERK 1/2 activity 
and clofarabine was more potent in these cells.
The results here show that ERK 1/2 inhibition reduces, although not 
completely, the activity of clofarabine in the MDAMB231 cells but 
clofarabine does not influence ERK 1/2 phosphorylation directly. The 
exact mechanism by how this occurs was not investigated further, it is 
possible that ERK 1/2 is involved upstream of activating process 
needed for apoptosis which has been shown previously (Blagosklonny 
et al. 1998; Ishikawa and Kitamura 1999). Further investigation of this 
interaction could lead to the development of treatments that could 
exploit these pathways.
These findings also indicate that increased basal ERK 1/2 activity is 
associated with increased sensitivity to clofarabine. This may have 
clinical relevance as tumours expressing higher basal ERK activity are 
associated with more aggressive tumours and reduced survival rates 
(Gee et al. 2001; Zhang et al. 2004; Derin et al. 2008; Chen et al. 
2009).
In conclusion, clofarabine was shown to be a potent cytotoxic agent 
against ER-negative breast cancers. The favourable 
pharmacodynamics, tolerability by patients and excellent potency of 
clofarabine dictate potential for the use of this drug clinically. This is 
important as, although ER-negative tumours generally respond well to 
cytotoxics, disease reoccurrence is high and is associated with high 
mortality (Carey et al. 2007). Clofarabine has the potential to be 
effective as a single agent or in combination therapy and could add a 
new class of drug to treat aggressive breast cancers.
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7.2 Future Perspectives
Solid tumours are known to be hypoxic due to delayed or reduced 
angiogenesis and stimulation of angiogenesis feeds the tumour and 
allows it to grow (Blay et al. 1997; Ryzhov et al. 2007). Therefore, the 
role of adenosine receptors in promoting angiogenesis could be 
investigated in vitro as this has been suggested as a function of 
adenosine receptors (Blay etal. 1997; Linden 2005; Merighi etai. 2007; 
Ryzhov et al. 2007). ELISAs could be used to look at the expression of 
angiogenesis promoting factors such as interleukin-8 (IL-8), fibroblast 
growth factor (FGF) and VEGF (Auchampach 2007) in the presence of 
adenosine and selective adenosine receptor agonists and antagonists.
Clofarabine shows the most clinical potential as demonstrated by its 
pharmacodynamics (Parker et al. 1991; Zhenchuk et al. 2009) and in 
vitro activity here. Extending the cytotoxicity/apoptosis studies into other 
breast cancer cell lines would help verify the data presented here. 
Extending these studies to in vivo models would also be necessary. 
Although clofarabine showed equal potency between ER-negative and 
leukaemia cells in vitro, the solid tumour microenvironment means that 
drugs often cannot reach all the cells of the tumour, especially those 
deep within the tumour that are not well vascularised (Minchinton and 
Tannock 2006). Limited studies have shown, however, that clofarabine 
did have good (nM) activity against a range of solid tumour xenograft 
models in vivo (Takahashi et al. 1999; Waud etal. 2000).
Further experimentation is needed to fully understand the mechanisms 
of action and sensitivity to clofarabine. These studies may then provide 
insight into which tumours are sensitive to clofarabine treatment. As 
primary phosphorylation by dCK is not rate-limiting (Gandhi et al. 2003) 
investigating the expression and enzyme kinetics of NMPKs and 
NDPKs would determine if these kinases are rate-limiting, and if they 
have a role in the sensitivity to clofarabine.
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Further work is needed to characterise the exact role cN-ll plays in 
resistance to NAs. This would require determining clofarabine mono-, 
di- and triphosphate metabolism by methods such as HPLC (Parker et 
al. 1991; Lotfi et al. 1999). Gene knockdown studies using methods 
such as siRNA would also be useful to determine if expression of cN-ll 
mediates clofarabine sensitivity.
Determining the exact role of ribonucleotide reductase in the activity 
and sensitivity of clofarabine in breast cancer cells would also be 
important. The results of this thesis showed that clofarabine was most 
likely working via inhibition of this enzyme and that increased resistance 
to clofarabine was correlated with increased p53R2 expression. 
Therefore studies could be carried out to first identify the inhibition of 
ribonucleotide reductase by clofarabine and subsequent physiological 
changes such as dNTP alterations. This could be looked at by HPLC to 
measure dNTP levels and also by looking at incorporation of clofarabine 
into the DNA using radiolabelled clofarabine (Mansson et al. 1999). 
Secondly, to determine the role of p53R2 in clofarabine sensitivity, 
siRNA studies would be useful.
Finally, future studies should characterise the different pathways of 
induction of apoptosis by clofarabine in different breast cell lines. 
Chapter 6 demonstrated that the ERK 1/2 pathway was important in the 
activity of clofarabine in MDAMB231 but not MCF-7 cells. 
Understanding how ERK 1/2 is important in transducing the apoptotic 
signal may offer new pathways to target. Clofarabine has been shown 
to act directly upon the mitochondria causing release of cytochrome c, 
APAF-1 and caspase 9 (Genini et al. 2000a), which could be studied 
using Western blotting or ELISA to quantify the accumulation of these 
inducers. This could be furthered by looking at accumulation of 
important molecules of the intrinsic apoptosis pathway such as pro- 
apoptotic (Bax, Bad and Bid) and anti-apoptotic (Bcl-2) proteins.
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7.3 Thesis Summary
In summation, the following conclusions are drawn from results 
presented in this thesis:
• MCF-7 and MDAMB231 cells express all four adenosine 
receptors, but these receptors may not be viable targets for 
breast cancer treatment.
• The endogenous compounds adenosine and 2’-deoxyadenosine 
can reduce cell viability by mechanisms requiring intracellular 
phosphorylation, and adenosine receptor activation to a lesser 
extent.
• Clofarabine has excellent in vitro activity against ER-negative 
breast cancer comparable to its activity in a leukaemic cell line.
• The activity of clofarabine is dependent upon phosphorylation by
dCK and it acts upon ribonucleotide reductase.
• In ER-negative MDAMB231 cells, the action of clofarabine is
partly dependent upon ERK 1/2 signalling, but clofarabine does
not effect ERK 1/2 phosphorylation directly.
• Increased resistance to clofarabine in the ER-positive cell lines is 
likely to be due to a combination of factors that include increased 
levels of the metabolising enzyme cN-ll and the DNA repair 
enzyme, p53R2.
• Clofarabine has therapeutic potential against ER-negative and 
TNBC and further work should be carried out to investigate this 
potential.
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